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ABSTRACT 
 
Acute limb compartment syndrome (CS), a devastating complication of 
musculoskeletal trauma, develops in response to elevation of the pressure within 
a closed osseofascial compartment, producing muscle- and limb-threatening 
ischemia. Full decompression of all involved compartments by fasciotomy is the 
current gold-standard therapy, but it must be performed within a surgical window 
of 6-8 hours, before tissue damage becomes permanent. 
Carbon monoxide (CO), a byproduct of heme metabolism, has been 
shown protective in ischemia. While inhalation of CO leads to elevation of 
carboxyhemoglobin (COHb), recent development of transitional metal carbonyls, 
CO-releasing molecules (CO-RMs), particularly the water-soluble CORM-3, 
delivers CO in a controlled manner without COHb formation, making it well suited 
to clinical applications. 
The purpose of this thesis was to examine the effects of CORM-3-derived 
CO on microvascular dysfunction due to elevated compartment pressure within 
skeletal muscle, using clinically relevant models of CS. The efficacy of both CO 
and CORM-3 was tested in the rat, demonstrating that CORM-3, just like inhaled 
CO, was able to prevent the CS-associated microvascular perfusion deficits, 
tissue injury and inflammation, all without the CO-generated elevation of COHb. 
The effects of CORM-3 were then tested in a preclinical large animal 
model of CS (pig), demonstrating the abolition of CS-induced systemic leukocyte 
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activation correlated with the inhibition of systemic TNF-α release, improved 
tissue microvascular perfusion, diminished tissue injury and apoptosis. 
To lay the foundation for translation of animal CS research to humans, CS 
was modelled in vitro, employing tissue culture of human vascular endothelial 
cells and serum of CS patients. CORM-3 was able to prevent free-radical 
formation, breakdown of endothelial barrier, apoptosis, leukocyte activation and 
transendothelial migration in response to CS stimulus. 
Thus, CORM-3 appears to have an enormous clinical potential; it might be 
capable of at least prolonging the surgical window, if not significantly reducing 
the need for fasciotomy. 
 
 
Keywords: compartment syndrome, elevated compartment pressure, 
fasciotomy, tissue injury, inflammation, leukocyte activation, 
cytokines, carbon monoxide, CORM-3, oxidative stress. 
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CHAPTER 1:  INTRODUCTION AND HISTORICAL REVIEW 
 
 
1.1 COMPARTMENT SYNDROME 
Compartment syndrome (CS) is a devastating limb- and life-threatening 
condition caused by elevated pressure within a closed osseofascial 
compartment, resulting in microvascular compromise, cellular anoxia and cell 
death (Mubarak, Owen et al. 1978, Rorabeck and Clarke 1978, Matsen, Winquist 
et al. 1980, Hartsock, O'Farrell et al. 1998). If left untreated, it produces 
significant tissue ischemia, which usually leads to severe functional impairment 
of the affected limb. CS can develop in response to a multitude of traumatic 
injuries and medical co-morbities: fractures, burns, exercise, crush injuries, and 
ischemia-reperfusion injury (McQueen, Gaston et al. 2000); less common causes 
may include bleeding disorders (Hope and McQueen 2004), diabetes, 
administration of statins (Chautems, Irmay et al. 1997, Jose, Viswanathan et al. 
2004), infection (Schnall, Holtom et al. 1994), hypothyroidism (Hsu, Thadhani et 
al. 1995), lithotomy position (Mathews, Perry et al. 2001), snake bites (Vigasio, 
Battiston et al. 1991), arterial rupture (Brumback 1990) and blast injuries (Born 
2005). 
Case reports of extremity contracture after trauma have been reported as 
early as 1840; most were, at that time, believed to be a result of direct neurologic 
injury. CS was first described in depth by Richard von Volkmann in 1881. 
Volkmann, a German surgeon, noted deformities of the hand and wrist following 
 3 
supracondylar fractures of the distal humerus; he believed that these 
contractures were related to (and always preceded by) the application of tight 
bandages to the injured limb, producing an “inflammatory myositis”. Eventually, 
Volkmann suggested that resulting limb paralysis and ischemic contracture were 
due to the interruption in arterial blood supply, leading to tissue ischemia; 
however, the precise cause of CS remained open for debate for decades to 
come (von Volkmann 1881). 
 
 
1.2 DIAGNOSIS OF CS 
1.2.1 Clinical Diagnosis 
Diagnosis of acute CS is challenging, as there is no ‘true’ diagnostic or 
imaging test; instead, the surgeon must rely on the clinical examination and 
observation of certain signs and symptoms. The first description of clinical criteria 
for the diagnosis of CS was provided by Griffiths in 1940. Griffiths established the 
original “four Ps”: pain out of proportion and pain on passive stretch, 
paraesthesia, paralysis and ‘puffiness’ (Griffiths 1940). Eventually, pallor and 
pulselessness were added to the signs of CS (Cascio, Wilckens et al. 2005). 
Today, those six criteria represent the basis of CS diagnostics. 
 
1.2.1.1 Pain 
The first symptoms of acute CS appear to be the disproportionate pain 
relative to the injury and pain on passive muscle stretch (PPS) (Whitesides and 
 4 
Heckman 1996). Thus, a progressive increase in analgesia requirements (or total 
unresponsiveness to narcotics) may be an indication of impeding CS (Bae, 
Kadiyala et al. 2001).  
Both pain out of proportion to what is expected of the injury (based on the 
physical examination) and PPS are the most sensitive clinical findings (19%) and 
are often the only observation that precede ischemic dysfunction in the nerves 
and muscles of the affected compartment (Whitesides and Heckman 1996, 
Ulmer 2002).  While the specificity of both pain measures is high (97%), the 
sensitivity is very poor (19%); thus, pain as a diagnostic criterion fails to identify a 
high percentage of individuals with acute CS (Ulmer 2002). Rather, the absence 
of pain is a more useful measure in ruling out acute CS, given the low false 
positive rate. However, an adequate level of suspicion must be maintained by the 
attending surgeon, as the absence of pain may indicate individual variation, 
altered states of pain perception, compartment syndrome of the deep posterior 
compartment, or missed acute compartment syndrome that has resulted in 
altered sensation (Whitesides and Heckman 1996).   
 
1.2.1.2 Paraesthesia, Paralysis 
Approximately 1 hour after the onset of ischemia, the patient may 
experience the first sensory changes (Whitesides and Heckman 1996). The first 
neurological signs of acute CS are usually hypoesthesia and paraesthesia in the 
dermatomal distribution of the nerve(s) of the involved compartment (Hargens, 
Akeson et al. 1978, Mubarak, Owen et al. 1978, Matsen, Winquist et al. 1980). 
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For example, altered sensation in the first web space of the foot is indicative of 
the involvement of the deep peroneal nerve and anterior compartment syndrome, 
while numbness of the dorsum of the foot may indicate lateral compartment 
syndrome with compression of the superficial peroneal nerve. Yet, these signs 
may also be caused by direct trauma to the nerve (Mubarak, Owen et al. 1978).  
As a clinical measure of acute CS, paraesthesia has a sensitivity of 13% 
and a specificity of 98% (Ulmer 2002). Unfortunately, paresis and/or paralysis of 
the muscles of the involved compartment are considered to be signs of a late 
acute CS; at this stage, the patient is less likely to respond to fasciotomy (Matsen 
and Clawson 1975, Ulmer 2002). 
 
1.2.1.3 Pallor, ‘Puffiness’, Pulselessness 
A pale, tense, swollen compartment resulting from increased intra-
compartmental pressure, sometimes with bruising of the skin, is recognized as 
an early physical sign of acute CS (Mubarak, Owen et al. 1978), although the 
measure may not be evident with isolated involvement of a deep compartment. 
Dressings and casts should be immediately removed to accurately assess 
swelling.  
The lack of a pulse rarely occurs in CS patients, as pressure that causes 
CS is often well below arterial pressure, and thus is not a feature of acute CS; 
additionally, the relevant artery may not be contained within the affected 
compartment (Shears and Porter 2006). Alternatively, the presence of a pulse 
does not exclude CS.  
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While congestion of the digits and prolonged capillary refill time may also 
indicate acute CS, these measures should not be relied upon, as they may be 
affected by many different external factors (e.g. shock, dehydration, decreased 
peripheral perfusion (Shears and Porter 2006). 
In addition to the observation and monitoring of the above-mentioned 
clinical signs, it has been suggested that intra-muscular (IM) pH monitoring may 
also be of benefit, as IM pH of less than 6.38 was found in 80% of CS cases 
(Elliot 2014). 
 
1.2.2 Compartment Pressure Monitoring 
Once a surgeon suspects a development of acute limb CS, diagnosis 
requires confirmation by the actual measurement of intra-compartmental 
pressure (ICP) (Hargens and Ballard 1995). Thus, measurement of ICP is a 
valuable tool for providing objective criteria for the diagnosis of acute CS, 
provided the proper technique is used. In order to capture the peak ICP value, 
measurements should be taken at the level of the fracture, as well as at sites up 
to 5 cm proximal and distal to injury (Heckman, Whitesides et al. 1994). In 
addition, pressures should also be measured in the other compartments of the 
affected limb, to ensure that a compartment syndrome is not missed. 
The indications for ICP measurement include unconscious patients 
(Gelberman, Garfin et al. 1981, Hargens, Akeson et al. 1989, Schwartz, 
Brumback et al. 1989); difficult-to-assess patients (e.g. young children, patients 
with psychiatric problems, or those under the influence of narcotics) (Whitesides, 
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Haney et al. 1975); patients with equivocal signs and symptoms (Gelberman, 
Garfin et al. 1981), especially when accompanied by nerve injury (Whitesides, 
Haney et al. 1975, Wright, Bogoch et al. 1989); and patients with multiple injuries 
(Schwartz, Brumback et al. 1989). Additionally, all tibial diaphyseal fractures 
(especially those in young men), high energy distal radial and forearm diaphyseal 
fractures in young patients, high energy fractures of the tibial metaphysis, and 
soft tissue injury or bleeding diathesis should also be monitored (McQueen, 
Gaston et al. 2000). 
 
1.2.2.1 Devices for ICP Measurement 
Current routine clinical compartment pressure monitoring uses one of the 
three main types of invasive devices: needle manometer, wick catheter (an 
adaptation of needle manometer), slit catheter (a modification of needle 
manometer), or electronic transducer-tipped catheter (Hargens and Ballard 
1995). Non-invasive ICP measurements, using near-infrared spectroscopy (NIR) 
to measure tissue oxygenation (Arbabi, Brundage et al. 1999), have also been 
proposed as an additional diagnostic tool, but require further research prior to 
their clinical use (Arbabi, Brundage et al. 1999, Gentilello, Sanzone et al. 2001, 
Katz, Nauriyal et al. 2008). Additionally, it has been demonstrated that 
temperature differences between the thigh and the foot show a unique pattern in 
individuals with acute CS (Katz, Nauriyal et al. 2008). 
The needle manometer consists of a 20cc syringe full of air, attached to a 
column that contains both air and saline. The ICP is the pressure required to 
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flatten the meniscus between the saline and the air (Whitesides, Haney et al. 
1975). The technique had been modified by Matsen et al (Matsen, Winquist et al. 
1980) to measure ICP as the amount of pressure required to overcome the 
pressure in the circuit and infuse a small amount of saline into the compartment.  
While this method is simple and low-cost, it is the least reliable, as the needle 
can easily be occluded (Moed and Thorderson 1993). 
The wick catheter is an adaptation of the needle manometer in which 
fibers project from the end of the catheter (Hargens and Ballard 1995). The fibers 
prevent tissue plugging, thus maintaining patency of the catheter to improve 
accuracy (Hargens and Ballard 1995). Disadvantages of this device include 
possible occlusion of the catheter tip by a blood clot and air in the fluid column, 
yielding falsely low measures.   
The slit catheter, described by Rorabeck et al (Rorabeck, Castle et al. 
1981) is another modification of the needle manometer technique that relies on 
the principle of increased surface area and increased patency (Hargens and 
Ballard 1995). The tip of the catheter is cut longitudinally, forming plastic petals.  
A fluid column, connected to a transducer, measures pressure. 
Transducer-tipped catheters designed with the transducer housed in the 
catheter tip have improved the accuracy of compartment measurements 
(Hargens and Ballard 1995). An early variant of this was the solid-state 
transducer intra-compartmental catheter (STIC), which offered increased 
accuracy compared to the slit and wick catheters; the disadvantage is that it still 
relies on an infusion for pressure measurement (McDermott, Marble et al. 1984). 
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This is not the case with the newer electronic transducer-tipped systems: 
electronic devices are independent of limb position and the height of the pressure 
transducer and do not require calibration (Mubarak, Hargens et al. 1976, 
Mubarak, Owen et al. 1978, McDermott, Marble et al. 1984, Moed and 
Thorderson 1993, Willy, Gerngross et al. 1999). Disadvantages of these devices 
are their high cost and difficulty with re-sterilization. 
 
1.2.2.2 ICP Measurement Threshold 
Although controversial, the role of ICP measurement in acute CS remains 
valuable. While the comparative benefit of ICP measurements relative to clinical 
assessment and the definition of an ICP measurement determining the need for 
fasciotomy are unclear, appropriately utilized ICP monitoring is a valuable 
diagnostic tool. Continuous compartment pressure monitoring decreases the 
delay to fasciotomy and may, therefore, decrease the long-term complications of 
the disorder (McQueen, Christie et al. 1996). In addition, ICP monitoring confirms 
clinical findings in difficult cases. 
While ICP monitoring is utilized in the diagnosis of acute CS, there is no 
clear protocol for a specific pressure threshold at which fasciotomy should be 
carried out. The threshold ICP for decompression has been listed as 30mmHg 
(Mubarak, Owen et al. 1978), 40mmHg (Schwartz, Brumback et al. 1989) and 
45mmHg (Matsen, Winquist et al. 1980). Whitesides et al (Whitesides, Haney et 
al. 1975) proposed the idea that the differential pressure (ΔP) is indicative of 
tissue ischemia. They suggested that tissue ischemia began when the difference 
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between ICP and diastolic pressure was 20mmHg (Whitesides and Heckman 
1996). McQueen et al (McQueen and Court-Brown 1996) recommended that the 
threshold ΔP be 30mmHg, based on the retrospective observation that this value 
lead to no apparent missed cases of acute compartment syndrome.  As of this 
day, many trauma surgeons prefer ΔP to the use of an absolute ICP threshold. 
The advantages of a differential pressure threshold include better utility in 
hypotensive trauma patients and a lower overall fasciotomy rate, compared to an 
absolute pressure threshold (Matsen, Winquist et al. 1980, McQueen and Court-
Brown 1996). 
 
1.2.3 Consequences of Missed Diagnosis of CS 
Early diagnosis of acute CS is absolutely critical to its successful 
management and subsequent clinical outcome. The failure of timely diagnosis 
appears to be the single most important cause of adverse outcomes (Matsen and 
Clawson 1975, Rorabeck 1984, McQueen, Christie et al. 1996, Mars and Hadley 
1998). Early diagnosis of CS is facilitated by the recognition of patient risk 
factors, understanding of the early clinical symptoms of CS, and the judicious use 
of compartment pressure monitoring (Matsen, Winquist et al. 1980, McQueen, 
Gaston et al. 2000). Risk factors for the development of acute compartment 
syndrome include gender (males are more prone to CS than females), young age 
group (below 30 years of age), tibial fracture, high-energy forearm fracture, high-
energy femoral diaphyseal fracture and bleeding diathesis or anticoagulation 
(McQueen, Gaston et al. 2000). 
 11 
Missed or late diagnosis of acute CS can result in serious complications: 
muscle infarction, muscle contracture, secondary deformity, weakness, and 
neurologic dysfunction (Whitesides and Heckman 1996). Less common sequelae 
include infection, gram-negative sepsis, amputation and end-organ involvement 
(Whitesides and Heckman 1996). Time from onset to necrosis is variable, with an 
accepted upper limit of 6 hours (Elliott and Johnstone 2003).  Determination of 
the exact time of onset of acute compartment syndrome is often difficult, as it 
may not parallel the onset of injury. 
Once irreversible myoneural ischemia occurs, some degree of permanent 
neurological deficit and muscle dysfunction will always be present. Depending on 
the proportion of tissue involvement, the severity can range from mild weakness 
to ischemic contractures. If there is a sufficient amount of muscle tissue involved, 
CS can lead to crush syndrome: rhabdomyolysis, renal failure (secondary to 
myoglobinuria) and shock (Sanghavi, Aneman et al. 2006, West 2007). Limb 
amputation will not be life saving at this point. 
Missed or late diagnosis is often a result of clinical inexperience, lack of 
suspicion, or a confusing clinical presentation (McQueen, Christie et al. 1996). 
Altered pain perception, as seen with changes in level of consciousness, regional 
anesthesia, patient-controlled analgesia and nerve injury are risk factors for late 
diagnosis (Mubarak and Wilton 1997, Harrington, Bunola et al. 2000). 
Maintaining an appropriate index of suspicion is important in preventing the 
negative sequelae of late-diagnosed acute compartment syndrome, as well as 
malpractice litigation (Bhattacharyya and Vrahas 2004). 
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1.3 THERAPEUTIC APPROACH TO CS 
The management goals of acute CS are to minimize permanent injury of 
the affected limb by restoring microcirculation to the muscle and nerve, and 
therefore avoiding the sequelae of ischemic contracture. While non-operative 
techniques may be employed initially in impending CS, surgical decompression 
of all involved compartments through fasciotomy remains the only gold standard 
therapy for acute established CS to this day, provided the diagnosis of CS is 
made within the recommended surgical window of 6-8 hours (Matsen, Winquist 
et al. 1980, McQueen and Court-Brown 1996, Lawendy and Sanders 2010). 
Given the fact that the consequences of delaying the fasciotomy are severe, non-
operative measures have been shown to have a very limited role; rather, medical 
management is restricted to an adjunctive role supplemental to fasciotomy. 
Although leg is most frequently involved (80% of all cases), followed by 
the forearm, CS has been reported in every muscle compartment of the upper 
extremity, lower extremity and trunk (McQueen, Gaston et al. 2000). 
 
1.3.1 Limb Anatomy 
1.3.1.1 Leg 
The leg consists of tibia and fibula, and is divided into four compartments: 
anterior, lateral, superficial posterior and deep posterior (Figure 1.1) (Gray 2000) 
Muscles of the anterior compartment, innervated by deep peroneal nerve and 
vascularized through anterior tibial artery, are responsible for the dorsiflexion of 
the  foot  and ankle.  The compartment is comprised of  tibialis anterior,  extensor   
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Figure 1.1. Compartments of the leg. Leg (shown in cross-section) consists 
of two bones, tibia and fibula, and several muscles that are 
separated into four different osseofascial compartments: anterior, 
lateral, superficial posterior and deep posterior. 
Reproduced with permission from Lawendy and Sanders (2010). 
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digitorum longus, extensor hallucis longus and peroneus tertius muscles (Gray 
2000). The compartment boundary is delineated medially by the extensor surface 
of the tibia, laterally by the intermuscular septum, and posteriorly by the extensor 
surface of the fibula and the interosseous membrane. The anterior compartment 
is completely enclosed by the deep fascia of the leg. 
Muscles of the lateral compartment, innervated by superficial peroneal 
nerve and vascularized by anterior tibial and fibular arteries, are responsible for 
plantarflexion and eversion of the foot. The compartment is comprised of 
peroneus longus and peroneus brevis muscles. The compartment boundary is 
delineated medially by the fibula, while the intermuscular septum surrounds it 
both anteriorly and posteriorly (Gray 2000). 
Muscles of the posterior compartments, innervated by the tibial nerve and 
vascularized through posterior tibial, fibular and popliteal arteries, are responsible 
for plantarflexion of the foot and ankle. The deep posterior compartment consists 
of popliteus, flexor hallucis longus, flexor digitorum longus and tibialis posterior 
muscles. The anterior boundary is delineated by the fibula, interosseous 
membrane, posterior intermuscular septum and the posterior surface of the tibia, 
while the posterior boundary is delineated by the transverse intermuscular 
septum (Gray 2000).  
The superficial posterior compartment consists of gastrocnemius, plantaris 
and soleus muscles, and its boundary is delineated anteriorly by the posterior 
intermuscular septum and posteriorly by the deep fascia of the leg (Gray 2000). 
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1.3.1.2 Forearm 
Forearm is made up of the antebrachium and hand. The antebrachium 
consists of the radius and ulna, and is divided into three interconnected 
compartments: “mobile wad”, anterior (volar) and posterior (dorsal) (Gray 2000) 
(Figure 1.2). The compartments are separated by antebrachial interosseous 
membrane between the radius and ulna; fascial extensions from the antebrachial 
fascia anatomically sequester the mobile wad into its own compartment. 
Muscles of the “mobile wad” (sometimes referred to as the lateral 
compartment) are innervated by the radial nerve and the posterior interosseous 
nerve; the blood supply comes primarily from the radial artery and the profunda 
brachii. The muscles of this compartment act collectively as elbow flexors (Gray 
2000). 
Muscles of the volar compartment, innervated primarily by the median 
nerve and vascularized by the ulnar and radial arteries, are divided into 
superficial, intermediate and deep groups; these are primarily involved with 
flexion and pronation (Gray 2000). 
Muscles of the dorsal compartment, innervated by the posterior 
interosseous nerve and supplied by the branches of ulnar and radial arteries, are 
further subdivided into superficial and deep groups; they are primarily involved 
with the extension of the wrist and digits, as well as supination of the forearm 
(Gray 2000). 
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Figure 1.2. Compartments of the forearm. Forearm (shown in cross-section) 
consists of two bones, radius and ulna, and several muscles that 
are separated into three different osseofascial compartments: 
dorsal, volar and mobile wad. 
 Reproduced with permission from Lawendy and Sanders (2010). 
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1.3.2 Fasciotomy 
Fasciotomy is a surgical procedure where the fascia is cut to relieve the 
elevated ICP within the affected compartments (Schmidt 2007, Lawendy and 
Sanders 2010). Wounds are usually left open for 48-72 hours prior to skin 
closure, with possible skin grafting necessary (Lawendy and Sanders 2010). 
Fasciotomy, as a therapeutic option in patients with impeding Volkmann’s 
contracture, was first described in 1911 by Bardenheuer (Bardenheuer 1911); he 
termed it an ‘aponeurectomy’. Eventually, Murphy (Murphy 1914) suggested 
early fasciotomy as a means of preventing paralysis and contracture when the 
pressure within fascial-enclosed space was increased due to hemorrhage and 
edema, stressing urgency in terms of preservation of function and patient 
outcomes. Murphy’s treatment is the mainstay of surgical practice today. 
In 1926, Jepson was able to demonstrate that surgical exploration and 
drainage of affected limb could avoid myonecrosis, and a relatively normal limb 
function could be resumed (Jepson 1926). Other authors (Jorge 1925, 
Moulonquet and Seneque 1928, Massart 1935) also stressed the need for 
fasciotomy in selected patients.  
The first detailed record of the actual operative technique for fasciotomy 
was provided by Benjamin (Benjamin 1957), who described the surgical 
approach to the forearm. This was followed by Eichler and Lipscomb (Eichler and 
Lipscomb 1967), Matsen and Clawson (Matsen and Clawson 1975), Eaton and 
Green (Eaton and Green 1972), Gelberman (Gelberman, Zakaib et al. 1978) and 
Henry (Henry 1973). 
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While initial fasciotomy technique descriptions came from the studies of 
the forearm, Reneman undertook the discussion of the proper surgical exposures 
during fasciotomy in the lower limb (Reneman 1975). Almost concurrently, 
Mubarak (Mubarak and Owen 1977) and Matsen (Sheridan and Matsen 1976) 
also released detailed descriptions of their techniques for leg fasciotomy; all of 
these are still in use today. 
 
1.3.2.1 Surgical Techniques for Fasciotomy 
In the leg, three surgical techniques for complete fascial release are most 
commonly described: two-incision fasciotomy (Mubarak and Owen 1977), single 
incision perifibular fasciotomy (Matsen 1979), and fibulectomy (Ernst and Kaufer 
1971) (Appendix I). In the forearm, most CS cases can be adequately treated by 
the release of superficial volar compartment (Matsen, Winquist et al. 1980, 
Ronel, Mtui et al. 2004); however, to avoid the possibility of missed CS, most 
surgeons prefer the technique where both volar and dorsal compartments are 
released at the same time (Jones, Santamarina et al. 2010) (Appendix I). 
 
1.3.3 Complications of Fasciotomy 
Fasciotomy, although being a gold standard therapy for CS (independent 
of its etiology), is not without complications – it is a procedure that carries 
significant risks, affecting patient morbidity and mortality. Possible complications 
include skin sloughing, infection, nerve, blood vessel and muscle damage, as 
well as scarring (Schmidt 2007). Some patients have been found to develop 
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deep chronic venous insufficiency (Bermudez, Knudson et al. 1998); 15-40% of 
patients reported wound healing complications (Johnson, Weaver et al. 1992, 
Heemskerk and Kitslaar 2003), neurological and vascular injury; 35% of patients 
suffered excessive bleeding, infection, scarring.  
In their retrospective study of trauma patients undergoing fasciotomy, 
Dover et al found that 20% of patients developed early post-operative 
complications; of these, severe symptoms were found in 80% of patients. After 
recovery, 70% of patients suffered persistent symptoms, which severely limited 
them either occupationally or socially (Dover, Marafi et al. 2011, Dover, Memon 
et al. 2012) 
Fitzgerald et al retrospectively assessed complications of fasciotomy in 
both upper and lower extremities over an 8-year period (Fitzgerald, Gaston et al. 
2000). They found that 77% had neurologic symptoms, such as altered sensation 
of wounds, and one in every ten patients had chronic pain associated with their 
fasciotomy wounds. Other frequent complications included dry skin, pruritus, and 
discolouration of wounds. Chronic swelling, tethering of tendons and scars, 
recurrent ulceration, and muscle herniation were also reported. The effect on 
patient’s life was also detrimental, as 28% changed hobbies and 12% changed 
occupation secondary to the complications of their fasciotomy. More than 20% of 
patients covered their scars due to the aesthetic appearance of the wound 
(Fitzgerald, Gaston et al. 2000). 
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CS may recur in as many as 3 to 20% of cases after fasciotomy (Barr 
2008). Causes include excessive formation of scar tissue and inadequate initial 
release of the fascia (Schmidt 2007). 
Timing of fasciotomy is absolutely critical in acute CS, as delay to 
treatment is associated with increased complications and negative outcomes 
(Finkelstein, Hunter et al. 1996).  Delay to fasciotomy of greater than 12 hours 
was found to increase the rate of infection to 28% versus 7.3% in patients treated 
early (Williams, Luchette et al. 1997). In one of the largest series in the literature, 
Ritenour et al (Ritenour, Dorlac et al. 2008) found significant complications 
secondary to fasciotomy revision surgery in military combat casualties. In their 
retrospective study of 336 patients who underwent 643 fasciotomies, they found 
an association between fasciotomy revision and increased rates of muscle 
excision, as well as a three-fold increase in mortality. Furthermore, delayed 
fasciotomies doubled the rate of amputation and increased the mortality rate 
fourfold, as compared with patients who underwent early fasciotomies (Ritenour, 
Dorlac et al. 2008). 
Thus, despite being the most effective treatment for CS, fasciotomy is not 
trivial to patient outcomes, and techniques, timing, and alternate therapies need 
to be further investigated. 
 
1.3.4 Non-Operative Treatment of CS 
Before 1911, CS treatments had placed emphasis on managing the 
sequelae of ischemic contracture. Thus, non-operative methods consisted mainly 
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of limb mobilization and muscle stretching. Today, in a patient who presents with 
a tight-fitting cast or occlusive dressing with increased neuritic and vascular 
symptoms, the removal of a cast or occlusive splints is the initial treatment of 
impending CS; if symptoms persist, fasciotomy is indicated. 
Non-operative management of CS is used only in the cases where 
fasciotomy is absolutely contraindicated: in cases where the affected limb is non-
viable due to multiple injuries or severe ischemia, which would almost certainly 
lead to multiple organ dysfunction (i.e. reperfusion syndrome) (Schmidt 2007). 
Thus, fasciotomy is the only gold standard therapy for CS. Given the fact that the 
consequences of delaying the fasciotomy are severe, non-operative measures 
are restricted to an adjunctive role supplemental to fasciotomy, and may be 
employed to attempt the prolongation of the window between the onset of CS 
and the time when irreversible changes occur.  
Lately, several non-operative options have been researched in various 
animal models of CS: mannitol (Daniels, Reichman et al. 1998), vitamin C 
(Kearns, Daly et al. 2004), N-acetyl cysteine (NAC) (Kearns, O'Briain et al. 2010), 
non-steroidal anti-inflammatory drugs (Manjoo, Sanders et al. 2010), tissue 
ultrafiltration (Odland, Schmidt et al. 2005), and hyperbaric oxygen therapy 
(Strauss, Hargens et al. 1983, Strauss, Hargens et al. 1986). 
Thus, while clinical trials are needed to assess their efficacy, these 
additional medical techniques may prove to be effective in patients presenting 
with an impending CS. 
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1.3.4.1 Mannitol 
Mannitol is a sugar alcohol that is clinically used as an osmotherapeutic 
agent, to reduce intracranial pressure after head trauma (Cruz, Minoja et al. 
2001), and in oliguric renal failure (Alvarez, Chatwin et al. 2000), among other 
things. Mannitol has been shown to increase water and sodium excretion, 
thereby decreasing extracellular fluid volume. 
Mannitol has been administered in canine and rabbit models of CS, where 
it appeared to act, presumably, by reducing the edema (Ricci, Corbisiero et al. 
1990, Better, Zinman et al. 1991, Oredsson, Plate et al. 1994, Daniels, Reichman 
et al. 1998). Case studies have been reported where fasciotomy was 
successfully averted following the use of mannitol in the context of clinically 
diagnosed CS (Daniels, Reichman et al. 1998, Gold, Barish et al. 2003). 
 
1.3.4.2 L-Ascorbic Acid 
L-ascorbic acid (vitamin C) is an essential nutrient produced by many 
animals and plants. Although a requirement of normal nutrition, humans and 
some other vertebrates lack the ability to produce it, and thus must obtain it from 
their diet (Sorice, Guerriero et al. 2014). 
Vitamin C is necessary for the formation of collagen within tissues; its 
deficiency causes scurvy (Sorice, Guerriero et al. 2014). In addition, it is a potent 
anti-oxidant that appears to play an important role in immune function (Jacob and 
Sotoudeh 2002). 
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It has been demonstrated that the administration of vitamin C in a rat 
cremaster muscle model of CS was capable of preserving muscle function, 
decreasing myeloperoxidase (MPO) activity and tissue edema (Kearns, Daly et 
al. 2004). 
 
1.3.4.3 N-Acetyl Cysteine 
N-acetyl cysteine (NAC) is a precursor to glutathione, a potent anti-
oxidant. NAC has been shown to have many clinical uses: protection of 
hepatocytes in acetaminophen overdose (Williamson, Wahl et al. 2013), 
nephroprotective agent in radiocontrast-induced nephropathy (Anderson, Park et 
al. 2011), as a mucolytic agent (emphysema, bronchitis, bronchiectasis, 
pneumonia, chronic obstructive pulmonary disease, pulmonary fibrosis) (Santus, 
Corsico et al. 2014), alleviation of cyclophosphamide-induced hemorrhagic 
cystitis (Palma, Villaca Junior et al. 1986), and interstitial lung disease (Santus, 
Corsico et al. 2014). 
Administration of NAC in a rat cremaster muscle model of CS has been 
shown to preserve muscle contractility (Kearns, O'Briain et al. 2010). 
 
1.3.4.4 NSAIDs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that 
interfere with arachidonic acid metabolism, via inhibition of cyclooxygenase 
(COX) enzyme. Two isoforms have been identified: the constitutively expressed 
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COX-1, and inducible COX-2. COX-2 expression can be upregulated in response 
to inflammatory stimuli and pro-inflammatory cytokines (Jan and Lowry 2009). 
Activation of leukocytes appears to play a significant role in the generation 
of tissue injury seen in CS (Lawendy, Bihari et al. 2015). As such, anti-
inflammatory medications may prove to be of benefit. It has been demonstrated 
that administration of indomethacin, a COX-2 inhibitor, in a rat model of CS led to 
an improvement in tissue perfusion and viability (Manjoo, Sanders et al. 2010). 
 
1.3.4.5 Tissue Ultrafiltration 
Tissue ultrafiltration has been used to reduce ICP by reducing fluid 
volume, thus decreasing the magnitude of tissue swelling (Odland, Schmidt et al. 
2005). Odland, Schmidt et al (Odland, Schmidt et al. 2005) have found that 
application of tissue ultrafiltration resulted in significant decrease in tissue injury 
in a porcine model of limb CS, presumably by lowering the actual fluid volume, 
hence tissue pressure, within the affected compartment. 
 
1.3.4.6 Hyperbaric Oxygen Therapy 
Hyperbaric oxygen therapy involves medical use of oxygen at levels 
higher than atmospheric pressure. The equipment consists of a hyperbaric 
pressure chamber and a means of delivering 100% oxygen (normal atmospheric 
oxygen content is approximately 21%). In the context of CS, the mechanism of 
action is thought to reduce edema within the affected compartment by inducing 
vasoconstriction in response to high oxygen, while maintaining oxygen perfusion 
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at lower perfusion pressure (Nylander, Nordstrom et al. 1987). Some case 
studies reported success in averting fasciotomy in patients with CS (Strauss, 
Hargens et al. 1983, Wattel, Mathieu et al. 1998, Gold, Barish et al. 2003). 
Unfortunately, this method has limited availability, due to the need for very 
specialized equipment.  
Hyperbaric oxygen has also been shown to improve wound healing, 
thereby reducing the need for amputation and unnecessary surgical procedures 
(Roeckl-Wiedmann, Bennett et al. 2005). 
 
1.3.5 Outcomes 
It is very difficult to determine the consequences of CS, since the injury 
itself might contribute to adverse outcomes. Very little published materials are 
available that specifically address the influence of fasciotomy on patient 
outcome. Mortality rates of 11-15% and amputation rates of 11-21% have been 
previously reported (Heemskerk and Kitslaar 2003). The outcome of patients with 
tibial fractures appeared to depend on the timing of fasciotomy: delayed 
fasciotomy resulted in muscle weakness and contractures, and higher risk of 
fracture healing complications (McQueen, Christie et al. 1996), as well as 
increased chance of death and amputations (Finkelstein, Hunter et al. 1996). 
In their review of lower limb fasciotomy, Heemskerk and Kitslaar (2003) 
found that 45% of patients had good limb function, 28% had successfully 
salvaged limbs with diminished function, 12% had to have a limb amputation and 
15% died. While all of the patients had serious overall morbidity, the only factor 
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predictive of poor outcome was patient age greater than 50 years; the underlying 
diagnosis did not contribute to the results after fasciotomy (Heemskerk and 
Kitslaar 2003). 
While they might be considered non-life threatening, the scars caused by 
fasciotomies are not negligible to patients’ functional outcomes: the study by 
Giannoudis et al (2000) found that patients who find their wounds aesthetically 
unappealing reported significantly poorer health-related quality of life as 
compared to patients who had no problem with the appearance of the wound. 
Rate of wound closure and need for skin graft were also associated with 
increased pain and discomfort (Giannoudis, Nicolopoulos et al. 2002). 
 
 
1.4 PATHOPHYSIOLOGY OF CS 
In order to improve diagnosis and treatment of CS, a much better 
understanding of its pathophysiology is needed; this would allow for the 
development of methods that would lessen (or prevent) tissue damage by 
targeting the specific mechanisms that contribute to the development and 
consequences of this condition. One common ‘prerequisite’ for the formation of 
CS is the rigidity of fascia; its unyielding nature (Gratz 1931) prevents expansion 
of tissue volume to compensate for an increase in fluid within the tissue. While 
multiple explanations for the complex pathophysiology of CS exist, the final 
commonality to all appears to be cellular anoxia and its consequences. 
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1.4.1 Historical Progression of Understanding CS Pathophysiology 
Historically, it was Volkmann, in 1881, who first suggested that limb 
paralysis due to CS was secondary to the interruption in arterial blood supply, 
producing ischemia (von Volkmann 1881). Following Volkmann, Leser in 1884 
designed animal models to test the idea; his experiments were crucial in 
confirmation of the muscle necrosis as a part of the condition (Leser 1884). 
Building on these studies, Hildebrand in 1890 demonstrated nerve involvement in 
addition to necrosis. Hildebrand was one of the first to coin the term “Volkmann’s 
contracture” (Hildebrand 1906). In 1909, based on his extensive retrospective 
review, Thomas also felt that neural tissue involvement was paramount to the 
understanding of the clinical presentation of CS; his findings were supported by 
the fact the deformity in Volkmann’s ischemic contracture was a claw hand, often 
caused by nerve damage to the upper extremity, although the observed 
deformity in Volkmann’s contracture was seen far more rapidly than what was 
observed with nerve compromise (Thomas 1909). In 1900, Bernays provided 
detailed description of the pathology of ischemic muscle and associated 
contracture, also making a reference to potential litigation and physician liability 
in these cases (Bernays 1900).  
In contrast to the previous ideas of arterial and nerve involvement, Murphy 
drew attention to the venous obstruction as a possible factor in contracture 
formation (Murphy 1914). His idea was then followed by Brooks, with the concept 
of increased pressure (as initially described by Volkmann) remaining as the early 
consistent feature and the cause of muscle damage in CS (Brooks 1922). In 
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1926, Jepson demonstrated that the occlusion of an extremity by the means of a 
tourniquet was always followed by an edema (Jepson 1926). Both Brooks and 
Jepson believed that the re-establishment of circulation to compromised tissue 
could inevitably contribute to the CS pathology; this is in full agreement with 
today’s understanding of ischemia-reperfusion injury. 
Subsequently, Leriche (Leriche 1928), Griffiths (Griffiths 1940) and Foisie 
(Foisie 1942) all noticed the correlation between the ‘arterial spasm’ and tissue 
injury, and thus tried to restore the notion of Volkmann that it was the arterial 
injury that caused ischemic paralysis. Although erroneously interpreting the 
cause of CS, Griffiths advocated that the treatment should be aimed at exploring 
the artery in an impending Volkmann’s contracture, inadvertently leading to 
secondary application of fasciotomy as a necessity of the surgical dissection 
(Griffiths 1940). 
The biggest shift in the paradigm of understanding the CS 
pathophysiology came during the World War II: in 1941, Bywaters and Beall 
noticed that the revascularization of injured limbs in otherwise stable patients led 
to decreased urine output, systemic deterioration, multi-organ failure and 
eventual death, even when the injured limbs had been amputated (Bywaters and 
Beall 1941). This led to the discovery of ‘crush syndrome’, defining the clinical 
findings associated with what is known today as a severe ‘reperfusion syndrome’. 
Up to this point, few case reports regarding lower extremity involvement 
had been documented. Hughes (Hughes 1948), and later Mavor (Mavor 1956) 
were among the first to present clinical cases of atraumatic onset of ischemic 
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necrosis in the lower extremity secondary to strenuous exercise. The link 
between elevation of ICP and surrounding fascia, and its effects on vascularity 
was an important milestone and observation in defining the pathophysiology of 
Volkmann’s ischemia. Mavor also independently demonstrated that with 
decompression of the fascial compartments, clinical resolution of symptoms was 
obtained (Mavor 1956). Both Hughes and Mavor brought forward the 
understanding that Volkmann’s ischemia is not isolated to the upper extremity; 
they stressed that it was equally as important that fascial release, independent of 
the underlying mechanism, may be a critical part of treating this disorder. 
Benjamin first correlated increased tissue pressure with the extent of injury 
seen in CS (Benjamin 1957). His idea was then later reinforced by Reneman, 
who also emphasized the importance of fasciotomy and discussed the proper 
surgical exposures during fasciotomy (Reneman 1975). Thus, by the mid-1970s, 
increased tissue pressure became accepted as the common basis of the CS 
disease process. 
Matsen, in his paper on the unified concept of CS, synthesized the state of 
knowledge of CS up to that point (Matsen 1975). He confirmed that not only was 
CS not isolated to the upper extremity, but also that an increase in tissue 
pressure was a critical feature in the pathophysiology of the condition – 
fasciotomy provided an effective treatment. Once the increased pressure 
became accepted as the cause, research could then focus on the pressure 
measurement and definition of the threshold for the treatment. 
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Whitesides et al (Whitesides, Haney et al. 1975) developed the 
methodology for measuring intra-compartmental tissue pressure, and suggested 
thresholds for fasciotomy. The methodology of ICP measurement was further 
improved upon by Mubarak et al (Mubarak, Hargens et al. 1976), Matsen et al 
(Matsen, Mayo et al. 1977) and Rorabeck (Rorabeck and Clarke 1978, 
Rorabeck, Castle et al. 1981). Rorabeck then confirmed that the absolute tissue 
pressures in CS might be quite variable, producing clinical symptoms in a range 
of pressures as low as 28mmHg to as high as 47mmHg; he suggested that the 
post-operative outcomes would most likely be dependent on the magnitude of 
tissue pressure the time of CS onset (Rorabeck 1984). 
 
1.4.2 Current Understanding 
While all previous research had focused on defining compartment 
pressure thresholds and diagnostics of CS, microscopic changes to the tissue 
and microvasculature were also being studied. Increased pressure within the 
closed compartment had been shown to create tissue ischemia, restricting the 
oxygen and nutrient delivery, thus failing to meet the metabolic demands of the 
affected tissue. Ischemia-generated anoxia was then shown to lead to 
microvascular perfusion derangements and severe inflammation (Lawendy, 
Sanders et al. 2011, Lawendy, Bihari et al. 2015). 
Thus, while the current understanding of CS pathophysiology is still not 
complete, microcirculatory dysfunction due to ongoing ischemia-reperfusion 
injury, early leukocyte activation and the ensuing inflammation appear to be the 
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driving forces behind generation of the CS, and the detrimental outcomes of CS 
injury. 
 
 
1.5 MICROCIRCULATION IN CS 
Normal skeletal muscle microcirculation is comprised of arterioles, 
capillaries and venules (Fig 1.3). Terminal vascular beds bring flowing blood into 
close proximity with parenchymal cells, where adequate exchange of materials 
between blood and tissues is met by large numbers of closely spaced capillaries. 
A single layer of vascular endothelial cells lines all vessels, sitting upon a 
condensed layer of extracellular matrix (basement membrane); the outer portions 
of the vessels are largely comprised of ordered layers of contractile 
mesenchymal cells (i.e. smooth muscle). While arterioles are comprised of 
smooth muscle cell-containing wall and have a divergent branching pattern, the 
post-capillary venules have no smooth muscle, and are instead lined by 
pericytes. Venules collect the blood from the capillaries, and have a larger cross 
sectional area than the corresponding arterioles, resulting in a lower flow velocity 
and wall shear stress. Thus, leukocyte adhesion (and inflammation) is normally 
restricted to venules; this is also augmented by the selective expression of 
adhesion molecules on venular (but not arteriolar or capillary) endothelium (Ley 
2008). 
As the ICP rises, generating CS, there is a disruption in microvascular 
perfusion,  reducing  oxygen  and  nutrient  delivery to the tissue to a point where  
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Figure 1.3. Microcirculation of the skeletal muscle. Normal microvascular 
unit is made up of an arteriole that branches into capillaries. 
Oxygenated blood flows from arterioles (red) into capillary beds; 
deoxygenated blood from the capillary beds is then collected in the 
post-capillary venules (blue). 
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the remaining perfusion can no longer meet the tissue demand (Lawendy, 
Sanders et al. 2011). This creates an ischemic insult, resulting in the production 
of reactive oxygen metabolites, oxidation of iron and membrane lipid 
peroxidation, causing significant damage to the affected tissues. Machinery to 
repair the damage is then initiated, triggering inflammatory response at both local 
and systemic levels. 
Thus, CS-associated microvascular dysfunction and the resulting tissue 
damage appear to be attributable to at least two mechanisms stemming from the 
elevated ICP: tissue ischemia due to disruption of the normal microvasculature, 
followed by reperfusion-induced inflammatory reaction due to neutrophil 
activation (Figure 1.4). 
 
1.5.1 Tissue Ischemia 
While the actual pathophysiological mechanism generating tissue 
ischemia is not known, three major theories have attempted to explain the 
microvascular dysfunction and ischemia, as they relate to tissue pressure and 
CS: critical closing pressure, microvascular occlusion, and arterio-venous 
gradient. 
 
1.5.1.1 Critical Closing Pressure Theory 
The main assumption in the critical closing pressure theory is that the 
active closure of arterioles would occur at a critical pressure secondary to a drop 
in transmural pressure (i.e.  the  difference  between the  intravascular and tissue   
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Figure 1.4. Microcirculatory dysfunction in compartment syndrome. Hypo-
perfusion of the capillary beds (i.e. low-flow ischemia) generates 
tissue injury (brown cells), which, in turn, activates leukocytes in 
post-sinusoidal venules and results in inflammation. LKC, 
leukocytes. 
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pressures) (Burton 1951). Arterioles, due to their small size, would experience 
high tension, and thus require high arteriolar tissue pressure gradient to maintain 
patency. Thus, CS would be caused by either extreme elevation of pressure, or a 
significant reduction in the arteriolar tissue pressure gradient, producing arteriolar 
collapse (Ashton 1975), thereby rendering the tissue ischemic. 
No supporting evidence for the theory, however, was produced when 
Vollmar et al (1999) tested the response of arterioles, capillaries and post-
capillary venules of various diameters to graded pressure elevation. Using the 
skinfold chamber in Syrian gold hamsters, the study was not able to demonstrate 
any signs of arteriolar spasm or collapse (Vollmar, Westermann et al. 1999). 
 
1.5.1.2 Microvascular Occlusion Theory 
The main assumption of the microvascular occlusion theory is that CS 
results from the capillary occlusion as a consequence to an increase in the 
absolute compartment pressure (Hargens, Akeson et al. 1978). Thus, in 
response to an increase in the tissue pressure above the normal resting capillary 
pressure, there should be a concomitant reduction in capillary blood flow, 
producing muscle ischemia and subsequent tissue necrosis. Therefore, even a 
modest increase in pressure would result in critical impairment of capillary 
patency, leading to microvascular compromise. 
The theory was, at least partially, discredited when the direct observation 
of rodent cremaster muscle subjected to sequential elevation of pressure did not 
produce vessel collapse, even when the pressure had been increased to a level 
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causing complete arrest of capillary flow; instead intraluminal pressure had also 
appeared to have increased to prevent the collapse of the vessel (Hartsock, 
O'Farrell et al. 1998). 
 
1.5.1.3 Arterio-Venous Gradient Theory 
The main prediction of arterio-venous (AV) theory is that an increase in 
tissue pressure, as seen in CS, would result in a net decrease of blood flow due 
to concomitant reduction of the AV pressure gradient (Matsen, Wyss et al. 1980). 
An increase in pressure would result in a rise in the intraluminal pressure – and 
the flow from arteries (i.e. high pressure) to veins (i.e. low pressure) depends on 
the pressure gradient maintenance. Thus, an elevation of ICP would diminish the 
AV gradient, reducing muscle blood flow and damaging the muscle. In addition, 
the decrease in AV gradient would also diminish the rate of clearance of the 
venous blood, causing fluid leakage into the interstitium, with edema ensuing, 
thereby elevating compartment pressure (Matsen and Krugmire 1978). 
The theory appears to be supported, at least in part, by the experiments 
on hamster striated muscle by Vollmar et al (Vollmar, Westermann et al. 1999). 
Using graded external pressure changes, Vollmar found that minimal increase in 
external pressure could halt the flow through capillaries and venules while 
maintaining arterial blood flow. Venules responded by decreasing diameter and 
flow; reestablishment of a pressure gradient, by relieving the external pressure, 
was able to restore blood flow. The study demonstrated the vulnerability of the 
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microvasculature to pressure fluctuation, and the need for pressure gradient to 
generate flow from capillaries to venules. 
The drawback of the AV gradient theory is that it relies on the assumption 
that the microvasculature passively responds to pressure. It does not account for 
the local adaptive responses of vasodilation, shunting of blood, endothelial 
structural changes, or the role of inflammation in the process (Gourgiotis, Villias 
et al. 2007). 
 
1.5.2 Reperfusion and Inflammation 
Reperfusion of previously ischemic tissue has been shown to elicit a 
strong inflammatory response in the microvasculature, characterized by 
vasodilation, production of inflammatory cytokines/chemokines, activation of 
complement cascade and leukocyte infiltration (Harris, Walker et al. 1986, 
Carden, Smith et al. 1990, Potter, Dietrich et al. 1993, Forbes, Carson et al. 
1995, Gute, Ishida et al. 1998, Ley 2008, Gillani, Cao et al. 2011). As a result, 
there is an increase in the production of reactive oxygen species (ROS) and 
soluble inflammatory mediators, enhanced adhesion of leukocytes and platelets 
to vascular endothelium and increased microvascular permeability. All of these 
then culminate in tissue damage and can lead to impaired organ function. 
Leukocyte recruitment to the site of injury (i.e. post-ischemic tissue), 
particularly neutrophils, occurs within the post-capillary venules (Forbes, Harris et 
al. 1996, Harris and Skalak 1996). A number of different cells are activated when 
ischemic tissues reperfuse with well-oxygenated blood: cells within the blood 
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vessel wall (endothelial cells) (Lefer, Tsao et al. 1991, Sabido, Milazzo et al. 
1994), those of perivascular compartment (macrophages) (Gute, Ishida et al. 
1998, Ley, Laudanna et al. 2007), and neutrophils (a class of polymorphonuclear 
(PMN) leukocytes) (Carden, Smith et al. 1990, Ley, Laudanna et al. 2007). 
Endothelial cells assume inflammatory phenotype: increased production of ROS, 
release of inflammatory cytokines, and changes in adhesion molecule expression 
to bind leukocytes (Seekamp, Warren et al. 1993, Schlag, Harris et al. 2001, Ley, 
Laudanna et al. 2007, Gillani, Cao et al. 2011). 
 
1.5.2.1 Endothelial Activation 
Resting endothelial cells are largely un-interactive with leukocytes and 
actually maintain leukocyte quiescence (Ley, Laudanna et al. 2007), probably 
due to the fact that adhesion molecules found at sites of inflammation are not 
expressed (like E-selectin or VCAM-1), or expressed at very low levels (like 
ICAM-1), and sequestered internally (like P-selectin). 
Activation of the endothelial cells in response to reperfusion injury consists 
of three stages: immediate (within minutes), acute (within hours) and chronic 
(within days) (Ley and Reutershan 2006). Each step serves a different function, 
with the ultimate goal being the repair of the damaged tissue. 
Immediate endothelial activation is triggered by many inflammatory 
chemokines, and results in endothelial degranulation, as well as endothelial cell 
contraction (Maier and Bulger 1996). P-selectin, normally stored within the 
Weibel-Palade bodies within the cytoplasm, is brought to the endothelial surface. 
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Its function is to facilitate leukocyte recruitment (Weibel and Palade 1964), by 
interacting with the P-selectin glycoprotein ligand-1 (PSGL-1) on white blood 
cells. 
Acute endothelial activation is characterized by increased gene 
transcription and production of E-selectin as well as ICAM-1 (Kurose, Anderson 
et al. 1994, Gute, Ishida et al. 1998, Ley, Laudanna et al. 2007). Pro-
inflammatory cytokines, particularly TNF-α and IL-1β are known triggers for this 
step. 
Chronic endothelial activation serves as a remodelling process. While no 
intravital video microscopy data on leukocyte behaviour or blood flow during this 
phase exists, the process appears to be reversible once the cause of 
inflammation is resolved (Ley, Laudanna et al. 2007).  
 
1.5.2.2 Increased Vascular Permeability 
Endothelial cell activation triggers massive endothelial cell contraction, 
producing gaps between the adjacent endothelial cells. This results in increased 
vascular permeability for plasma proteins, producing protein-rich exudate in the 
extravascular tissue (Michel and Curry 1999). While it may augment the release 
of antibodies into the affected site, it also causes tissue edema and swelling, 
resulting in (temporary) loss of function and pain; this effect is most likely 
mediated by bradykinin, histamine and leukotrienes release (McDonald, Thurston 
et al. 1999). 
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1.5.2.3 Vasomotor Response 
Strong vasodilatory response usually accompanies acute inflammation, 
resulting in several-fold increase in the blood flow to the inflamed tissue (Ley 
2008). The principal mediator appears to be nitric oxide (NO), derived from the 
endothelium (Moncada, Radomski et al. 1988) In addition to increased oxygen 
delivery, vasodilation also increases the delivery of nutrients, glucose and 
leukocytes themselves. Leukocytes use glycolysis to produce energy (Ley and 
Reutershan 2006), not oxidative phosphorylation; thus vasodilation may also 
serve as a means of glucose delivery, to supply the neutrophil requirements. 
Moreover, vasodilation-triggered blood flow alterations most likely produce 
changes in shear, which may then facilitate better leukocyte-endothelial 
interaction. 
 
1.5.2.4 Cytokine Release 
Inflammation is regulated by the release of chemokines and cytokines (a 
subset of chemokines), both at tissue level and systemically (Jan and Lowry 
2009). Of the 45 or so known chemokines, some 20 have been shown to have 
pro-inflammatory effects; a majority of them appear to promote neutrophil 
infiltration. Of the inflammatory mediators, TNF-α, IL-1β and IL-6 are three of the 
most important cytokines playing a role in reperfusion injury (Seekamp, Warren 
et al. 1993, Jan and Lowry 2009). 
TNF-α is a cell signalling protein that is produced by many cell types, 
particularly by activated macrophages and neutrophils. Although the circulating 
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half-life of TNF-α is brief (Beutler, Milsark et al. 1985), its activity elicits many 
metabolic and immunomodulatory functions. Upon binding to TNF-α receptor, the 
cytokine is able to induce inflammation and apoptosis by controlling the 
expression of transcription factor NF-κB, MAPK (particularly the stress-related 
JNK group) and proteolytic caspases (Seekamp, Warren et al. 1993, Roebuck, 
Carpenter et al. 1999, Ley 2008). While there appears to be a lot of extensive 
cross-talk among the different pathways, such complicated signalling probably 
ensures that various cells with vastly diverse functions and conditions can all 
respond appropriately to inflammation. 
IL-1β is produced by activated macrophages, monocytes, endothelial 
cells, fibroblasts, and appears to be involved in cell proliferation, differentiation 
and apoptosis. It mediates an inflammatory sequence similar to that of TNF-α (Yi 
and Ulich 1992). 
IL-6 has pleiotropic functions in different organs and tissues. It is produced 
by macrophages and T-cells to stimulate immune response after trauma 
(Gebhard, Pfetsch et al. 2000), by osteoblasts to stimulate osteoclast formation 
(Hashizume and Mihara 2011), as well as by the muscle in response to 
contraction (Munoz-Canoves, Scheele et al. 2013), in response to inflammatory 
mediators, such as TNF-α and IL-1. It is a very long-lived cytokine that can be 
considered both pro- and anti-inflammatory, depending on the type of injury and 
the involved tissue. Its counter-regulatory function on the inflammatory cascade 
appears to be through the inhibition of TNF-α and IL-1 (Song and Kellum 2005). 
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1.5.2.5 Leukocyte Activation 
Activated leukocytes display a very specific multistep behavioural 
sequence of leukocyte adhesion cascade, first described by Rudolph Wagner, a 
prominent pathologist of the nineteenth century (Wagner 1839). Both activated 
leukocytes and activated endothelium mediate this process by expressing 
different classes of adhesion molecules (selectins, integrins, Ig superfamily) in a 
temporally-coordinated fashion. The current paradigm consists of several steps: 
(1) capture or tethering by the endothelium, where leukocyte makes the first 
contact with the endothelium; (2) rolling along the endothelium, during which 
leukocytes sample chemokines presented by the endothelium (slow rolling); (3) 
chemokine release, which then triggers (4) firm adhesion; (5) adhesion 
strengthening, which then leads to (6) integrin clustering; and in the presence of 
appropriate endothelial/leukocyte stimuli, (7) transmigration occurs; the final 
result is (8) extravasation into the affected tissue (Ley, Laudanna et al. 2007) 
(Figure 1.5). 
Initial leukocyte capture and rolling appear to be mediated by selectins (L-
selectin on leukocytes, P-selectin and E-selectin on endothelial cells); slow rolling 
by integrins; lastly, firm adhesion and extravasation by the adhesion molecules of 
Ig superfamily: ICAM-1 (binds CD11/CD18, Mac-1 and LFA-1) on endothelium, 
VCAM-1 (binds VLA-4) on the endothelial surface, PECAM-1 on neutrophils 
(Albelda, Muller et al. 1991, Barreiro, Yanez-Mo et al. 2002, Yang, Froio et al. 
2005). Neutrophil accumulation appears to be the cause (not a consequence) of 
ischemia-reperfusion-induced endothelial barrier failure.  
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Figure 1.5. Leukocyte activation sequence in inflammation. Activated 
leukocyte paradigm consists of leukocyte capture/tethering, 
leukocyte rolling, firm adhesion, arrest and extravasation. The 
sequence is mediated by various adhesion molecules (selectins, 
integrins, Ig superfamily). 
 Adapted from Ley, Laudanna et al (2007).   
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Leukocyte rolling serves to sufficiently reduce the velocity of leukocyte 
movement along the endothelium, to allow for firm adhesion. Thus, the 
upregulation of P-selectin expression is very rapid (within 15-30 minutes of 
activation), as this molecule is normally stored in the pre-formed pools within the 
Weibel-Palade bodies of the endothelium, from where it can be rapidly mobilized 
to the cell surface in response to stimuli (e.g. reactive oxygen species, 
leukotrienes, histamine). E-selectin, on the other hand, is under transcriptional 
control, and as such, requires up to 3 hours to achieve peak expression. L-
selectin is constitutively expressed on the leukocytes on the microvillus cell 
surface protrusions. Upon activation, leukocyte L-selectin interacts with 
endothelial cell P- and E-selectins, mediating leukocyte rolling (Ley, Laudanna et 
al. 2007). As leukocyte activation progresses, L-selectin is then rapidly shed from 
the cell surface via a protease-dependent mechanism. 
The transition of rolling to firm arrest can be triggered by arrest 
chemokines (e.g. IL-8, GRO, MCP-1, MIP-1α). Firm adhesion and/or 
transendothelial migration are mediated by ICAM-1, VCAM-1, and PECAM-1 
expressed on the surface of the endothelium, under the control of transcription 
factors NFκB and AP-1, resulting in increased expression of ICAM-1 and VCAM-
1 within 4 to 6 hours. These molecules engage with leukocyte counter-receptors 
(i.e. CD11/CD18, Mac-1, LFA-1 and VLA-4) to mediate firm adhesion and/or 
transendothelial migration. CD11 (a and b) are constitutively expressed within 
most leukocytes, where they are stored in granules, and can be rapidly (i.e. 
within minutes) mobilized to the surface of leukocytes. The simultaneous rapid 
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up-regulation of CD11/CD18 and shedding of L-selectin on leukocytes upon 
activation enables leukocytes to rapidly transition between the rolling and firmly 
adherent states (Ley 2008). 
Leukocyte transmigration can be triggered by chemoattractant 
transendothelial gradient. The whole process can take up to 25 minutes. 
Emigrating leukocytes encounter three distinct barriers: endothelial cells, 
endothelial basement membrane and pericytes. While the migration through the 
endothelial cell barrier can be rapid (within less than 2 minutes), penetration of 
the endothelial basement membrane takes much longer (upwards of 5-15 
minutes). The process is driven by differential expression of adhesion molecules 
on the leukocytes and endothelial junctions. These include PECAM-1, ICAM-1, 
ICAM-2, JAM-A, JAM-B and JAM-C. Different molecules mediate leukocyte 
transmigration in either a stimulus-specific or leukocyte specific manner (Ley 
2008). 
 
1.5.2.6 Reactive Oxygen Species (ROS) 
ROS are small molecules that are highly reactive due to the presence of 
unpaired outer orbit electrons. Oxygen radicals are produced as a byproduct of 
oxygen metabolism, and by anaerobic processes. The main areas of ROS 
production include mitochondrial electron transport chain, peroxisomal fatty acid 
metabolism, cytochrome P450 and the respiratory burst of phagocytic cells (Jan 
and Lowry 2009). Under normal conditions, host cells are protected from the 
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damaging effects of ROS by endogenous anti-oxidants such as superoxide 
dismutase, catalase and glutathione peroxidase. 
Ischemia results in many changes to normal intracellular metabolism. One 
of these is the accumulation of hypoxanthine due to inadequate oxidative 
phosphorylation of ATP (Smith, Carden et al. 1989, Idstrom, Soussi et al. 1990); 
another is the conversion of xanthine dehydrogenase (normally kept oxidized by 
NAD+-dependent mechanism) into xanthine oxidase (Granger 1988). Upon re-
introduction of oxygen (i.e. reperfusion), xanthine oxidase will convert molecular 
oxygen into ROS, such as superoxide and hydroxyl radicals; additionally, 
superoxide will react with nitric oxide, producing peroxynitrites. ROS are known 
to attack cell membrane lipids (lipid peroxidation), proteins and 
glycosaminoglycans causing further tissue damage, which, in turn, triggers the 
inflammatory cascade by bringing leukocytes (neutrophils) to the affected tissue. 
Neutrophils themselves are equipped with enzymatic machinery that is 
capable of producing respiratory burst: oxygen-, nitrogen- and chlorine-derived 
free radicals (Bellavite 1988, Weiss 1989, Hampton, Kettle et al. 1998). Activated 
neutrophil accumulation, and their subsequent degranulation (which leads to the 
release of myeloperoxidase, a free-radical producing enzyme) will then ultimately 
be the cause of endothelial barrier failure. 
 Unfortunately, while inflammation and ROS production serve a useful 
function (i.e. clean up of the diseased/dead cells and tissue repair), 
overwhelming inflammation will contribute to the extensive tissue and organ 
damage. 
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1.6 HEME METABOLISM AND OXIDATIVE STRESS 
As multicellular life developed the ability to sustain itself by the use of 
oxygen gas (which is inherently toxic), it also had to evolve mechanisms that 
would allow it to survive oxidative stress. One of the most ubiquitous means to do 
this is that of heme oxygenase (HO), an enzyme whose presence and function is 
absolutely critical to the living organisms. HO deficiency in mammals is lethal – 
only one case of a human child deficient in this enzyme had been identified; the 
child did not survive beyond the age of 3 years (Yachie, Niida et al. 1999). 
 
1.6.1 Heme Oxygenase 
HO degrades heme by cleaving the heme ring at the α-methene bridge to 
form equimolar amounts of biliverdin (which is immediately converted into 
bilirubin by the enzyme biliverdin reductase), free iron and carbon monoxide 
(CO)  (Ryter, Alam et al. 2006)  (Figure 1.6).  The correlation of endogenous CO 
found in the blood with hemoglobin-derived heme degradation, and the α-carbon 
selectivity of this process, predates the discovery of HO by several decades 
(Hallberg 1955). 
It was Tenhunen et al who first characterized HO, a distinct enzyme 
system responsible for heme degradation (Tenhunen, Marver et al. 1968). 
Subsequently, three separate isoforms have since been defined: the 
constitutively expressed HO-2 and HO-3, and the inducible HO-1 (Maines, 
Trakshel et al. 1986, McCoubrey, Huang et al. 1997). 
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Figure 1.6. Heme degradation pathway. Hemoglobin-derived heme is broken 
down into biliverdin by heme oxygenase (HO), which is then rapidly 
converted into bilirubin by biliverdin reductase (BVR). Carbon 
monoxide (CO) and free iron (Fe2+) are generated by this reaction.  
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Normally, stress-induced proteins are generated or activated by an 
organism in response to stressors such as fever, heat, infection, toxins or 
radiation (Choi and Otterbein 2002). Not only do they protect cells from 
immediate stress, but also fortify the organism to withstand future stresses 
originating from a different source. In the 1980s, a 32kD mammalian stress 
protein, known as the heat shock protein-32 (HSP32), had been identified 
(Shibahara, Muller et al. 1987). HSP32 was later proven to be HO-1, the 
inducible form of HO (Keyse and Tyrrell 1989). 
Several studies have demonstrated that upregulation of HO, either by the 
use of various protoporphyrins (heme PPIX, cobalt PPIX) (Maines and Kappas 
1977), or by transfecting animals with adenovirus containing HO gene construct, 
can be beneficial in protecting tissues from ischemia-reperfusion injury 
(Otterbein, Kolls et al. 1999, Otterbein, Lee et al. 1999, McCarter, Badhwar et al. 
2004). Conversely, inhibition of HO (by pharmacological or gene knockout 
means) was found to be detrimental, leading to the conclusion that upregulation 
of HO provides protective benefits to the tissue (Dungey, Badhwar et al. 2006). 
Clinically speaking, however, upregulation of HO by adenoviral transfer may not 
be a feasible method to be employed in patients; therefore, the downstream 
byproducts of the HO-catalyzed heme degradation pathway have been examined 
for their contribution to the observed protective effects. Since HO activity results 
in production of bilirubin and CO, research has focused on the examination of the 
potential beneficial role of these compounds, particularly CO. 
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1.6.2 Carbon Monoxide 
CO is a low-molecular weight diatomic molecule that occurs in nature as 
an odourless gas. CO is considered a ubiquitous pollutant, arising primarily from 
the partial combustion of organic molecules by oxidation of natural hydrocarbon 
pools or burning fossil fuels, automobile emissions, catastrophic events (e.g. 
volcanic emissions and forest fires), plant metabolism and oceanic activity. 
CO is relatively stable in biological systems. It functions as heme iron 
ligand, and forms complexes with a number of hemoproteins and 
metalloenzymes (Coburn 1979, Maines 1997), binding only to reduced (ferrous) 
iron centres (Omura and Sato 1964). 
 
1.6.2.1 CO Toxicity 
Due to its invisibility and lack of odour, CO presents an especially 
dangerous inhalation hazard. Common causes of exposure are due to improper 
use of furnaces, engines, heaters, or incomplete combustion (i.e. in inadequately 
ventilated areas). Clinical manifestations of CO poisoning include dizziness, 
drowsiness, headache, vomiting and loss of motor coordination; prolonged 
exposure causes respiratory difficulty, disorientation, chest pain, loss of 
consciousness, coma and death (Weaver 1999). 
While symptoms of hypoxic CO poisoning begin to appear at 20% 
carboxyhemoglobin (COHb) levels, death likely occurs in the range of 50-80% 
COHb (Weaver 1999). Inhalation studies have revealed that CO can cause 
oxidative damage in the brain, as demonstrated by an increase in lipid 
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peroxidation (Thom 1990) and apoptotic cell death (Piantadosi, Zhang et al. 
1997). 
In 1857, Claude Bernard first realized that CO is capable of binding heme 
within hemoglobin, leading to formation of COHb (Bernard 1857). In 1912, 
Douglas demonstrated that the binding of CO to hemoglobin is reversible 
(Douglas, Haldane et al. 1912). The affinity of CO for heme within hemoglobin 
has been shown to be approximately 240 times that of oxygen (Weaver 1999). 
There are four oxygen-binding sites within one molecule of hemoglobin at which 
CO competes for occupancy. It has been demonstrated that half saturation (i.e. 
the partial occupation of the binding sites by two CO molecules) inhibits the 
release of oxygen from the remaining heme groups. This results in a left shift of 
the oxy-hemoglobin dissociation curve, reducing the oxygen-carrying capacity of 
the blood, thus generating the anemic hypoxia that appears to account for the 
asphyxiating properties of CO (Weaver 1999). 
The formation of COHb complex is reversible by the out-competition of CO 
in favour of oxygen. In some severe cases, hyperbaric oxygen therapy has been 
successfully applied as an antidote to CO poisoning (Weaver 1999). 
 
1.6.2.2 Endogenous Sources of CO 
A considerable amount of CO arises endogenously, as a byproduct of 
metabolism. At least 86% originates from heme metabolism, while the remaining 
fractions may arise from other metabolic processes, including lipid oxidation and 
xenobiotic metabolism (Vreman, Wong et al. 2000, Archakov, Karuzina et al. 
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2002). It was Coburn in 1967, who first demonstrated that CO in the body is 
derived from metabolic conversion of hemoglobin (Coburn, Williams et al. 1967), 
and estimated the rate of endogenous CO production at around 0.42ml/h 
(Coburn 1967). 
Under normal conditions, in the absence of significant ambient CO, the 
majority of blood COHb comes from endogenous production, and corresponds to 
blood CO levels of 0.4-1% (Vreman, Wong et al. 2000). The values increase in 
the presence of CO in the environmental background: for example, cigarette 
smokers display, on average, 3-8% COHb (Vreman, Wong et al. 2000). 
Certain pathological or toxicological conditions have been shown to lead 
to upregulation of HO-1 expression, which would produce increased blood CO 
levels: inflammation, physical stress, and environmental exposure to a variety of 
agents. As an example, several studies have demonstrated that the exhaled 
breath of patients suffering from asthma or COPD (i.e. pro-inflammatory 
conditions) contains increased levels of CO (Zayasu, Sekizawa et al. 1997, 
Kawane 2002). 
 
1.6.3 Biological Effects of Carbon Monoxide 
It appears that CO has profound influence on intracellular signaling 
processes, which culminate in anti-inflammatory, anti-proliferative, anti-apoptotic, 
and anti-coagulative effects. The physiological outcomes of CO action have been 
related to its endogenous production by both the constitutive (HO-2 and HO-3) 
and inducible HO (HO-1) activity. While it remains unclear whether exogenous 
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application of CO represents true physiological levels, it has been demonstrated 
that it can produce the effects similar to those that can be achieved by the 
induction of HO-1 protein. 
 
1.6.3.1 Cellular Signalling 
CO, as a gaseous molecule, has a very low reactivity; therefore, it can 
reach various cellular and molecular targets with great ease. Nevertheless, to-
date, very few mechanisms have been defined over which CO has particular 
influence. CO has high binding affinity for transition metals and heme proteins 
containing iron in ferrous form (Fe2+) (Kajimura, Fukuda et al. 2010), particularly 
hemoglobin and myoglobin. The selectivity depends on the intrinsic reactivity of 
ferrous heme, the chemical nature and geometry of the ligand, as well as steric 
constraint and electrostatic interactions of the bound ligand on the distal side of 
heme. The most common mode of action of CO in the biological systems 
appears to be the modulation of soluble guanylate cyclase (sGC) and the 
subsequent production of cGMP (Ryter and Otterbein 2004). The binding of 
heme iron within sGC by CO stimulates its activity, which, in turn, leads to 
several-fold increase in cGMP. For example, direct treatment of vascular smooth 
muscle cells with CO resulted in an increase in cellular levels of cGMP; hypoxia 
(which would cause an induction of HO-1, thus endogenous production of CO) 
also produced the same effect (Morita, Perrella et al. 1995). However, unlike NO 
(another potent activator of sGC), CO causes only a minor increase in the activity 
of this enzyme, due to the formation of a 6-coordinate complex (rather than 5-
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coordinate complex, as is the case with NO – which causes more than 100-fold 
activation of the enzyme). When both CO and NO are present simultaneously at 
the site, NO will bind sGC with much greater affinity than CO; in addition, CO will 
modestly but significantly attenuate the activation of NOS, thus serving as a 
partial antagonist to NO-induced sGC effects (Kajimura, Fukuda et al. 2010). 
Although sGC appears to be the most common cellular signalling pathway 
implicated in CO action, other intermediaries may also be involved. While these 
represent a downstream rather than primary target, as they do not bind CO 
directly, they include the modulation of various MAPK activation and stimulation 
of calcium-dependent potassium channel activity (Ryter, Otterbein et al. 2002). 
Large conductance calcium and voltage-activated potassium channel 
(BKCa), implicated in the control of hypoxic response in the carotid body, the 
control of vessel relaxation and neuronal activity (Jaggar, Li et al. 2005), is 
another target for CO action. Additionally, other ion channels have also been 
found to be regulated by CO: epithelial sodium channels (Althaus, Fronius et al. 
2009), ligand-gated P2X receptors (Wilkinson, Gadeberg et al. 2009), L-type 
calcium channels (Scragg, Dallas et al. 2008) and tandem P domain potassium 
channels (Dallas, Scragg et al. 2008). 
Studies suggest that cystathionine β-synthase, one of the enzymes 
responsible for the synthesis of endogenously-produced hydrogen sulfide 
(another biologically active signalling gaseous molecule) may act as a CO sensor 
in vivo (Kajimura, Fukuda et al. 2010). There appears to be a lot of cross-talk 
between CO and other gas-transducing biologic systems (i.e. nitric oxide, oxygen 
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and hydrogen sulfide), although the exact purpose, control and mechanisms of 
this action still remain to be fully elucidated. 
 
1.6.3.2 Vasodilation 
CO appears to exert a variable and multimodal effect on vasodilation, 
which involves at least several mechanisms. The dilatory effects are usually 
attributed to the direct, endothelium-independent effects on vascular smooth 
muscle cells (including the modulation of sGC and cGMP, as well as the effect on 
the potassium channels), while indirect effects appear to affect the expression of 
endothelial-derived vasoconstrictors and myogenic factors (Motterlini and 
Otterbein 2010).  
In 1978, Sylvester at al demonstrated that application of CO resulted in 
dilatation of pulmonary artery and a reversal of hypoxia-induced vasoconstriction 
in isolated perfused porcine lung (Sylvester and McGowan 1978). McFaul and 
McGrath demonstrated that CO was capable of reversing methoxamine-induced 
vasoconstriction in rat coronaries (McFaul and McGrath 1987). These effects 
have since been confirmed in rat thoracic aorta, pig, rabbit and dog coronary 
arteries (Lin and McGrath 1988, Graser, Vedernikov et al. 1990, Furchgott and 
Jothianandan 1991). Intact endothelium was not required in any of the above; 
tissue hypoxia caused by CO was also excluded as the driving force behind the 
observed effects. 
Although activation of sGC and subsequent increase in cGMP plays a 
major role in CO-induced vasodilation in aorta, cGMP-independent mechanisms 
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of vasodilation have also been demonstrated in peripheral vasculature in some 
experiments, where CO appeared to directly activate BKCa, calcium-dependent 
potassium channels (Wang, Wang et al. 1997); inhibition studies using 
ryanodine, a known calcium release channel blocker, have shown that CO-
induced vasodilation could be inhibited by this treatment (Jaggar, Leffler et al. 
2002). Limited evidence has also been found that would suggest the direct 
association of HO-2 with large-capacity potassium channels in the carotid body 
(Williams, Wootton et al. 2004); however, it still remains to be confirmed whether 
the same mechanism would occur in peripheral vasculature. 
Additionally, neural CO may also play an indirect role in vasoregulation by 
signalling in the autonomous nervous system (Verma, Hirsch et al. 1993). 
 
1.6.3.3 Anti-Inflammatory Effects 
Many studies, both in vitro and in vivo, have demonstrated that exogenous 
application of CO produces potent anti-inflammatory effects. For example, in an 
in vitro model of sepsis, stimulation of macrophages with LPS led to an increase 
in production of pro-inflammatory cytokines, particularly TNF-α (Otterbein, Bach 
et al. 2000). Exogenous administration of low dose CO inhibited this response, 
and when given as a pre-treatment, it also inhibited the expression of additional 
pro-inflammatory cytokines (IL-1β, MIP-1β) while augmenting the expression of 
anti-inflammatory cytokine IL-10. 
Beneficial effects of exogenous application of CO in systemic inflammation 
have also been documented in vivo. Similar to HO-1 overexpression, Ott et al 
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(2005) and Scott et al (2009) demonstrated that low-dose inhaled CO was able to 
prevent microvascular dysfunction in the liver and small intestine following 
ischemia-reperfusion-induced systemic inflammatory response syndrome (SIRS), 
respectively (Ott, Scott et al. 2005, Scott, Cukiernik et al. 2009). Song et al 
demonstrated anti-inflammatory effects of CO in orthotopic lung transplant (Song, 
Kubo et al. 2003). 
 
1.6.3.4 Anti-Apoptotic Effects 
Cell death can be classified according to its morphological appearance, 
enzymological criteria, functional aspects or immunological characteristics. 
Apoptosis describes a specific morphological aspect, characterized by rounding-
up of the cell, retraction of pseudopods, pyknosis, chromatin condensation, 
karyorrhexis, little or no ultrastructural modifications of cytoplasmic organelles, 
plasma membrane blebbing (although its integrity is maintained until the final 
stages of the process), and engulfment by resident phagocytes (Kroemer, 
Galluzzi et al. 2009). Apoptosis is mediated by the activation of proteolytic 
caspases. Under inflammatory conditions, increased recruitment of neutrophils to 
the site of injury contributes to the induction of apoptotic signalling through 
oxidative and proteolytic stress. 
Many studies have demonstrated the anti-apoptotic effects of CO to-date, 
both in vivo and in vitro. Similar to overexpression of HO-1, TNF-α-induced 
apoptosis has been shown to be abolished in an in vitro model in mouse 
fibroblasts and endothelial cells (Petrache, Otterbein et al. 2000). In the 
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endothelial cell model, p38 MAPK pathway appeared to be involved (Brouard, 
Otterbein et al. 2000). 
In several in vivo models of disease and/or tissue injury (e.g. ischemia-
reperfusion, lung transplantation), a low dose of CO pretreatment led to net anti-
apoptotic effects (Ryter, Alam et al. 2006), although higher concentrations of CO 
(i.e. at CO poisoning levels) produced pro-apoptotic brain injury in a rat 
(Piantadosi, Zhang et al. 1997). 
 
1.6.3.5 Anti-Proliferative Effects 
The inhibitory effects of CO on cell growth were examined by Morita et al 
(Morita, Perrella et al. 1995). They found that HO-1-induced endogenous CO 
production, triggered by hypoxia, inhibited vascular smooth muscle cell 
proliferation. The effect appeared to be due to cGMP-dependent downregulation 
of the expression of endothelial-derived mitogens, such as platelet-derived 
growth factor and endothelin-1. These investigators were also the first to suggest 
that CO inhibited cell growth by influencing the expression and/or activation of 
cell cycle-related factors, particularly transcription factor E2F (Morita, Perrella et 
al. 1995). 
 
1.6.4 Carbon Monoxide Releasing Molecules (CO-RMs) 
Given the observed beneficial effects of HO and a possible therapeutic 
application of exogenous CO gas, the need for a better method of CO delivery 
had, by this point, become apparent. The first breakthrough occurred when 
 59 
Motterlini et al synthesized a novel class of transition metal carbonyls, capable of 
releasing CO on demand (Motterlini, Clark et al. 2002). These carbon monoxide-
releasing molecules (CO-RMs) are capable of delivering CO to the tissues in a 
controlled manner, and they do so without the detrimental formation of COHb 
(Motterlini, Clark et al. 2002), thus providing an alternative approach to CO/HO 
delivery (rather than adenoviral transfer or inhalational CO). In addition to 
providing a much better method of CO delivery, these compounds also provide 
the means for further mechanistic insight into the behaviour of CO in biological 
systems. 
Most CO-RMs contain a central metal core (manganese, ruthenium, iron, 
boron) to which carbonyl groups are attached (Table 1.1). The general formula 
for a CO-RM is [Mx(CO)y]n. 
The first CO-RM to be synthesized, CORM-1 (formula [Mn2(CO)10]), is a 
rapid  CO  releaser (Motterlini 2007).  The molecule contains  manganese  in its 
centre, but is hydrophobic and requires photo-activation to initiate the CO 
release, thereby making its applicability limited to in vitro use only. The second 
CO-RM prototype, CORM-2 (formula [Ru(CO3Cl2)], contains ruthenium metal 
dimer at its centre. CO is rapidly released by dissolving CORM-2 in an organic 
solvent (e.g. DMSO), by ligand substitution; again, hydrophobic character or the 
molecule makes its use in the clinical setting rather limited (Motterlini 2007). 
The first water-soluble CO-RM to be synthesized was CORM-3 (formula 
[Ru(CO)3Cl(glycinate)]), also a ruthenium-based compound. CORM-3 is relatively 
stable in water, but promptly releases CO by ligand substitution when it comes in   
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Table 1.1. Most common carbon monoxide-releasing molecules (CO-
RMs). CORM-1 and CORM-2 are fast CO releasers, but not water-
soluble. CORM-3 and CORM-A1 are water-soluble. 
 Adapted from Motterlini et al (2009). 
 
Name  Chemical Structure  Solubility CO Release 
 
CORM-1      DMSO Light-dependent 
Fast (t1/2<1min) 
1M CO/mole CO-RM 
 
 
 
CORM-2    DMSO Ligand substitution 
     Fast (t1/2=1min) 
     0.7M CO/mole CO-RM 
 
 
CORM-3      Water Ligand substitution 
        Fast (t1/2=1min) 
        1M CO/mole CO-RM 
 
 
 
CORM-A1      Water pH dependent 
        Slow (t1/2=21min) 
        1M CO/mole CO-RM 
 
 
 
CORM-F3      DMSO Metal oxidation 
        Slow (t1/2=55min) 
       0.25M CO/mole CORM 
 
 
 
  
 61 
contact with biological stimuli directly interacting with ruthenium metal (Motterlini 
2007). It is stable at an acidic pH (i.e. less than pH 5), and rapidly releases 
equimolar amounts of CO in physiological conditions. 
In parallel, a second class of CO-RM chemicals able to generate CO in 
aqueous solutions was soon manufactured: CORM-A1 (formula [Na2H3BCO2]) 
and CORM-401. Unlike CORM-3, CORM-A1 does not contain transition metal at 
its centre, but a boron-bound carboxylic group that can slowly liberate CO 
through hydrolysis under physiological conditions; the release of CO is initiated 
by a pH shift, rather than by ligand substitution.  CORM-A1, however, is a very 
slow CO releaser, thus giving it a very long half-life (t1/2=21min); this property 
makes its clinical use rather limited. CORM-401 contains manganese at its 
centre, instead of ruthenium (Crook, Mann et al. 2011). Upon activation by 
deprotonation in physiological solution, it releases three moles of CO per one 
mole of CORM-401 (Crook, Mann et al. 2011). While its long half-life is similar to 
that of CORM-1A (i.e. approximately 21 minutes) (Fayad-Kobeissi, 
Ratovonantenaina et al. 2016), making it a slow CO releaser, the fact that it does 
not contain any heavy metals not normally found in the body, and that it releases 
three times as much CO makes it an attractive alternative option for future clinical 
explorations. 
The release of CO from each CO-RM has been validated 
spectroscopically, by monitoring the conversion of myoglobin into 
carboxymyoglobin (Motterlini 2007), while the biological effects have been 
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confirmed in numerous experiments by observing lack of effect with the 
deactivated form of the compound. 
 
1.6.5 CORM-3 
Carbon monoxide releasing molecule-3 (CORM-3) is a water-soluble CO 
donor. Originally, the molecule was synthesised by Motterlini et al by glycination 
of the water-insoluble CORM-2. CORM-3 is stable at an acidic pH, and rapidly 
releases equimolar amounts of CO in physiological conditions. 
Beneficial effects of CORM-3 have been demonstrated in multiple in vitro 
and in vivo studies. For example, vascular inflammation in endothelial cells, 
particularly that involving oxidative burst of PMNs (Masini, Vannacci et al. 2008, 
Song, Bergstrasser et al. 2009, Bergstraesser, Hoeger et al. 2012), bacterial 
activity (Davidge, Sanguinetti et al. 2009, Desmard, Davidge et al. 2009), 
leukocyte-endothelial interaction under flow in acute pancreatitis (Urquhart, 
Rosignoli et al. 2007) and inflammatory response induced by LPS and/or IFN-γ 
(Sawle, Foresti et al. 2005, Bani-Hani, Greenstein et al. 2006, Bani-Hani, 
Greenstein et al. 2006) were all reduced by the application of CORM-3 in many 
in vitro experiments. Additionally, CORM-3 has been demonstrated to affect 
multiple cell types and pathways that coordinate the inflammatory cascade: 
production of TNF-α, fibrinogen/fibrin, cellular infiltration, ICAM-1 expression and 
activation of transcription factors (NFκB, MAPK) have been reported to be 
significantly diminished in in vivo models of vascular thrombosis (Kramkowski, 
Leszczynska et al. 2012), hemorrhagic stroke (Yabluchanskiy, Sawle et al. 
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2012), polymicrobial sepsis (Lancel, Hassoun et al. 2009, Tsoyi, Lee et al. 2009), 
I/R injury (Katada, Bihari et al. 2009, Katada, Bihari et al. 2010, Caumartin, 
Stephen et al. 2011), arthritis (Ibanez, Alcaraz et al. 2012), xenotransplantation 
(Vadori, Seveso et al. 2009), neuropathic pain due to nerve injury (Hervera, 
Leanez et al. 2012), post-operative ileus (De Backer, Elinck et al. 2009) and 
cutaneous wound healing (Ahanger, Prawez et al. 2011) in animals treated with 
CORM-3. 
Interestingly, in relation to the pathology studied, the mode of action and 
efficacy of CORM-3 appear to depend on the timing of administration. CORM-3 
pretreatment (5 minutes) or post-treatment (3 days) after the onset of 
hemorrhage in the rat model of hemorrhagic stroke provided protective effects. 
On the contrary, administration of CORM-3 three hours after the stroke (the 
timing corresponds to the acute phase of the disease process) resulted in 
exacerbated damage (Yabluchanskiy, Sawle et al. 2012). 
The mechanisms of CORM-3 action appear to be linked not only to its 
anti-inflammatory properties, but also stimulation of mitochondrial biogenesis and 
the control of oxidative stress. CORM-3 administration was able to conserve 
cardiac mitochondrial function by preserving membrane potential and respiration; 
it also led to the induction of mitochondrial biogenesis in sepsis-mediated cardiac 
damage and metabolic syndrome-like disorder (Lancel, Hassoun et al. 2009, 
Lancel, Montaigne et al. 2012), while inhibiting NADPH activity and 
overproduction of superoxide anion (Taille, El-Benna et al. 2005, Lo Iacono, 
Boczkowski et al. 2011). 
 64 
1.7 AIM OF THIS THESIS 
While the pathophysiology of CS is not well understood, ischemia-
reperfusion injury appears to be a major driving force behind the observed 
detrimental outcomes. The effects of complete ischemia (where the onset is 
known, as all circulation is cleanly cut off) and subsequent reperfusion injury 
have been extensively described in the literature; we borrow from these studies 
in our attempt to design rational therapeutic approaches to CS.  
In response to the initial limb trauma, tissue edema develops. Rigidity of 
fascia prevents muscle compartments from expanding, resulting in the elevation 
of ICP and compression of the microvasculature, with tissue ischemia as the end 
result. However, unlike complete ischemia, CS appears in the face of patent 
vessels – after all, distal pulses are present in the majority of CS patients. Thus, 
the macrocirculation within the involved compartments is still intact, while the 
microcirculation becomes dysfunctional. Although some degree of microvascular 
perfusion may still be maintained, the metabolic demands for oxygen and 
nutrients cannot be fully met; ‘low-flow’ ischemic state leads to ROS and toxic 
metabolite formation, initiating local inflammatory response much earlier than that 
seen in complete ischemia. Subsequent cytokine release leads to early local 
leukocyte activation (particularly neutrophils) (Lawendy, Bihari et al. 2015), also 
triggering systemic inflammatory response coupled with remote organ injury 
(Lawendy, Bihari et al. 2016). In CS, ischemia and reperfusion phases happen 
almost concurrently, not only making it impossible to pinpoint the exact timing of 
CS onset, but initiating the reperfusion injury much earlier than that of complete 
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ischemia, with the degree of severity correlated to the duration of CS (Lawendy, 
Sanders et al. 2011). 
While different tissues have different tolerance for the survival of hypoxia, 
irreversible damage occurs within 6-8 hours, making it crucial that fasciotomy is 
carried out within that surgical window. Given the unclear nature of the CS onset 
and severe consequences of missed CS, the necessity of developing therapy 
aimed at prolongation of surgical interval becomes obvious. 
Exogenous application of CO appears to be beneficial in animal models of 
ischemia-reperfusion injury, but it has never been tried in the context of low-flow 
ischemia (i.e. CS). The purpose of this thesis was to test CO as a possible 
therapeutic agent for the treatment of CS. 
We hypothesized that exogenous application of carbon monoxide (either 
in inhalational form, or as CORM-3 derived CO) would be of immense benefit in 
acute compartment syndrome. We believe that CO could be used as an adjunct 
to fasciotomy; it may have the capacity to at least prolong the surgical window, if 
not dispense with the need for fasciotomy altogether. 
CORM-3 as CO donor was chosen due to its water solubility and rapid CO 
release upon activation. It is also important to note that, for the purpose of this 
thesis, the terms ‘elevated ICP’ and ‘CS’ are used interchangeably; however, CS 
is a clinical definition, and as such, can only be applied to humans. 
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CHAPTER 2 
 
THE EFFECT OF EXOGENOUS APPLICATION OF CARBON MONOXIDE ON 
SKELETAL MUSCLE MICROCIRCULATION IN THE RAT MODEL OF ACUTE 
LIMB COMPARTMENT SYNDROME. 
 
 
 
 
 
 
A portion of this chapter formed the basis for the patent application titled 
‘Therapeutic Use of Carbon Monoxide in Acute Limb Compartment Syndrome’, 
awarded to Dr. Lawendy and his Trauma lab research team. 
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CHAPTER 2: THE EFFECT OF EXOGENOUS APPLICATION OF CARBON 
MONOXIDE ON SKELETAL MUSCLE MICROCIRCULATION IN 
THE RAT MODEL OF ACUTE LIMB COMPARTMENT 
SYNDROME. 
 
 
2.1 INTRODUCTION 
Acute limb compartment syndrome (CS), a complication of 
musculoskeletal trauma, results from an increase in pressure within a closed 
osseofascial compartment, leading to muscle-threatening and limb-threatening 
ischemia (Matsen 1975, Whitesides, Haney et al. 1975, Mubarak, Owen et al. 
1978, Rorabeck and Clarke 1978, Matsen 1980, Hartsock, O'Farrell et al. 1998). 
Emergency fasciotomy, to fully decompress all the tissues in the involved 
compartments, remains the only effective treatment and current gold-standard 
surgical therapy, but it must be performed in a timely manner, before the injury to 
the tissues becomes permanent. Despite ongoing research dedicated to 
understanding the pathophysiology of CS, the mechanisms of CS-induced tissue 
damage are still poorly understood, making therapeutic targets rather limited. 
CS, as a form of ischemia-reperfusion (I/R) injury, results in significant 
microvascular dysfunction within the affected muscle (Lawendy, Sanders et al. 
2011). Leukocytes appear to play a major role in the pathophysiology of this 
condition (Lawendy, Bihari et al. 2015). However, unlike complete ischemia, CS 
occurs in the face of patent vessels (i.e. low-flow ischemia), making it impossible 
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to pinpoint the exact time when the metabolic demand of the tissue exceeds the 
actual supply of oxygen, thereby triggering oxidative stress, cytokine release, 
inflammation and consequent tissue damage. 
Previously, the upregulation of heat shock proteins, particularly heme 
oxygenase (HO), has been shown to be beneficial in various models of 
reperfusion injury (Nie, McCarter et al. 2002, McCarter, Scott et al. 2003, 
Akamatsu, Haga et al. 2004, McCarter, Badhwar et al. 2004, Lee, Gao et al. 
2007). HO is a rate-limiting enzyme involved in catabolic degradation of heme 
into biliverdin and carbon monoxide (CO) (Tenhunen, Marver et al. 1968). 
Numerous studies have demonstrated potent cytoprotective and anti-
inflammatory effects of HO/CO in various models (Motterlini and Otterbein 2010), 
making HO a potential therapeutic target.  While systemic upregulation of HO 
(e.g. by the use of adenoviral transfer) may not be clinically feasible, 
administration of its byproducts, particularly CO, on the other hand, can be 
accomplished with relative ease. 
Several studies have demonstrated that exogenous administration of low-
dose CO by inhalation offers both protection to microvascular perfusion, and anti-
inflammatory benefits during systemic inflammation (Nakao, Kimizuka et al. 2003, 
Hegazi, Rao et al. 2005, Mazzola, Forni et al. 2005, Ott, Scott et al. 2005, Scott, 
Cukiernik et al. 2009), sepsis (Mazzola, Forni et al. 2005, Koulouras, Li et al. 
2011), and organ preservation for transplantation (Neto, Nakao et al. 2004, 
Hanto, Maki et al. 2010). However, the possible therapeutic application and 
efficacy of CO have never been assessed in CS. 
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The purpose of this study was to test the effect of inhalational CO on the 
severity of microvascular dysfunction following CS. It was hypothesized that 
application of CO may be beneficial by reducing the degree of microvascular 
perfusion deficits, inflammation, and tissue injury normally seen in CS. The 
ultimate goal of this study is the development of pharmacological adjunctive 
therapy that would allow the prolongation of the fasciotomy surgical window, or 
completely eliminate the need for it. 
 
 
2.2 MATERIALS AND METHODS 
2.2.1 Animal Preparation 
The experimental protocol was approved by the Council on Animal Care of 
the University of Western Ontario (Appendix III), and has been previously 
described in detail (Lawendy, Sanders et al. 2011). Briefly, male Wistar rats 
(body weight 180-250g) were anesthetized by inhalational isoflurane (5% 
induction, 2% maintenance) in 1:1 oxygen/nitrogen mixture. Left carotid artery 
was cannulated to allow for the monitoring of systemic blood pressure, fluid 
administration and blood sampling. 
Compartment pressure monitoring probe (Synthes, Westchester PA) was 
inserted into the posterior compartment via gauge 16 angiocatheter (BD), while 
gauge 24 angiocatheter (BD) attached to an IV line was placed into the anterior 
compartment of the rat hind limb (Figure 2.1). CS was induced by an infusion of 
isotonic saline,  leading to an elevation of intra-compartmental pressure  (ICP)  to  
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Figure 2.1 Schematics of the experimental setup of a rat model of 
compartment syndrome. Elevation of intra-compartmental 
pressure to 30-40mmHg was achieved by an infusion of isotonic 
saline into the anterior compartment of the rat hind limb. Elevated 
compartment pressure was continuously monitored and maintained 
for 2 hours, producing compartment syndrome-like conditions.  
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30-40 mmHg. Elevated ICP was maintained for 2 hours. Fasciotomy was 
performed to decompress the hind limb compartments; the muscles were allowed 
to reperfuse for 45 minutes, followed by intravital video microscopy (IVVM). 
 
2.2.2 Exogenous Application of CO 
CO was exogenously applied to animals at fasciotomy, by inhalation. The 
inhaled gas mixture contained 250ppm CO in medical air, pumped into the 
facemask through the anesthesia circuit. Inhalation of CO to animals commenced 
right before fasciotomy; animals were subjected to inhalational CO during the 
whole reperfusion period of 45 minutes. 
 
2.2.3 Experimental Groups 
Animals were randomly assigned into one of the four groups: (1) sham 
(n=4), (2) sham under CO inhalation (n=4), (3) CS under normal air (n=4) and (4) 
CS followed by CO inhalation (n=4). Sham animals underwent all procedures as 
CS animals, but the ICP was maintained at baseline level (0mmHg). 
At the conclusion of the experiment, systemic levels of carboxyhemoglobin 
(COHb) were assessed in all animals. 
 
2.2.4 Intravital Video Microscopy 
The extensor digitorum longus (EDL) muscle was dissected to the level of 
its distal tendon, which was tied with a suture and cut from its bony insertion. The 
animal was transferred onto the stage of an inverted microscope (Nikon); the 
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EDL was reflected into a saline bath containing 5µg/ml each of the fluorescent 
vital dyes bisbenzimide (BB; exc. 343nm, em. 483nm) and ethidium bromide (EB; 
exc. 482nm, em. 616nm). BB stains the nuclei of all cells while EB stains the 
nuclei of only those cells with damaged cell membrane; thus, EB/BB ratio 
provided an index of tissue injury. 
Microvascular perfusion and leukocytes within the post-capillary venules 
were recorded by translumination with 20x and 40x objectives, respectively, in 
five adjacent fields of view. Fluorescence microscopy was used to visualize the 
BB and EB from the same fields of view that had been selected for the 
measurement of capillary perfusion. At the conclusion of the experiment, rats 
were euthanized by an overdose of anesthetic agent. 
 
2.2.5 Offline Video Analysis 
Capillary perfusion was assessed by counting the number of continuously-
perfused (CPC), intermittently-perfused (IPC) and non-perfused (NPC) capillaries 
that crossed three parallel lines drawn perpendicular to the capillary axis on the 
video monitor, and was expressed as % of total capillaries. Tissue injury was 
assessed by counting the number of EB- and BB-labelled nuclei, and expressed 
as EB/BB ratio. Leukocyte activation was assessed by counting the numbers of 
rolling and adherent leukocytes in post-capillary venules and expressed per unit 
area (i.e. 1000µm2). Venular area was measured using ImageJ (NIH, Bethesda, 
MD). A leukocyte was considered adherent if it remained stationary for at least 
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30 seconds, and a cell was considered rolling if it remained in contact with the 
wall of the vessel during its movement. 
 
2.2.6 Statistical Analysis 
All parameters were expressed as mean ± SEM and analyzed using one-
way ANOVA, with Bonferroni post-hoc test as needed.  p<0.05 was considered 
statistically significant. 
 
 
2.3 RESULTS 
2.3.1 Microvascular Perfusion 
Elevation of ICP led to significant changes in microvascular perfusion, as 
shown in Figure 2.2. The number of continuously-perfused capillaries decreased 
from 74±6% in sham to 22±3% in CS group (p<0.0001), while the number of non-
perfused capillaries increased from 12±3% in sham to 54±3% in CS group. 
Inhalation of CO, commenced upon fasciotomy, was able to restore the number 
of perfused capillaries to 57±3% (p<0.001). Inhalational CO had no effect on 
capillary perfusion in sham animals (76±2%, not significant). 
 
2.3.2 Tissue Injury 
Elevation of ICP resulted in a significant increase in muscle tissue injury, 
as measured by EB/BB ratio, from 0.05±0.03 in sham to 0.31±0.05 in CS group 
(p<0.001).  Inhalation  of  CO  significantly  decreased  tissue  injury to 0.02±0.02  
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Figure 2.2. The effect of CO inhalation on skeletal muscle microvascular 
perfusion following CS. Two hours of elevated ICP were followed 
by fasciotomy, 45min reperfusion coupled with CO inhalation, and 
IVVM.  CS-associated perfusion changes were partially reversed by 
CO inhalation (*p<0.001 from sham and sham+CO; †p<0.001 from 
CS; see the text for additional details). CPC, continuously-perfused 
capillaries; IPC, intermittently-perfused capillaries; NPC, non-
perfused capillaries. 
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Figure 2.3. The effect of CO inhalation on skeletal muscle tissue injury 
following CS. Two hours of elevated ICP were followed by 
fasciotomy, 45min reperfusion coupled with CO inhalation, and 
IVVM.  CS-associated tissue injury was reversed by CO inhalation 
(*p<0.001 from sham and sham+CO; †p<0.001 from CS).  
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(p<0.0001) (Figure 2.3). CO by itself had no effect on tissue injury (0.02±0.02, 
not significant). 
 
2.3.3 Inflammation 
Elevation of ICP resulted in leukocyte activation, as demonstrated by an 
increase in adhesion to the vascular endothelium. Leukocyte adherence in the 
post-capillary venules of the skeletal muscle was significantly increased from 
1.9±0.5 in sham to 17.5±0.9 leukocytes/30s/1000µm2 in CS group (p<0.0001). 
Leukocyte rolling only moderately increased from 1.7±0.7 to 3.3±0.7 
leukocytes/30s/1000µm2. Inhalation of CO led to a significant, 10-fold decrease 
in CS-triggered leukocyte adherence (0.6±0.2 adherent leukocytes/30s/1000µm2, 
p<0.001), while having no statistically significant effect on leukocyte rolling 
(2.0±0.6 rolling leukocytes/30s/1000µm2, not significant) (Figure 2.4). 
 
2.3.4 Systemic COHb Level 
Inhalation of CO led to significant increase in carboxyhemoglobin (COHb) 
levels in both sham and CS animals (7.6±1.6% in CS+CO and 7.4±1.3% in 
sham+CO, respectively versus 0.3±0.1% in sham, p<0.0001) (Figure 2.5). 
Elevation of ICP by itself did not produce any changes in COHb (0.4±0.2%, not 
significant). 
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Figure 2.4. The effect of CO inhalation on leukocyte adhesive interactions 
with endothelium of skeletal muscle microvasculature in CS-
challenged rat. Two hours of elevated ICP were followed by 
fasciotomy and 45min reperfusion coupled with CO inhalation. 
Leukocyte adhesion (A) and rolling (B) were assessed by IVVM. 
CO inhalation was able to prevent leukocyte adhesion within the 
post-capillary venules (*p<0.001 from sham and sham+CO; 
†p<0.001 from CS).  
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Figure 2.5. The effect of inhaled CO on systemic COHb levels. Two hours 
of elevated ICP were followed by fasciotomy and 45min reperfusion 
under CO inhalation. Inhalation of CO caused a significant increase 
in COHb, while elevation of ICP by itself had no effect  (*p<0.0001 
from sham and CS). 
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2.4 DISCUSSION 
Compartment syndrome is a challenging complication of musculoskeletal 
trauma. Therapeutic applications, aside from the gold-standard fasciotomy, are 
limited, and only address the sequelae of CS rather than pathophysiological 
mechanisms leading to CS formation (Olson and Glasgow 2005). In the present 
study, we demonstrated the benefit of inhalational carbon monoxide on improving 
capillary perfusion, reducing cellular damage and leukocyte recruitment following 
compartment syndrome and fascial release. 
CO is a signalling molecule produced endogenously by the degradation of 
heme, a reaction catalyzed by inducible and constitutively expressed heme 
oxygenases (HO-1 and HO-2, respectively) (Otterbein 2009). CO has been 
shown to generate vasodilatory effects, mitigate intracellular apoptosis and 
suppress inflammatory pathways in various models of inflammation, including 
ischemia-reperfusion (Otterbein 2002, Motterlini 2007). In our study, exogenous 
application of CO by inhalation demonstrated a beneficial effect by preserving 
microvascular flow in CS-challenged muscle. 
Continuous perfusion is characterized by the non-stop passage of blood 
through the capillary bed, supplying the tissue with the necessary oxygen and 
nutrients. Any derangement in the blood movement (i.e. shift to intermittency or 
no flow) compromises gas exchange, and results in ischemia (Lawendy, Sanders 
et al. 2011). In our study, we demonstrated that CO inhalation was capable of 
improving the capillary perfusion, restoring the number of continuously-perfused 
capillaries almost to sham levels (Figure 2.2). Moreover, CO inhalation was very 
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effective in restoring tissue injury levels back to baseline levels, as those seen in 
the sham group (Figure 2.3). Thus, CO appeared to provide a substantial 
protective effect within the CS-challenged muscle. To the best of our knowledge, 
this study is the first to demonstrate such potent protective effects of CO in the 
context of acute CS.  
CS pathophysiology is, at least in part, driven by I/R injury. The effects of 
complete ischemia on the skeletal muscle have been well documented in 
literature, with predictable alterations in the microcirculation (Harman 1948, 
Strock and Majno 1969, Labbe, Lindsay et al. 1987, Belkin, Brown et al. 1988, 
Lindsay, Liauw et al. 1990, Hickey, Hurley et al. 1992, Sabido, Milazzo et al. 
1994). Ischemia results in a shift of the cellular metabolism into oxidative mode, 
producing pro-inflammatory environment (Gute, Ishida et al. 1998, Gillani, Cao et 
al. 2011). Upon the restoration of blood flow (i.e. reperfusion), pro-inflammatory 
mediators (e.g. reactive oxygen species (ROS), cytokines/chemokines, platelet 
activating factor (PAF), etc.) released from the activated vascular endothelial 
cells and leukocytes enter the circulation, leading to systemic activation of 
leukocytes and subsequent recruitment into the reperfused tissue (Hernandez, 
Grisham et al. 1987, Kubes, Suzuki et al. 1990, Schlag, Harris et al. 2001). 
During inflammation, leukocyte extravasation from the blood is controlled by well-
coordinated adhesive interactions between leukocytes and vascular endothelial 
cells, which involves rolling (P-, E-, L-selectins), firm adhesion (integrins, ICAM-1, 
VCAM-1) and migration across the endothelium (PECAM-1, CD99, JAMs) (Ley, 
Laudanna et al. 2007). 
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Activated leukocytes produce ROS and proteolytic enzymes that cause 
further cellular damage and increased vascular permeability to plasma proteins, 
thereby contributing to the formation of progressive edema (Sexton, Korthuis et 
al. 1990, Forbes, Carson et al. 1995, Rubin, Romaschin et al. 1996, Kurose, 
Argenbright et al. 1997, Gute, Ishida et al. 1998). In the context of CS, fluid 
accumulation in the muscle will lead to an increase in the interstitial pressure, 
compressing the neighbouring capillaries and causing further shift to non-
perfusion (Lawendy, Sanders et al. 2011). 
In our rat model of CS, the blood flow through the capillary beds was not 
completely blocked; rather, the elevated ICP created a low-flow ischemic state, 
with reperfusion injury happening almost concurrently with ischemia. Upon 
fasciotomy, the full restoration of blood flow resulted in additional reperfusion 
damage, further accentuating the CS-induced microvascular dysfunction. We 
observed a substantial inflammatory response, characterized by an increase in 
leukocyte adhesion under conditions of flow, and recruitment of activated 
leukocytes into muscle vasculature in response to elevation of ICP and 
fasciotomy (Figure 2.4). CO inhalation led to a complete inhibition of leukocyte 
activation, with respect to suppressed leukocyte adhesion within post-capillary 
venules (Figure 2.4). This was coupled with more than 75% inhibition of tissue 
injury (Figure 2.3), implying that inflammation (i.e. overwhelming leukocyte 
recruitment) imparts a considerable pathological process driving the CS-
associated parenchymal damage. Indeed, activated leukocytes have been shown 
to be one of the most significant contributors to the parenchymal injury seen in 
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CS (Manjoo, Sanders et al. 2010, Lawendy, Bihari et al. 2015); the findings 
parallel those obtained from the models of reperfusion injury after complete 
ischemia (Forbes, Harris et al. 1996, Gute, Ishida et al. 1998). Given the potent 
anti-inflammatory nature of CO (Otterbein, Bach et al. 2000, Otterbein 2002, 
Song, Kubo et al. 2003, Motterlini, Haas et al. 2012), our data provides further 
confirmation of the critical role of inflammation in the pathophysiology of CS. 
Despite some key findings, it is important to note that while inhalation of 
CO significantly improved the overall microvascular perfusion in CS-challenged 
rats, some degree of perfusion derangement still remained (Figure 2.2). This 
suggests that the microvascular dysfunction and pathophysiology of CS may also 
be driven by other, not yet understood, factor(s). 
Elevated levels of COHb may represent a serious challenge when 
considering inhaled CO as a potential therapy for treatment of CS. Affinity of CO 
for hemoglobin is approximately 240 times higher than that for oxygen (Weaver 
1999); in our study, 45 minute inhalation of 250ppm CO resulted in an increase 
of COHb to 8%, in both sham and CS-challenged rats (Figure 2.5). It is important 
to note, however, that similar levels (i.e. 3-8% COHb) are detected in the blood of 
cigarette smokers (Vreman, Wong et al. 2000). While such level of COHb in 
normal, healthy subjects is unlikely to be toxic, it may not be negligible in trauma 
patients, majority of whom already experience insufficient levels of oxygenation.  
This study, as a proof of concept, demonstrates that exogenous 
application of CO may be of benefit in patients at risk of acute CS. While an 
increase in COHb level may not be inconsequential, with the rapid advancements 
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in the development of transition metal carbonyls, pharmacological means of CO 
delivery might open further avenues for research into prolongation of the surgical 
window and tissue preservation.  
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CHAPTER 3 
 
THE SEVERITY OF MICROVASCULAR DYSFUNCTION DUE TO 
COMPARTMENT SYNDROME IS DIMINISHED BY THE SYSTEMIC 
APPLICATION OF CO-RELEASING MOLECULE-3 (CORM-3). 
 
 
 
 
 
 
 
A version of this chapter was published in the Journal of Orthopaedic Trauma 
2014, vol. 28(11): e263 – e268. Reproduced with permission. 
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CHAPTER 3: THE SEVERITY OF MICROVASCULAR DYSFUNCTION DUE TO 
COMPARTMENT SYNDROME IS DIMINISHED BY THE 
SYSTEMIC APPLICATION OF CO-RELEASING MOLECULE-3 
(CORM-3). 
 
 
3.1 INTRODUCTION 
Acute limb compartment syndrome (CS), a potentially devastating 
complication of musculoskeletal trauma, is characterized by an increase in 
pressure within a closed osseofascial compartment, resulting in muscle-
threatening and ultimately limb-threatening ischemia (Matsen 1975, Whitesides, 
Haney et al. 1975, Mubarak, Owen et al. 1978, Rorabeck and Clarke 1978, 
Matsen 1980, Hartsock, O'Farrell et al. 1998). Fasciotomy, to fully decompress 
all the muscles in the involved compartments, remains the only effective 
treatment and current gold-standard surgical therapy. Despite a large body of 
literature dedicated to understanding the pathophysiology of CS, the 
mechanisms of CS-induced tissue damage are rather poorly understood. 
Extremity CS occurs once swelling within a muscle compartment develops 
to such a degree that the tissue perfusion becomes compromised. The 
established view of the pathophysiological process of CS development is that 
increasing compartmental pressure compromises microcirculatory perfusion, thus 
restricting oxygen and nutrient delivery to vital tissues, ultimately resulting in 
cellular anoxia and severe tissue necrosis (Sheridan and Matsen 1975, 
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Whitesides, Haney et al. 1975, Rorabeck and Clarke 1978, Matsen, Winquist et 
al. 1980). Unlike complete ischemia, CS causes myonecrosis in the face of 
patent vessels.  As such, the pathologic contribution of inflammation to the 
pathophysiology of CS is being increasingly recognized; studies from our group 
(Lawendy, Sanders et al. 2011) and others (Sadasivan, Carden et al. 1997, 
Kalns, Cox et al. 2011) have broadly implicated leukocytes as playing a primary 
role in both microvascular and parenchymal injury during CS. 
Despite active investigation, few therapeutic options have been shown to 
be effective. Recently, carbon monoxide (CO), a byproduct of heme oxygenase 
(HO) activity has been shown to offer both protection to microvascular perfusion, 
and anti-inflammatory benefits during systemic inflammation (Nakao, Kimizuka et 
al. 2003, Hegazi, Rao et al. 2005, Mazzola, Forni et al. 2005, Ott, Scott et al. 
2005, Scott, Cukiernik et al. 2009). Although the exogenous administration of CO 
via inhalation (250ppm) has been shown beneficial during systemic inflammatory 
response syndrome (Ott, Scott et al. 2005, Scott, Cukiernik et al. 2009), such 
method of administration results in increased carboxyhemoglobin (COHb) levels, 
thus presenting a potential threat to the host. 
Lately, transitional metal carbonyls, CO-releasing molecules (CO-RMs) 
have been used to deliver CO in a controlled manner without significantly altering 
COHb (Motterlini, Clark et al. 2002, Clark, Naughton et al. 2003, Motterlini 2007). 
The major advantage of using CO-RMs versus inhaled CO is the ability to control 
CO delivery without significantly increasing COHb, and choice of various routes 
(intravenous, intraperitoneal, subcutaneous or tissue superfusion) of CO 
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administration to target specific organs/tissues. Consequently, CO-RMs have 
received an increased attention for the potential pharmaceutical application 
(Motterlini, Clark et al. 2002, Motterlini 2007, Motterlini and Otterbein 2010). CO-
RMs have been shown to act pharmacologically in rat aortic and cardiac tissue, 
where liberation of CO produced vasorelaxant effects, decreased myocardial 
ischemia/reperfusion damage, and reduced inflammatory response in LPS-
stimulated macrophages (Clark, Naughton et al. 2003, Cepinskas, Katada et al. 
2008, Mizuguchi, Stephen et al. 2009, Katada, Bihari et al. 2010). 
The purpose of this study was to investigate the effects of CO, liberated 
from a novel, water-soluble CO donor, CORM-3, on the microvascular function of 
CS-challenged muscle, using our clinically relevant rodent model of CS 
(Lawendy, Sanders et al. 2011). The ultimate goal is the development of a 
pharmacologic adjunctive treatment for compartment syndrome, which would 
reduce the morbidity and disability in patients. 
 
 
3.2 MATERIALS AND METHODS 
3.2.1 Animal Preparation 
The experimental protocol was approved by the Council on Animal Care of 
the University of Western Ontario (Appendix III), and has been previously 
described in detail (Lawendy, Sanders et al. 2011). Briefly, male Wistar rats 
(body weight 180-250g) were anesthetized by inhalational isoflurane (5% 
induction, 2% maintenance) in 1:1 oxygen/nitrogen mixture. Left carotid artery 
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was cannulated to allow for the monitoring of systemic blood pressure, fluid 
administration and blood sampling. 
Compartment pressure monitoring probe (Synthes, Westchester PA) was 
inserted into the posterior compartment via gauge 16 angiocatheter (BD), while 
gauge 24 angiocatheter (BD) attached to an IV line was placed into the anterior 
compartment of the rat hind limb. CS was induced by an infusion of isotonic 
saline, leading to an elevation of intra-compartmental pressure (ICP) to 30 mmHg. 
Elevated ICP was maintained for 2 hours. Fasciotomy was performed to 
decompress the hind limb compartments; the muscles were allowed to reperfuse 
for 45 minutes, followed by intravital video microscopy. 
 
3.2.2 CORM-3 Synthesis 
A water-soluble CORM-3 (tricarbonylchloro-glycinate-ruthenium(II), 
[Ru(CO)3Cl-glycinate]; molecular weight 295 gmol-1) was synthesized by us, in 
accordance with the previously-published method (Motterlini and Otterbein 2010). 
CORM-3 (10mg/ml stock solution) was prepared fresh by dissolving CORM-3 in 
isotonic saline just prior to injection. As a control, inactive CORM-3 (iCORM-3) 
was generated by dissolving CORM-3 in saline 72 hours prior to the experiment 
and allowing it to release all CO from the solution (Clark, Naughton et al. 2003). 
 
3.2.3 Experimental Groups 
Rats were randomly assigned to one of four experimental groups: sham 
(n=4), CS (n=4), CS+CORM-3 (n=8) and CS+iCORM-3 (n=8). CO-releasing 
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molecule-3 (CORM-3), or its inactive form (iCORM-3), was administered to 
animals undergoing CS upon fasciotomy at the dose of 10mg/kg, IP. Sham 
animals underwent all the procedures as CS groups, but they did not receive 
saline infusion into the anterior compartment of the hind limb, and the ICP was 
maintained at the baseline level (0mmHg). 
 
 
3.2.4 Intravital Video Microscopy (IVVM) 
The extensor digitorum longus (EDL) muscle was dissected to the level of 
its distal tendon, which was tied with a suture and cut from its bony insertion. The 
animal was transferred onto the stage of an inverted microscope (Nikon); the 
EDL was reflected into a saline bath containing 5µg/ml each of the fluorescent 
vital dyes bisbenzimide (BB; exc. 343nm, em. 483nm) and ethidium bromide (EB; 
exc. 482nm, em. 616nm). BB stains the nuclei of all cells while EB stains the 
nuclei of only those cells with damaged cell membrane. Thus, EB/BB ratio 
provided an index of tissue injury. 
Microvascular perfusion and leukocytes within the post-capillary venules 
were recorded by translumination with 20x and 40x objectives, respectively, in 
five adjacent fields of view. Fluorescence microscopy was used to visualize the 
BB and EB from the same fields of view that had been selected for the 
measurement of capillary perfusion. At the conclusion of the experiment, rats 
were euthanized by an overdose of anesthetic agent. 
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3.2.5 Offline Video Analysis 
Capillary perfusion was assessed by counting the number of continuously-
perfused (CPC), intermittently-perfused (IPC) and non-perfused (NPC) capillaries 
that crossed three parallel lines drawn perpendicular to the capillary axis on the 
video monitor, and was expressed as % of total capillaries. Tissue injury was 
assessed by counting the number of EB- and BB-labelled nuclei, and expressed 
as EB/BB ratio. Leukocyte activation was assessed by counting the numbers of 
rolling and adherent leukocytes in post-capillary venules and expressed per unit 
area (i.e. 1000µm2). Venular area was measured using ImageJ (NIH, Bethesda, 
MD). A leukocyte was considered adherent if it remained stationary for at least 
30 seconds, and a cell was considered rolling if it remained in contact with the 
wall of the vessel during its movement. 
 
3.2.6 Serum Tumor Necrosis Factor Alpha (TNF-α) Measurements 
TNF-α levels were measured from arterial blood samples drawn at 9 time 
points: (1) baseline, (2) 15 minutes into CS, (3) 45 minutes into CS, (4) 90 
minutes into CS, (5) 2 hours into CS – just prior to fasciotomy and CORM-3 (or 
iCORM-3) injection, (6) 10 minutes post-fasciotomy, (7) 20 minutes post 
fasciotomy, (8) 30 minutes post fasciotomy, (9) 45 minutes post fasciotomy, just 
before IVVM. TNF-α was assessed using enzyme-linked immunosorbent assay 
(ELISA, Pierce Biotechnology, c/o Thermo Scientific, Rockford, IL) according to 
manufacturer’s instructions. The TNF-α ELISA was sensitive to less than 5 pg/mL. 
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3.2.7 Statistical Analysis 
All parameters were expressed as mean ± SEM and analyzed using one-
way ANOVA.  p<0.05 was considered statistically significant. 
 
 
3.3 RESULTS 
3.3.1 Systemic Leukocyte Count and Carboxyhemoglobin (COHb) 
Elevation of ICP, coupled with subsequent fasciotomy and 45 minutes of 
reperfusion, led to a small, but significant rise in leukocyte count; CORM-3 
treatment was able to decrease the severity of this response (Table 3.1). 
Application of CORM-3 or iCORM-3 had no effect on COHb levels (Table 3.1). 
 
3.3.2 Microvascular Perfusion 
Elevation of ICP resulted in significant changes to microvascular perfusion, 
as shown in Figure 3.1. The number of continuously-perfused capillaries 
decreased from 76±4% in sham to 23±2% in CS+iCORM-3 (p<0.0001), while the 
number of non-perfused capillaries increased from 13±2% in sham to 55±2% in 
CS+iCORM-3 (p<0.0001). CORM-3 treatment was able to restore the number of 
continuously-perfused capillaries to 57±5% (p<0.001), while iCORM-3 had no 
effect.  
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Table 3.1. The effects of CORM-3 on systemic leukocyte count and COHb 
levels. Two hours of elevated ICP were followed by fasciotomy, 
injection of CORM-3 (or iCORM-3) and 45min reperfusion. CS-
associated rise in systemic leukocyte count was reversed by 
CORM-3 application (*p<0.01 from sham; †p<0.05 from CS and 
CS+iCORM-3). CORM-3 and iCORM-3 caused no changes in 
systemic levels of COHb. LKC, leukocyte counts; COHb, 
carboxyhemoglobin. 
 
 
 
 
 
 
   
LKC 
(Units x109/L) 
 
Hemoglobin 
(g/L) 
 
COHb 
(%) 
 
Sham 
 
 
1.5 ± 0.2 
 
125.0 ± 2.3 
 
1.5 ± 0.2 
 
CS+iCORM-3 
 
 
4.1 ± 0.7* 
 
124.8 ± 2.9 
 
1.6 ± 0.1 
 
CS+CORM-3 
 
 
2.3 ± 0.2† 
 
129.5 ± 2.7 
 
1.6 ± 0.1 
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Figure 3.1. The effect of CORM-3 on skeletal muscle microvascular 
perfusion following CS. Two hours of elevated ICP were followed 
by fasciotomy, injection of CORM-3 (or its inactive form, iCORM-3), 
45min reperfusion and IVVM.  CS-associated perfusion changes 
were reversed by CORM-3 application (one-way ANOVA p<0.05; 
*p<0.001 from sham; †p<0.001 from CS and CS+iCORM-3; see the 
text for additional details). CPC, continuously-perfused capillaries; 
IPC, intermittently-perfused capillaries; NPC, non-perfused 
capillaries. 
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3.3.3 Tissue Injury 
 Muscle injury, as measured by EB/BB ratio, significantly increased from 
0.05±0.03 in sham to 0.31±0.05 (p<0.0001) in CS+iCORM-3 group. CORM-3 
treatment was able to diminish tissue injury to 0.07±0.01 (p<0.001) (Figure 3.2). 
 
3.3.4 Serum TNF-α 
 Elevation of ICP led to a progressive serum TNF-α release, reaching its 
maximum level at 2 hours (just prior to fasciotomy; p<0.01) (Figure 3.3). TNF-α 
levels continued to rise in the post-fasciotomy/reperfusion period in animals 
treated with iCORM-3. In contrast, CORM-3 injection effectively prevented the 
latter response at 30 and 45 minutes post-fasciotomy (p<0.001) (Figure 3.3).  
 
3.3.5 Inflammation 
 Elevation of ICP led to significant leukocyte activation, as demonstrated by 
the adhesive interactions with vascular endothelium. Leukocyte adherence in the 
post-capillary venules of the skeletal muscle was increased from 1.8±0.5 in sham 
to 13.7±0.9 leukocytes/30s/1000µm2 in CS+iCORM-3 (p<0.0001). Leukocyte 
rolling, while not statistically significant, also increased from 1.7±0.6 to 3.3±0.7 
leukocytes/30s/1000µm2. CORM-3 treatment led to a significant, 8-fold decrease 
in leukocyte adherence, while having no effect on leukocyte rolling (0.6±0.3 
adherent leukocytes/30s/1000µm2, p<0.001 and 3.0±0.8 rolling 
leukocytes/30s/1000µm2, not significant, respectively) (Figure 3.4). 
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Figure 3.2. The effect of CORM-3 on skeletal muscle tissue injury 
following CS. Two hours of elevated ICP were followed by 
fasciotomy, injection of CORM-3 (or its inactive form, iCORM-3), 
45min reperfusion, and IVVM. CS-associated tissue injury was 
reversed by CORM-3 application (one-way ANOVA p<0.05; 
*p<0.001 from sham; †p<0.001 from CS and CS+iCORM-3). 
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Figure 3.3. The effect of CORM-3 on serum TNF-α levels in CS. Two hours 
of elevated ICP were followed by fasciotomy, injection of CORM-3 
(or its inactive form, iCORM-3) and 45min reperfusion. Serum TNF-
α levels were assessed at each time point indicated. Any further 
post-fasciotomy TNF-α elevation was reversed by CORM-3 
application (one-way ANOVA p<0.05; *p<0.01 from baseline; 
†p<0.001 from CS+iCORM-3). F, fasciotomy. 
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Figure 3.4. The effect of CORM-3 on modulation of leukocyte recruitment 
to the skeletal muscle vasculature following CS. (A) Leukocyte 
adhesion; (B) leukocyte rolling. Two hours of elevated ICP were 
followed by fasciotomy, injection of CORM-3 (or its inactive form, 
iCORM-3), 45min reperfusion and IVVM. CORM-3 application was 
able to prevent leukocyte adhesion within the post-capillary venules. 
(one-way ANOVA p<0.05; *p<0.001 from sham; †p<0.001 from CS 
and CS+iCORM-3). 
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3.4 DISCUSSION 
Compartment syndrome poses a challenging problem. Aside from the gold 
standard of fasciotomy and supportive treatment to prevent other systemic 
sequelae during the recovery period, few other treatment modalities exist (Olson 
and Glasgow 2005). In the present study, we demonstrated the benefit of 
supraphysiologic levels of carbon monoxide in improving capillary perfusion, 
reducing cellular damage and leukocyte adherence following compartment 
syndrome and fascial release.  While the benefits of this compound have been 
well described in the literature, finding a suitable method of administration to 
reduce additional risk to the host has posed a long-standing problem. CO 
delivery via transitional metal carbonyls is a recent discovery and has shown to 
provide the vasorelaxant, antiapoptotic, and anti-inflammatory effects without the 
risk of elevated carboxyhemoglobin seen previously through inhalation (Guo, 
Stein et al. 2004, Motterlini and Otterbein 2010). This method of CO delivery may 
provide a useful pharmacologic agent in the treatment of patients at risk for, or 
recovering from, compartment syndrome. 
CO is a signalling molecule produced endogenously by the degradation of 
heme, catalyzed by heme oxygenases (HO-1 and HO-2) (Otterbein 2009). CO 
can exert vasodilatory effects, mitigate intracellular apoptosis, suppress 
inflammatory pathways and have anti-ischemic effects (Motterlini 2007). In our 
study, CORM-3 (a water-soluble formulation, administered IP) demonstrates a 
beneficial effect in preserving microvascular flow in CS-challenged muscle. 
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Continuous perfusion is defined as a physiologic flow through the capillary 
bed, whereas intermittent perfusion results from a marked decrease in red blood 
cell flow (Lawendy, Sanders et al. 2011). Non-perfused capillaries are seen when 
no red cell movement is observed. The change from continuous perfusion to a 
predominantly non-perfused profile demonstrates a pathologic shift in the 
microvascular bed in response to CS. In the current study, animals treated with 
CORM-3 had shown significant improvement in capillary perfusion rates, 
restoring the number of continuously-perfused capillaries to levels comparable to 
those of the sham group (Figure 3.1). Microvascular perfusion was virtually 
unchanged at 2 hours of elevated ICP in the presence of CORM-3, suggesting a 
substantial protective role of exogenously applied CO in the maintenance of 
skeletal muscle blood flow during CS. To the best of our knowledge, this study is 
the first to demonstrate such potent protective effects of CORM-3 in an acute and 
overwhelming inflammatory onset, such as CS. Moreover, administration of 
CORM-3 was very effective in restoring tissue injury levels back to baseline 
levels, as those seen in the sham group (Figure 3.2).  
Ischemia-reperfusion injury, a major component of CS pathophysiology, 
produces a pro-inflammatory environment, resulting in the upregulation of 
cytokines and chemokines, both systemically and within the affected tissues 
(Forbes, Carson et al. 1995). Inflammation-relevant cytokines/chemokines, 
particularly those produced during the acute phase of inflammatory response 
(TNF-α, IL-1β, IL-6, IL-8), in turn, stimulate leukocyte activation (primarily 
polymorphonuclear leukocytes, PMN) and recruitment into the inflamed tissues. 
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Once activated, leukocytes produce reactive oxygen species (ROS) and release 
proteolytic enzymes that (individually or concurrently) cause cellular damage and 
contribute to the increased vascular permeability, as well as subsequent 
formation of edema. As a result, increased interstitial pressure compresses 
adjacent capillaries, creating non-perfused segments (Kurose, Anderson et al. 
1994, Forbes, Harris et al. 1996, Gute, Ishida et al. 1998). In our study, we 
observed a marked increase in the levels of circulating TNF-α (one of the most 
potent pro-inflammatory cytokines) in CS-challenged animals, particularly post-
fasciotomy. This was associated with overwhelming leukocyte recruitment to the 
CS-challenged muscle, as demonstrated by adherent leukocytes in the post-
capillary venules (Figure 3.4). Interestingly, the increase in number of adherent 
leukocytes was completely prevented in animals treated with CORM-3, but not its 
inactive counterpart, iCORM-3. It is important to note that the decrease in 
leukocyte recruitment to CS-challenged muscle correlated with the CORM-3-
dependent suppression of serum TNF-α levels (Figure 3.3). 
 The exact mechanisms of CORM-3-derived protection/anti-inflammatory 
effects in our CS model are, at the moment, unknown. However, given the 
complex and multi-component nature of CS pathophysiology (ischemic episode, 
oxidative stress, cytokine production, local and systemic responses), it is 
plausible to assume that the beneficial effects of CORM-3-derived CO are most 
likely due to its simultaneous action on multiple targets in various cell types. In 
this regard, our current findings are all in agreement with previous studies 
showing that CORM-3 is able to reduce pro-inflammatory cytokine production, 
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and, therefore, cytokine-dependent upregulation of leukocyte-endothelium 
adhesive interaction (Song, Bergstrasser et al. 2009, Vadori, Seveso et al. 2009, 
Katada, Bihari et al. 2010, Mizuguchi, Capretta et al. 2010, Bergstraesser, 
Hoeger et al. 2012). The identity of adhesion molecules expressed by the 
leukocytes and/or endothelial cells due to CS remain to be elucidated; however, 
our data (i.e. CORM-3 ability to reduce the leukocyte adhesion to post-capillary 
venule endothelium in CS-challenged animals) suggests that CORM-3 may 
directly or indirectly interfere with the expression of Ig-superfamily adhesion 
molecules (such as ICAM-1, VCAM-1, etc.) on endothelial cells. The lack of 
significant changes in leukocyte rolling in CORM-3-treated animals suggests that 
CORM-3 does not modulate expression/function of selectins (E-selectin, P-
selectin or L-selectin), molecules responsible primarily for the leukocyte rolling 
but not adhesion to the vascular endothelium per se (Ley, Laudanna et al. 2007). 
Previous studies have demonstrated that CORM-3 suppresses oxidative 
stress in vascular endothelial cells (Mizuguchi, Capretta et al. 2010), cardiac 
myocytes (Lancel, Hassoun et al. 2009) and inflammatory cells (PMN and 
macrophages) (Mizuguchi, Stephen et al. 2009); this effect may be responsible 
for our observation of CORM-3-dependent suppression of acute skeletal muscle 
cell injury during CS (Figure 3.2). In addition, CORM-3-dependents protection of 
vascular perfusion could also be attributed to the potent vasodilatory properties 
of CO (Foresti, Hammad et al. 2004), which could improve capillary flow of the 
affected tissue in the post-fasciotomy state. Previous studies have demonstrated 
	 126 
CO-dependent modulation of the blood vessel tone through the mechanisms 
involving soluble guanylate cyclase signalling (Motterlini and Otterbein 2010). 
While the results of our experiments look promising, the study is not 
without limitations. Although a rodent model of compartment syndrome has many 
benefits (it is reliable, small and cost effective), with relatively simple regulation of 
both compartment pressure and blood pressure, its limitations are equally as 
important. First we employed an absolute compartment threshold of 30 mmHg, 
which may not be as severe an insult in a human model; thus the severity of our 
rat CS model may be relatively mild compared to a full-scale CS in humans. 
Given the differences in size and metabolic parameters, rats appear to be more 
sensitive to ischemic injury (unpublished observation); however, it remains to be 
seen how the severity of CS in rats compares to that in humans. In addition, the 
timing of CORM-3 administration may have to be optimized. In our study, CORM-
3 was administered once, at fasciotomy; we did not study the effects of CORM-3 
beyond 1 hour post-administration. It is highly unlikely that one injection of 
CORM-3 would prevent CS, but it might be able to prolong the surgical window, 
in case of delayed fasciotomy. Future studies are needed to examine the effect 
of CORM-3 administration on CS injury, but without fasciotomy. Unfortunately, 
direct method of visualization of microvasculature in rats requires fasciotomy; 
thus, any future studies will have to employ indirect means of assessing the 
tissue damage (e.g. functional gait assessment). 
The potential toxicity of CORM-3 is yet to be established. While very little 
data exists on the safety of the systemic CORM-3 administration in large animals, 
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preclinical studies employing non-human primates suggest that there are few 
side effects associated with both single and repeated injections (Vadori, Seveso 
et al. 2009). In the future, CORM-3 may need to be tested in an animal more akin 
to humans. Larger animals appear to be more sensitive to the effects of CORM-3 
(Vadori, Seveso et al. 2009); thus a lower therapeutic dose may be sufficient, 
minimizing potential side effects.  
To our knowledge, this is the first study demonstrating the beneficial 
effects of carbon monoxide, delivered by a carbon-monoxide releasing molecule, 
in the treatment of acute compartment syndrome. While the exact mechanisms of 
CORM-3 protective action remain to be determined, the obtained data strongly 
indicate a potential therapeutic application of CORM-3 to patients at risk of 
developing CS. 
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CHAPTER 4 
 
SYSTEMIC ADMINISTRATION OF CARBON MONOXIDE RELEASING 
MOLECULE-3 (CORM-3) PROTECTS THE SKELETAL MUSCLE IN PORCINE 
MODEL OF COMPARTMENT SYNDROME. 
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CHAPTER 4: SYSTEMIC ADMINISTRATION OF CARBON MONOXIDE 
RELEASING MOLECULE-3 (CORM-3) PROTECTS THE 
SKELETAL MUSCLE IN PORCINE MODEL OF 
COMPARTMENT SYNDROME. 
 
 
4.1 INTRODUCTION 
Compartment syndrome (CS) is a serious and devastating complication of 
musculoskeletal trauma. CS develops as a result of an increased pressure within 
a closed osseofascial compartment, resulting in muscle-threatening and limb-
threatening ischemia (Matsen 1975, Matsen 1980, Matsen, Winquist et al. 1980, 
Hartsock, O'Farrell et al. 1998). Fasciotomy, to fully decompress all involved 
compartments, remains the only gold standard surgical treatment, but the 
surgery must be performed within a narrow window of 6-8 hours, before the 
damage to the involved tissues becomes permanent (Mubarak and Owen 1977, 
Mubarak, Owen et al. 1978, Hargens, Romine et al. 1979). 
An elevation in intra-compartmental pressure (ICP) during CS 
compromises microcirculation (Hartsock, O'Farrell et al. 1998), restricting oxygen 
and nutrient delivery to the point where metabolic demands of the tissue cannot 
be met. This results in cellular anoxia and severe tissue necrosis; however, 
unlike complete ischemia, it occurs in the face of patent vessels (Whitesides, 
Haney et al. 1975). Reperfusion of previously ischemic tissue is known to trigger 
severe inflammation, both local and systemic (Blaisdell 2002, Gillani, Cao et al. 
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2011, Lawendy, Bihari et al. 2016, Bihari, Cepinskas et al. 2017). Since CS 
appears to be a form of reperfusion injury, the contribution of inflammation to the 
pathophysiology of CS is increasingly being recognized; studies from our group 
and others have demonstrated that leukocytes appear to play a primary role in 
producing both microvascular and parenchymal damage during CS (Sadasivan, 
Carden et al. 1997, Gute, Ishida et al. 1998, Lawendy, Sanders et al. 2011, 
Lawendy, Bihari et al. 2015). The effect appears to be mediated by the release of 
pro-inflammatory cytokines, particularly TNF-α (Lawendy, Bihari et al. 2014, 
Donohoe 2015). 
Apart from fasciotomy, few therapeutic options have been shown to be 
effective, primarily due to the lack of understanding the CS pathophysiology. 
Recently, exogenous application of carbon monoxide (CO), a normal byproduct 
of heme metabolism, has been shown to be protective to microvascular perfusion 
and provide anti-inflammatory benefits during various ischemic and inflammatory 
conditions (Otterbein, Bach et al. 2000, Ott, Scott et al. 2005, Scott, Cukiernik et 
al. 2009). With the advent of development of water-soluble carbon monoxide 
releasing molecules (CO-RMs), particularly CORM-3, CO can be safely delivered 
to the tissue without significantly affecting the levels of carboxyhemoglobin 
(COHb) (Motterlini and Otterbein 2010, Lawendy, Bihari et al. 2014). 
Previously, we have demonstrated that CORM-3 application at fasciotomy 
was able to diminish the CS-associated tissue injury and leukocyte activation, as 
well as block the systemic release of pro-inflammatory cytokine TNF-α in a rat 
model of CS (Lawendy, Bihari et al. 2014). Additionally, CORM-3 was capable of 
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blocking the formation of reactive oxygen species (ROS) within the human 
endothelial cells subjected to CS stimulus in the form of serum obtained from CS 
patients (Bihari, Cepinskas et al. 2014). While the results of these studies are 
promising, preclinical testing in a large, more human-like animal model of CS has 
not been undertaken yet; in addition, the effects and mechanisms of CORM-3 on 
modulation of CS-induced skeletal muscle injury and dysfunction remain to be 
elucidated. 
The purpose of this study was to test the effect of CORM-3 on the severity 
of microvascular dysfunction, tissue injury and the activation of circulating 
leukocytes in a pre-clinical setting, using porcine model of CS. The ultimate goal 
is the development of a safe pharmacologic adjunctive treatment for 
compartment syndrome, which would reduce the morbidity and disability in 
patients. 
 
 
4.2 MATERIALS AND METHODS 
4.2.1 Animal Preparation 
The experimental protocol was approved by the Animal Use 
Subcommittee of the Council on Animal Care at the University of Western 
Ontario. Male Yorkshire-Landrace pigs, body weight 49-60kg, were used for all 
experiments. Anesthesia was induced by TKX (0.5mg/kg telazol, 0.5mg/kg 
ketamine, 0.5mg/kg xylazine) injection. Animals were then intubated (ETT 6.5-
8.0) and switched to mechanical ventilation (14-20 breaths/min) under 
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inhalational isoflurane (1.5-3% maintenance) in 100% oxygen for the remainder 
of the experiment. End-tidal CO2, heart rate, oxygen saturation and arterial blood 
gases were continuously monitored. 
Left femoral artery was cannulated percutaneously, using 6F introducer 
(Medtronic), for the invasive blood pressure monitoring and arterial blood 
sampling. A 24-gauge IV catheter (BD Insyte) was placed in the right auricular 
vein for continuous fluid replacement and intravenous drug administration. Body 
temperature was continuously monitored and kept at 38.0-38.5°C by BairHugger 
thermal blanket. 
Compartment pressure monitoring probe (Synthes, Westchester PA) was 
inserted into the anterior compartment via gauge 16 angiocatheter (BD) of the pig 
right hind limb; a gauge 16 needle (BD) attached to an IV line was also inserted 
into the subfascial plane within the same compartment. The limb was then placed 
in a plaster cast. CS was induced by an infusion of isotonic saline enriched with 
0.4g/L bovine serum albumin, leading to an elevation of intra-compartmental 
pressure (ICP) to 40-65 mmHg. Elevated ICP was maintained for 6 hours. A 
single-incision fasciotomy was performed to decompress the hind limb 
compartments; the muscles were allowed to reperfuse for 3 hours, followed by 
imaging of the microvascular perfusion of tibialis anterior (TA) and peroneus 
tertius (PT) muscles with a hand-held Cytoscan microscope equipped with 
orthogonal polarization spectroscopy (OPS) (Cytometrics). 
Thirty minutes prior to OPS imaging, animals were injected intravenously 
with 50µg/kg each of the fluorescent vital dyes ethidium bromide (EB; exc. 
	 136 
482nm, em. 616nm), bisbenzimide (BB; exc. 343nm, em. 483nm) and 
carboxyfluorescein-labelled in vivo marker of apoptosis (FLIVO, 
ImmunoChemistry Technologies; exc. 492nm, em. 517nm). Following the OPS 
microscopy, TA and PT muscles were excised and fixed in 10% formalin for 
further analysis. Pigs were then euthanized by an overdose of anesthetic agent. 
 
4.2.2 CORM-3 
A water-soluble CORM-3 (tricarbonylchloro-glycinate-ruthenium(II), 
[Ru(CO)3Cl-glycinate]; molecular weight 295gmol-1), an equimolar CO donor, was 
synthesized by us (Mizuguchi, Stephen et al. 2009), in accordance with a 
previously-published method (Clark, Naughton et al. 2003). CORM-3 (10mg/ml 
stock solution) was prepared fresh by dissolving CORM-3 in isotonic saline just 
prior to injection. CO release from CORM-3 was confirmed 
spectrophotometrically, by conversion of deoxy-myoglobin to 
carbonmonoxymyoglobin. As a control, inactive CORM-3 (iCORM-3) was 
generated by dissolving CORM-3 in saline 72 hours prior to the experiment and 
allowing it to release all CO from the solution (lack of CO release was confirmed 
by myoglobin-binding assay) (Clark, Naughton et al. 2003, Lawendy, Bihari et al. 
2014). 
 
4.2.3 Experimental Design 
Following induction of anesthesia, intubation and placement of all 
catheters, animals were randomly assigned into one of the three experimental 
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groups: Sham (n=4), CS+CORM-3 (n=4) and CS+iCORM-3 (n=4). CO-releasing 
molecule-3 (CORM-3), or its inactive form (iCORM-3), was administered to 
animals undergoing CS upon fasciotomy at the dose of 2mg/kg, IV.  
Sham animals underwent all procedures, but the compartment pressure 
was maintained at the baseline level (0mmHg). In addition, the contralateral limb 
of each animal used in these experiments served as a control; it underwent all 
the procedures as the experimental limb, but did not receive saline infusion into 
the anterior compartment, and the ICP was maintained at the baseline level 
(0mmHg). 
 
4.2.4 OPS Imaging 
The hand-held objective of Cytoscan OPS microscope (Cytometrics, 
Devon, UK) was applied to the surface of the exposed TA and/or PT muscle, 
recording microvascular perfusion using epi-illumination with green polarized light 
at 10x objective, in five to ten adjacent fields of view. The microcirculation was 
recorded with a digital recorder (Sony) and stored on DV tapes for offline 
analysis. 
 
4.2.4.1 Offline Video Analysis 
Capillary perfusion was assessed by counting the number of continuously-
perfused (CPC), intermittently-perfused (IPC) and non-perfused (NPC) capillaries 
that crossed three parallel lines drawn perpendicular to the capillary axis on the 
video monitor, and was expressed as % of total capillaries. 
	 138 
4.2.5 Tissue Leukocyte Infiltration and Necrosis 
Following formalin fixation, TA and PT samples were processed and 
embedded in paraffin; 5µm sections were cut with a microtome. Sections were 
put on poly-L slides, cleared in xylene, rehydrated with graded alcohols and then 
subjected to a standard H&E staining protocol. 
Levels of tissue leukocyte infiltration and tissue necrosis were assessed 
semi-quantitatively, by a blinded pathologist, Dr. Lee Ang of London Health 
Sciences Centre, in 5 adjacent fields of view in each muscle sample using 
conventional light microscopy. Histopathology grading scale ranged from 0 (no 
leukocyte infiltration, no necrosis, i.e. normal tissue) to 3 (severe leukocyte 
infiltration and/or severe tissue necrosis) (Table 4.1). 
 
4.2.6 Tissue Injury and Apoptosis 
Paraffin-embedded 5µm sections were cut with a microtome. Sections 
were put on poly-L slides, cleared in xylene, rehydrated with graded alcohols and 
mounted with Vectashield fluorescence mounting medium. 
Levels of tissue injury (EB/BB) and apoptosis (FLIVO/BB) were quantified 
using conventional fluorescence microscopy. EB stains the nuclei of only those 
cells with damaged cell membrane, while BB stains the nuclei of all cells. FLIVO, 
a non-toxic marker, stains only the cells with apoptosis-associated caspases 
activation. Thus, EB/BB and FLIVO/BB ratios provided an index of tissue injury 
and apoptosis, respectively. 
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Table 4.1. Histopathology grading scale for skeletal muscle tissue 
leukocyte infiltration and necrosis in porcine model of CS. 
Four grades were assigned by a blinded pathologist (Dr Lee Ang at 
London Health Sciences Centre) to both leukocyte infiltration and 
tissue necrosis, with 0 representing normal tissue and 3 
corresponding to severe fiber necrosis and/or leukocyte infiltration. 
 
 
 
 
 
Grade 
 
Muscle Leukocyte Infiltration 
 
Muscle Necrosis 
 
 
0 
 
 
Normal, no infiltration 
 
Normal, no necrosis 
 
1 
 
 
Mild 
 
Mild 
 
2 
 
 
Moderate 
 
Moderate 
 
3 
 
 
Severe 
 
Severe 	
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4.2.7 Systemic Leukocyte Isolation and Activation Assay 
Systemic leukocyte activation was measured in arterial blood samples 
drawn at 16 time points: (1) baseline, (2) 1 hour into CS, (3) 2 hours into CS, (4) 
3 hours into CS, (5) 4 hours into CS, (6) 5 hours into CS, (7) 6 hours into CS – 
just prior to fasciotomy and CORM-3 (or iCORM-3) injection, (8) 20 minutes post-
fasciotomy, (9) 40 minutes post-fasciotomy, (10) 60 minutes post fasciotomy, 
(11) 75 minutes post-fasciotomy, (12) 90 minutes post-fasciotomy, (13) 105 
minutes post-fasciotomy, (14) 2 hours post-fasciotomy, (15) 2.5 hours post-
fasciotomy, (16) 3 hours post-fasciotomy – just before OPS imaging. 
Polymorphonuclear (PMN) leukocytes were isolated by density gradient 
centrifugation (Histopaque-1077, Sigma), as previously described by us 
(Mizuguchi, Stephen et al. 2009), followed by the lysing of red blood cells 
(ammonium chloride solution). Isolated leukocytes were reconstituted in 0.1M 
phosphate buffer saline, pH 7.4, adjusting the buffer volume to achieve the final 
cell count of 1x109 leukocytes/ml. Leukocyte activation (i.e. superoxide (O2-) 
production) was assessed by L-012 assay, and expressed as relative 
luminescence units (RLU)/106 PMN. 
 
4.2.8 Serum Tumor Necrosis Factor Alpha (TNF-α) Measurements 
TNF-α levels in arterial blood samples were assessed using enzyme-
linked immunosorbent assay (ELISA, Pierce Biotechnology, c/o Thermo Scientific, 
Rockford, IL) according to manufacturer’s instructions. The TNF-α detection limit 
was 5pg/mL. 
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4.2.9 Statistical Analysis 
All parameters were expressed as mean ± SEM and analyzed using one-
way ANOVA, repeated measures two-way ANOVA (systemic leukocyte activation, 
serum TNF-α), or Kruskal-Wallis test (histopathology scores), with Bonferroni or 
Dunn’s post-hoc test as appropriate (GraphPad Prism 6.0 for Mac). Sample size 
calculation was performed using StatMate (GraphPad Software Inc., San Diego, 
CA), with power set at 85%. p<0.05 was considered statistically significant. 
 
 
4.3 RESULTS 
4.3.1 Systemic Leukocyte Count and COHb 
Elevation of ICP, coupled with subsequent fasciotomy and 3 hours of 
reperfusion led to a significant rise in leukocyte count; CORM-3 treatment was 
able to decrease the severity of the response (Table 4.2). Importantly, application 
of CORM-3 or iCORM-3 had no effect on COHb levels (Table 4.2). 
 
4.3.2 Organ Function 
4.3.2.1 Liver Enzymes 
 Elevation of ICP led to a significant increase in aspartate transaminase 
(AST), from 25.0±2.0U/L to 88.5±43.5U/L (p<0.05), and alkaline phosphatase 
(ALP) (208.5±27.5U/L versus 107.5±16.5U/L in sham), while having no effect on 
alanine transaminase (ALT) or bilirubin (Table 4.2). Systemic administration of 
CORM-3 resulted in  a  significant  decrease in  AST to 41.5±1.2U/L (p<0.05) and 
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Table 4.2. The effect of CORM-3 on hematological and biochemical 
parameters in porcine model of CS. CORM-3 at fasciotomy led to 
a significant decrease in systemic leukocytes and creatinine levels 
(*p<0.05 from sham and/or baseline, †p<0.05 from CS+iCORM-3) 
  
Sham 
 
CS+iCORM-3 
 
 
CS+CORM-3 
 
LKC (Units x109/L) 
 
 
12.9 ± 1.9 
 
20.2 ± 5.4* 
 
8.1 ± 0.5† 
 
Hemoglobin (g/L) 
 
 
98.5 ± 7.5 
 
97.3 ± 2.8 
 
100.3 ± 2.3 
 
COHb (%) 
 
 
2.7 ± 0.1 
 
2.0 ± 0.7 
 
2.1 ± 0.5 
 
Urea (mM) 
 
 
6.0 ± 0.4 
 
17.4 ± 4.4* 
 
8.6 ± 0.6† 
 
Creatinine (mM) 
 
 
109.0 ± 1.0 
 
191.5 ± 5.5* 
 
128.5 ± 2.0† 
 
Bilirubin (mM) 
• Total 
• Direct 
 
 
 
2.5 ± 0.1 
0.9 ± 0.1 
 
 
3.7 ± 0.5 
2.1 ± 0.5 
 
 
4.6 ± 0.9 
1.7 ± 0.3 
 
ALT (U/L) 
 
 
36.5 ± 0.5 
 
32.5 ± 3.5 
 
30.0 ± 2.9 
 
AST (U/L) 
 
 
25.0 ± 2.0 
 
88.5 ± 43.5* 
 
41.5 ± 1.2† 
 
ALP (U/L) 
 
 
107.5 ± 16.5 
 
208.5 ± 27.5* 
 
171.0 ± 13.5† 
 
Lactate (mM) 
• Baseline 
• 6hr CS 
• Final 
 
 
0.44 ± 0.04 
0.50 ± 0.16 
0.54 ± 0.11 
 
 
 
0.43 ± 0.18 
1.60 ± 0.08* 
3.07 ± 1.26* 
 
 
0.40 ± 0.08 
0.97 ± 0.23*† 
1.93 ± 0.36*† 
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ALP to 171.0±13.5U/L. No changes were observed in ALT or bilirubin due to 
CORM-3 administration. 
 
4.3.2.2 Kidney 
 Elevation of ICP led to a significant increase in blood urea and creatinine 
levels, from 6.0±0.4mM and 109.0±1.0mM, respectively, in sham to 17.4±4.4mM 
and 191.5±5.5mM, respectively in CS (p<0.05). Systemic administration of 
CORM-3 at fasciotomy resulted in a significant decrease of both blood urea and 
creatinine, to 8.6±0.6mM and 128.5±2.0mM, respectively (Table 4.2). 
 
4.3.2.3 Skeletal Muscle - Lactate 
 Elevation of ICP resulted in a significant increase in systemic lactate levels, 
from 0.43±0.18µmol/L at baseline, to 1.60±0.08µmol/L at 6hr CS (p<0.05). 
Following reperfusion, lactate levels rose to 3.07±1.26µmol/L, while in sham 
animals they remained unchanged from the baseline for the duration of the 
experiment. 
 Administration of CORM-3 at fasciotomy resulted in significant decrease of 
lactate levels measured at the conclusion of the experiment, to 1.93±0.36µmol/L 
(p<0.05) (Table 4.2). 
 
4.3.3 Systemic Leukocyte Activation and TNF-α Levels 
Elevation of ICP led to a progressive increase in systemic leukocyte 
activation, from the baseline of 1.0±0.0 RLU/106 PMNs to 1.4±2.0 RLU/106 PMNs, 
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4.1±2.1 RLU/106 PMNs, 6.2±2.9 RLU/106 PMNs, 13.5±6.3 RLU/106 PMNs, 
16.5±7.9 RLU/106 PMNs and 14.7±5.7 RLU/106 PMNs at 1hr, 2hr, 3hr, 4hr, 5hr 
and 6hr, respectively (Figure 4.1A). Fasciotomy resulted in a transient decrease 
in leukocyte activation to 8.8±2.4 RLU/106 PMNs, followed by gradual 
progressive increase to 7.5±4.7 RLU/106 PMNs, 10.2±6.0 RLU/106 PMNs, 
11.2±5.8 RLU/106 PMNs, 15.2±3.3 RLU/106 PMNs, 16.5±1.0 RLU/106 PMNs, 
21.1±1.1 RLU/106 PMNs, 22.9±4.4 RLU/106 PMNs and 38.1±11.3 RLU/106 
PMNs at 20min, 40min, 60min, 75min, 90min, 105min, 120min, 150min and 
180min, respectively (p<0.05). Application of CORM-3 at fasciotomy decreased 
leukocyte activation to 5.5±2.5 RLU/106 PMNs, 6.3±2.9 RLU/106 PMNs, 6.0±3.4 
RLU/106 PMNs, 6.3±3.5 RLU/106 PMNs, 6.2±3.1 RLU/106 PMNs, 6.9±3.8 
RLU/106 PMNs, 7.4±3.2 RLU/106 PMNs, 10.4±5.5 RLU/106 PMNs and 11.1±5.8 
RLU/106 PMNs at 20min, 40min, 60min, 75min, 90min, 105min, 120min, 150min 
and 180min, respectively (p<0.05 from CS control group) (Figure 4.1B). 
Elevation of ICP led to a progressive increase in systemic levels of pro-
inflammatory cytokine TNF-α, from the baseline level of 8.9±5.8pg/ml to 
14.6±7.1pg/ml, 20.8±8.2pg/ml, 30.9±7.8pg/ml, 48.7±5.0pg/ml, 72.5±11.9pg/ml 
and 99.2±22.1pg/ml at 1hr, 2hr, 3hr, 4hr, 5hr and 6hr, respectively (Figure 4.2A). 
Following fasciotomy, TNF-α levels continued to rise to 117.9±31.9pg/ml, 
147.6±41.6pg/ml, 164.6±38.5pg/ml, 196.7±55.6pg/ml, 211.6±56.9pg/ml, 
164.0±50.1pg/ml, 184.1±68.3pg/ml, 208.2±65.5pg/ml and 251.2±47.3pg/ml at 
20min, 40min, 60min, 75min, 90min, 105min, 120min, 150min and 180min, 
respectively. Application of CORM-3 (but not iCORM-3) at fasciotomy completely   
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Figure 4.1. The effect of CORM-3 on systemic leukocyte activation in 
porcine model of CS. Elevated ICP resulted in (A) a progressive 
increase in leukocyte (PMN) activation, as assessed by O2- 
production; (B) fasciotomy resulted in a further circulating PMN 
activation, which was prevented by CORM-3 treatment; (repeated 
measures ANOVA; *p<0.001 from PRE, †p<0.05 from iCORM-3). 
PRE, pre-CS (i.e. baseline).  
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blocked the systemic TNF-α production by 20min reperfusion and for the 
remainder of the experiment (p<0.05) (Figure 4.2B). 
 
4.3.4 Microvascular Perfusion 
Six hours of elevated ICP, followed by fasciotomy and 3 hours of 
reperfusion resulted in 44±1% CPC versus 76±4% in sham (p<0.001) and 39±3% 
NPC in CS versus 13±2% in sham (p<0.001) (Figure 4.3). Application of CORM-
3 (but not iCORM-3) at fasciotomy partially restored the microvascular perfusion 
to 68±3% CPC (p<0.001) and 25±3% NPC (p<0.05), while having no effect on 
the perfusion of the control limb (data not shown). 
 
4.3.5 Tissue Injury and Apoptosis 
Six hours of elevated ICP, coupled with fasciotomy and 3 hours of 
reperfusion resulted in EB/BB tissue injury index of 0.31±0.07 in CS versus 
0.17±0.03 in sham (p<0.05) (Figure 4.4A), and FLIVO/BB apoptosis index of 
0.26±0.06 in CS versus 0.13±0.03 in sham (p<0.05) (Figure 4.4B). 
Systemic application of CORM-3 at fasciotomy resulted in EB/BB tissue 
injury index of 0.13±0.04 (p<0.05 from CS+iCORM-3) and FLIVO/BB apoptosis 
index of 0.12±0.03 (p<0.05 from CS+iCORM-3), while having no effect on the 
control limb (Figure 4.4). 
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Figure 4.2. The effect of CORM-3 on serum TNF-α levels in porcine model 
of CS. (A) Elevated ICP resulted in a progressive increase in 
systemic TNF-α; (B) fasciotomy further upregulated circulating 
levels of TNF-α, which was effectively prevented by CORM-3 
treatment (repeated measures ANOVA; *p<0.001 from PRE; 
†p<0.001 from CS+iCORM-3). 
 PRE, pre-CS (i.e. baseline).  
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Figure 4.3. The effect of CORM-3 on skeletal muscle perfusion in porcine 
model of CS. Six hours of elevated ICP, coupled with fasciotomy 
and 3 hours of reperfusion resulted in severe microvascular 
perfusion deficit (indicated by a decreased number of CPC and an 
increased number of NPC); CORM-3 effectively reversed the 
microvascular perfusion deficit (one-way ANOVA; *p<0.05 from 
control, †p<0.05 from CS+iCORM-3; see the text for additional 
details).  
	 149 
Sham CS+iCORM-3 CS+CORM-3
0.0
0.1
0.2
0.3
0.4
*
†
Ti
ss
ue
 A
po
pt
os
is
 (F
LI
VO
/B
B
)
Sham CS+iCORM-3 CS+CORM-3
0.0
0.1
0.2
0.3
0.4
*
†
Ti
ss
ue
 In
ju
ry
 (E
B
/B
B
)
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Figure 4.4. The effect of CORM-3 on skeletal muscle (A) tissue injury and 
(B) apoptosis in porcine model of CS. Six hours of elevated ICP, 
coupled with fasciotomy and 3 hours of reperfusion resulted in a 
significant increase in both (A) tissue injury and (B) apoptosis; the 
phenomenon was completely blocked by CORM-3 treatment (one-
way ANOVA; *p<0.05 from control, †p<0.05 from CS+iCORM-3).  
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4.3.6 Tissue Leukocyte Infiltration and Necrosis 
Elevation of ICP led to a histopathology leukocyte infiltration score of 2.5 
(moderate to severe) versus 0 (none) in sham and control (p<0.05). Systemic 
administration of CORM-3 at fasciotomy resulted in a significant decrease of 
leukocyte infiltration to 1.5 (mild to moderate) within the skeletal muscle (Figure 
4.5). 
Elevation of ICP produced a histopathology tissue necrosis score of 2 
(moderate) versus 0 (none) in contralateral limb and/or sham muscle (p<0.05). 
Systemic administration of CORM-3 at fasciotomy resulted in necrosis 
histological score of 1 (mild) within the skeletal muscle (p<0.05) (Figure 4.5). 
 
 
4.4  DISCUSSION 
Acute CS remains a challenging problem in the field of traumatology, not 
the least because the pathophysiology behind the CS injury is not well 
understood. Despite ongoing research, fasciotomy and supportive therapy to 
prevent other systemic sequelae during the recovery period remain the only gold-
standard treatment choices of CS (McQueen, Gaston et al. 2000, Cascio, 
Pateder et al. 2005, Mithoefer, Lhowe et al. 2006, Ritenour, Dorlac et al. 2008, 
Farber, Tan et al. 2011, Dover, Memon et al. 2012). 
In the current study, we demonstrated for the first time an improvement in 
skeletal muscle microvascular perfusion, inhibition of inflammation (both systemic 
and local) and attenuation  of  tissue  injury, as well as apoptosis, by the systemic  
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Figure 4.5. The effect of CORM-3 on skeletal muscle tissue necrosis and 
leukocyte infiltration in porcine model of CS. Six hours of 
elevated ICP, coupled with fasciotomy and 3 hours of reperfusion 
resulted in a significant increase in leukocyte infiltration (open bars) 
and tissue necrosis (solid bars) in skeletal muscle; CORM-3 
treatment significantly reduced both leukocyte infiltration and tissue 
necrosis (Kruskall-Wallis ANOVA; *p<0.01 from sham, †p<0.05 
from CS+iCORM-3). 
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administration of carbon monoxide (derived from a water-soluble CO donor, 
CORM-3) in a pre-clinical setting in a large animal model of CS. 
CO, a gaseous signalling molecule produced endogenously, as a 
byproduct of heme degradation pathway (Ryter, Otterbein et al. 2002), has been 
shown to exhibit vasodilatory, anti-apoptotic and anti-inflammatory effects in 
various animal models (Motterlini and Otterbein 2010, Lawendy, Bihari et al. 
2014). Nevertheless, therapeutic administration of CO via inhalation is hampered 
by the production of COHb, limiting its clinical applicability. It has been shown 
previously that, despite some beneficial effects, CO inhalation in humans 
(500ppm for 1 hour) increased COHb in the range of 1.2-7% (Mayr, Spiel et al. 
2005). Similar findings were obtained from in vivo animal models, where COHb 
of 5-6% were obtained (Ott, Scott et al. 2005), some even reaching 15-25% 
(Fujita, Toda et al. 2001), depending on the experimental conditions. 
Recently, transitional metal carbonyls, CO-RMs, have been developed as 
means of CO delivery in biological systems, with minimal or no effect on COHb 
formation (Clark, Naughton et al. 2003, Guo, Stein et al. 2004, Katada, Bihari et 
al. 2010, Lawendy, Bihari et al. 2014), making them potential candidates for 
therapeutic agents. Availability of water-soluble CO-RMs capable of liberating 
CO under physiological conditions makes their use even more attractive, due to 
the ease of application and no production of toxic levels of COHb (Lawendy, 
Bihari et al. 2014) (Table 4.1). In this regard, CO-RM-mediated protection against 
ischemia-reperfusion-induced injury to the heart (Clark, Naughton et al. 2003, 
Guo, Stein et al. 2004), kidney (Caumartin, Stephen et al. 2011), liver (Wei, Chen 
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et al. 2010) and intestine (Katada, Bihari et al. 2010), as well as the efficacy of 
CO-RMs to suppress severe systemic inflammatory conditions (e.g. sepsis) have 
been demonstrated (Mizuguchi, Stephen et al. 2009, Katada, Bihari et al. 2010). 
Continuous perfusion is required in order to provide nutrients and oxygen 
to all tissues. CS has been shown to lead to a hypo-perfusion state within the 
affected compartment(s), to a point where the metabolic demands of the tissue 
cannot be met. This generates tissue ischemia, albeit a reduced-flow (rather than 
a complete) one (Blaisdell 2002, Lawendy, Sanders et al. 2011). Additionally, 
because not all microcirculation is shut down, a degree of reperfusion happens at 
the same time, producing a reperfusion injury concurrent with ischemia; this 
appears to be even more damaging than a complete ischemia itself (Better, 
Abassi et al. 1990, Gute, Ishida et al. 1998). Ischemia-reperfusion injury is 
comprised of a complex chain of events, leading to upregulation of the pro-
inflammatory phenotype, and subsequent inflammatory interactions between the 
vascular endothelial cells, cells of the interstitium (e.g. fibroblasts, myofibroblasts, 
smooth muscle cells) and circulating cells (leukocytes). In turn, this leads to 
impaired vascular cell integrity, increased vascular permeability, and formation of 
edema (Sabido, Milazzo et al. 1994, Gute, Ishida et al. 1998, Hua, Al-Badawi et 
al. 2005). As a result, the ensuing increased interstitial pressure compresses 
adjacent capillaries, diminishing the continuous perfusion and increasing the 
degree of non-perfusion. The temporal changes in microvascular perfusion (i.e. 
the no-reflow phenomenon) appear to be caused not just by passive alterations 
in external pressure caused by edema, but also spastic changes in the 
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vasculature, leading to vasoconstriction (Nanobashvili, Neumayer et al. 2003). 
The non-perfused capillaries potentiate further damage by contributing to the 
endothelial cell swelling, capillary narrowing due to edema and increased 
intravascular blood viscosity from hemoconcentration (Tuma, Durian et al. 2008). 
An increase of non-perfused capillaries from those being continuously 
perfused is a characteristic response of microvasculature to CS. In the current 
study, animals treated with CORM-3 had shown significant improvement in 
capillary perfusion, restoring the number of continuously-perfused capillaries, to a 
level well above that of the CS group (Figure 4.3). Thus, the exogenously applied 
CO, in the form of CORM-3, appeared to provide a significant protection in the 
maintenance of skeletal muscle blood flow. While it is unlikely that CORM-3-
derived CO would have directly prevented ischemia-reperfusion-induced 
formation of edema, the potent vasodilatory properties of CO (mediated by 
soluble guanylate cyclase) (Foresti, Hammad et al. 2004) could explain the 
diminished spasticity of the microvasculature, resulting in the decreased severity 
of the no-reflow phenomenon and improved capillary flow of the affected tissue in 
the post-fasciotomy state (Motterlini and Otterbein 2010). 
The parenchymal damage seen in CS appears to be associated, at least 
in part, with the direct microvascular dysfunction (resulting in severe hypoxia), 
and subsequent inflammation (recruitment of PMN and generation of oxidative 
stress) (Forbes, Carson et al. 1995, Gute, Ishida et al. 1998) that leads to the 
depletion of tissue ATP and initiation of tissue necrosis (Lindsay, Liauw et al. 
1990). In our experiments, CS resulted in severe tissue injury, necrosis, tissue 
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and apoptosis within the muscle; all markers of tissue injury and dysfunction 
were significantly diminished in CORM-3-treated animals, suggesting a 
substantial protective role of exogenously applied CO (Figure 4.4 and Figure 4.5). 
The tissue protective effects of CORM-3 may be attributed, at least in part, 
to its ability to interfere with the levels of oxidative stress in vascular endothelial 
cells (Mizuguchi, Capretta et al. 2010), cardiac myocytes (Lancel, Montaigne et 
al. 2012), and inflammatory cells (PMN, macrophages) (Sawle, Foresti et al. 
2005, Mizuguchi, Stephen et al. 2009). While CO and CORM-3 (as well as other 
CO-RMs) may not act as free radical scavengers themselves, they may suppress 
the oxidative stress by interfering with the activity of heme-containing redox 
enzymes (e.g. cytochrome c oxidase, NADPH oxidase, etc.) (Kajimura, Fukuda 
et al. 2010). CORM-3 appears to be a potent inhibitor of myeloperoxidase activity 
(a PMN-derived enzyme responsible for the production of both hydrogen 
peroxide and hypochlorous acid – two of the most potent oxidizers in biological 
systems) (Patterson, Fraser et al. 2014), thus it may suppress/inhibit leukocyte 
(i.e. PMN)-induced oxidative damage/dysfunction to the vascular endothelium 
and interstitial cells. 
Production of the pro-inflammatory cytokines within the tissue(s) and in 
the circulation, and a subsequent activation of leukocytes are considered key 
events contributing to induction/amplification of the inflammatory response under 
various conditions, including CS (Forbes, Harris et al. 1996, Sadasivan, Carden 
et al. 1997, Hua, Al-Badawi et al. 2005, Galasso, Schiekofer et al. 2014, 
Lawendy, Bihari et al. 2014, Lawendy, Bihari et al. 2016, Bihari, Cepinskas et al. 
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2017). It is well accepted that the production of acute-phase inflammation-
relevant cytokines/chemokines (e.g. TNF-α, IL-1β, IL-6, IL-8) leads to PMN 
activation and recruitment into inflamed tissues (Gute, Ishida et al. 1998). 
Activated leukocytes, through the induction of oxidative and proteolytic stress, 
impair surrounding cell viability (Toyokuni 1999), and thus contribute to the tissue 
injury, dysfunction and a subsequent development of systemic inflammation and 
remote organ injury (Brock, Lawlor et al. 1999).  
In our study, we observed a marked increase in the levels of circulating 
TNF-α (one of the most potent pro-inflammatory cytokines) in animals 
undergoing CS, particularly post-fasciotomy. This was associated with 
overwhelming systemic leukocyte activation, as well as leukocyte 
recruitment/infiltration within the CS-challenged muscle. Additionally, the effects 
could also be noticed in the diminished function of other organs, particularly the 
kidney and liver. Interestingly, the increase in tissue leukocyte infiltration was 
significantly diminished in animals treated with CORM-3, but not its inactive 
counterpart, iCORM-3. It is important to note that the decrease in leukocyte 
recruitment to CS-challenged muscle correlated with the CORM-3-dependent 
suppression of serum TNF-α and leukocyte activation in circulation (Figures 4.1 
and 4.2). These findings are in line with our previous studies indicating that 
leukopenia diminished the degree of CS-associated tissue injury in a rodent 
model of CS (Lawendy, Bihari et al. 2015). 
While the exact mechanism(s) of CORM-3-induced protective/anti-
inflammatory effects are yet not completely understood, given the complex and 
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multi-component nature of CS pathophysiology (ischemic episode, oxidative 
stress, cytokine production, local and systemic responses), it is plausible to 
assume that the beneficial effects of the systemically administered CORM-3 may 
be related to the ability of CO to act simultaneously on multiple cellular and 
molecular targets (Otterbein, Bach et al. 2000, Ryter, Otterbein et al. 2002, 
Kajimura, Fukuda et al. 2010, Motterlini, Haas et al. 2012).  Our current findings 
are in agreement with previous studies demonstrating CO-RM-dependent 
suppression of both vascular endothelial cell and leukocyte pro-adhesive 
phenotypes (e.g. reduced expression of adhesion molecules ICAM-1, VCAM-1, 
E-selectin, CD11b, L-selectin), and subsequent reduction/prevention of 
leukocyte-endothelium adhesive interaction (Urquhart, Rosignoli et al. 2007, 
Cepinskas, Katada et al. 2008, Mizuguchi, Stephen et al. 2009, Song, 
Bergstrasser et al. 2009, Vadori, Seveso et al. 2009, Mizuguchi, Capretta et al. 
2010, Bergstraesser, Hoeger et al. 2012). As leukocytes are a significant 
contributor to tissue damage, any inhibition of leukocyte activation and/or 
reduced recruitment of these cells to the tissue(s) would reduce the magnitude of 
leukocyte-induced tissue injury and dysfunction (Patterson, Fraser et al. 2014). 
Whether CORM-3 preferentially interferes with the inflammatory activation of 
leukocyte or vascular endothelial cell (or both) in the model of limb CS used in 
this study remains to be determined. 
While the results of our study are novel and look promising, there are 
some limitations that need to be addressed. First, we used only a single 
concentration of CORM-3 and a single route of administration (i.e. IV). Different 
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dosage, frequency, and alternative routes of CORM-3 administration (e.g. 
topical) may provide different dynamics of CORM-3-dependent protection. 
Second, despite the fact that CO-RMs (e.g. CORM-3) used at micromolar 
concentrations show no cytotoxic effects in cultured vascular endothelial cells 
and PMN (data not shown), the potential toxicity of various concentrations of 
CORM-3 in vivo is yet to be determined. Very little data exists on the safety of the 
systemic CORM-3 administration in large animals, although preclinical studies 
employing non-human primates suggest that there are few side effects 
associated with both single and repeated injections (Vadori, Seveso et al. 2009). 
As larger animals appear to be more sensitive to the effects of CORM-3 (Vadori, 
Seveso et al. 2009, Lawendy, Bihari et al. 2014) (for example, rats required 10 
times the dose necessary to elicit a response in a pig), a lower therapeutic dose 
may be sufficient if this substance is to be used in humans, thus minimizing 
potential side effects. In support to the above, our previously published study 
using rodent model of CS (Lawendy, Bihari et al. 2014) and data presented in the 
current study indicate that, at concentrations that offer potent protective/anti-
inflammatory effects, CORM-3 does not appear to be harmful with respect to 
hepatotoxicity and formation of toxic levels of COHb (Table 4.2). 
 In summary, this is the first study demonstrating the beneficial effects of 
CORM-3-derived CO as a therapeutic agent capable of mitigating the extent of 
acute CS-induced microvascular dysfunction in the skeletal muscle in a large 
animal model of CS. Our findings indicate that CORM-3 offers strong 
protective/anti-inflammatory effects by diminishing the post-fasciotomy tissue 
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injury to the skeletal muscle, and thus may potentially be used as a 
pharmacological adjunct therapy to fasciotomy. 
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CHAPTER 5: CARBON MONOXIDE-RELEASING MOLECULE-3 (CORM-3) 
OFFERS PROTECTION IN AN IN VITRO MODEL OF 
COMPARTMENT SYNDROME. 
 
 
5.1 INTRODUCTION 
Compartment syndrome (CS) is a devastating complication of 
musculoskeletal trauma. CS develops when the pressure within the closed 
osseofascial compartment rises, producing muscle-threatening and limb-
threatening ischemia (Whitesides, Haney et al. 1975, Matsen 1980, Mubarak and 
Hargens 1983, McQueen, Christie et al. 1996). Fasciotomy, to fully decompress 
all affected compartments, remains the only gold-standard surgical therapy 
(Eaton and Green 1972, Rorabeck 1984), but the procedure must be carried out 
within 6-8 hours of CS onset, before the damage to the affected limb becomes 
permanent. 
An increase in extremity compartmental pressure during CS compromises 
microcirculatory perfusion, thus restricting oxygen and nutrient delivery to vital 
tissues, resulting in cellular anoxia and severe tissue necrosis (Whitesides, 
Haney et al. 1975, Hargens, Schmidt et al. 1981, Matsen and Rorabeck 1989). 
Unlike complete ischemia, CS causes myonecrosis in the face of patent vessels.  
As such, the pathologic contribution of inflammation to the pathophysiology of CS 
is being increasingly recognized; studies from our group (Lawendy, Sanders et al. 
2011, Lawendy, Bihari et al. 2015) and others (Sadasivan, Carden et al. 1997, 
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Kalns, Cox et al. 2011) have broadly implicated leukocytes as playing a primary 
role in both microvascular and parenchymal injury during CS. 
Few therapeutic options have been shown to be effective. Recently, 
carbon monoxide (CO), a byproduct of heme oxygenase (HO) activity, has been 
shown to offer both protection to microvascular perfusion, and anti-inflammatory 
benefits during systemic inflammation. While exogenous administration of CO via 
inhalation results in increased carboxyhemoglobin (COHb) levels (presenting a 
potential threat to the host), transitional metal carbonyls, CO-releasing molecules 
(CO-RMs) can be used to deliver CO in a controlled manner without significantly 
altering COHb (Motterlini, Clark et al. 2002, Clark, Naughton et al. 2003, 
Motterlini 2007). While most CO-RMs are only soluble in organic solvents, 
carbon monoxide releasing molecule-3 (CORM-3) is water soluble (Motterlini and 
Otterbein 2010), making it well suited to clinical applications. 
It has been demonstrated that application of CORM-3 at fasciotomy was 
able to diminish the CS-associated tissue injury and leukocyte activation, as well 
as block the systemic release of pro-inflammatory cytokine TNF-α in a rodent and 
porcine models of CS (Lawendy, Bihari et al. 2014, Bihari, Cepinskas et al. 2015). 
While the results of the animal studies look promising, CORM-3 would have to be 
thoroughly tested before being used as a therapeutic agent in human patients. 
Moreover, the actual effects and cellular mechanisms of CORM-3-derived CO 
protection still remain to be elucidated. 
The purpose of this study was to lay the foundation for the translation of 
the animal studies into human subjects: to test the effect of CORM-3-derived CO 
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on human endothelial cells. We undertook the task of developing an in vitro 
model of CS, in order to investigate the mechanisms of CORM-3-derived CO 
protection on human vascular endothelial cells. The ultimate goal is the 
development of a safe pharmacologic adjunctive treatment for compartment 
syndrome, which would reduce the morbidity and disability in patients. 
 
 
5.2 MATERIALS AND METHODS 
5.2.1 Reagents 
Medium-199 (M199), fetal bovine serum, penicillin, streptomycin and 
Dulbecco’s PBS (DPBS) (pH 7.4) were purchased from Invitrogen Canada (Life 
Technologies Inc., Burlington, ON). Dihydrorhodamine (DHR)-123 was obtained 
from Molecular Probes Inc. (Eugene, OR), and L-012 was purchased from Wako 
Pure Chemical (Osaka, Japan). Sera of CS patients (acquired at fasciotomy) 
(Appendix IV) (N=12) and healthy volunteers (N=6) were obtained from venous 
blood by whole blood coagulation and subsequent centrifugation at 1,500xg for 
20min, as per standard operating procedures (Gillio-Meina, Cepinskas et al. 
2012), and stored at -80°C until use. A water-soluble CORM-3 (tricarbonylchloro-
glycinate-ruthenium(II), [Ru(CO)3Cl-glycinate]; molecular weight 295 gmol-1) was 
synthesized by us (Mizuguchi, Stephen et al. 2009), in accordance with the 
previously-published method (Motterlini, Clark et al. 2002). CORM-3 (100µM 
stock solution) was always prepared fresh by dissolving CORM-3 in M199 just 
prior to use. Inactive CORM-3 (iCORM-3) was generated by leaving CORM-3 
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solution for 72hrs at room temperature, to liberate all CO from the molecule, as 
previously described (Clark, Naughton et al. 2003). 
 
5.2.2 Cells 
Human vascular endothelial cells (HUVECs), isolated from human 
umbilical veins by collagenase treatment (Cepinskas, Savickiene et al. 2003), 
were grown to confluence on fibronectin-coated cellware (12-well plates, 
transwell inserts with 3µm and/or 1µm diameter pores, 96-well plates and 
parallel-flow perfusion microslides). HUVECs at passages 1-3 were used for all 
of the experiments. 
Human neutrophils (PMNs) were isolated from the venous blood of 
healthy adults by 1% Dextran (Sigma, Mississauga, ON) sedimentation and 
gradient separation on Histopaque-1077 (Sigma, Mississauga, ON), as 
previously described (Kuhns, Long Priel et al. 2015). PMN viability was confirmed 
by Trypan blue dye exclusion test. 
 
5.2.3 In vitro Model of CS 
HUVECs were stimulated for 3 or 6 hours with human serum (40% v/v, 
diluted in isotonic saline) isolated from CS patients (N=12) (Appendix IV). Sera of 
healthy human volunteers (N=6) were used as a time-matched control. All 
experiments were performed in triplicate, in the presence of CORM-3 (100µM), or 
its inactive form, iCORM-3. 
 
	 170 
5.2.5 Reactive Oxygen Species (ROS) Production 
The production of ROS in HUVECs was measured by intracellular 
oxidation of DHR-123, a pan-oxidant-sensitive fluorochrome, as previously 
described (Mizuguchi, Stephen et al. 2009). HUVECs (1x106 cells), grown to 
confluence in 12-well fibronectin-coated plates, were loaded with DHR-123 
(10µM) for 45min, and then stimulated for 3 hours with CS serum or serum 
obtained from healthy volunteers, in the presence of CORM-3, or its inactive 
counterpart, iCORM-3. After stimulation, cells were washed with PBS, lysed in 
0.5% CHAPS buffer and analysed spectrofluorometrically (FR-1501 
spectrofluorometer, Shimadzu) at excitation/emission wavelengths of 495/523nm. 
Protein concentration in the cell lysate was assessed by DC protein assay 
(BioRad, Mississauga, ON). ROS production was expressed as DHR-123 
fluorescence intensity (FI) per mg protein. 
In parallel, levels of extracellular ROS production by PMNs were assessed 
using L-012, an O2--sensitive chemiluminescence probe, as previously described 
(Mizuguchi, Stephen et al. 2009). Briefly, freshly isolated PMNs (1x106 cells) 
were resuspended in 120µl DPBS containing 5.5mM glucose and 100µM L-012. 
Cells were placed in Lumitrac 96-well plates (Greiner Bio-One); subsequently, 
PMNs were stimulated in the presence of CORM-3 (or iCORM-3) by the CS 
serum or serum of healthy volunteers, continuously recording 
chemiluminescence intensity over 30 minutes at 37°C in a Victor-3 Multilabel 
plate reader (Perkin-Elmer). Superoxide production was expressed as relative 
luminescence units (RLU)/106 PMN. 
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5.2.5 Measurement of the Endothelial Monolayer Integrity 
HUVECs were grown to confluence on fibronectin-coated transwell inserts 
(1µm diameter pores) (BD Falcon). Cells were stimulated with CS serum or 
serum obtained from healthy volunteers in the presence of CORM-3 (or iCORM-
3). The integrity of the endothelial layer was assessed by measuring the trans-
endothelial electrical resistance (TEER) using EndOhm chamber method 
(EndOhm-6, World Precision Instruments) following 1hr, 3hr and 6hr serum 
exposure, and expressed as Ωcm2. Changes in TEER (ΔTEER) from the 
baseline were evaluated at each time point. 
 
5.2.6 Quantification of Apoptosis 
HUVECs grown on black fibronectin-coated 96-well plates with clear 
bottom (Greiner Bio-One) were stimulated with CS serum or serum obtained from 
healthy volunteers for 6 hours, in the presence of CORM-3 (or iCORM-3). Levels 
of the activation of active caspases were assessed by FAM-FLICA poly caspase 
apoptosis kit (Immunochemistry Technologies, LLC), as per manufacturer’s 
instructions. Briefly, cells were incubated with FAM-FLICA poly caspase reagent 
for one hour at 37°C, washed and immediately assessed for fluorescence using 
Victor-3 plate reader (Perkin-Elmer), at excitation/emission wavelengths of 
480nm/530nm. Levels of apoptosis were expressed as relative fluorescence 
units (RFU) (i.e. fluorescence intensity/104). 
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5.2.7 PMN Rolling/Adhesion Assay 
HUVECs grown on the parallel-flow perfusion microslides (µ-slide VI0.4; 
ibidi, Madison, WI) were stimulated with CS serum or serum of healthy 
volunteers for 6 hours in the presence of CORM-3 or iCORM-3. Following this, 
microslides with HUVECs were placed into an air-heated chamber (37°C) 
attached to an inverted phase-contrast microscope (Diaphot 300, Nikon). 
Following the 10min wash with M199 in the presence of CORM-3 or iCORM-3 at 
a shear stress of 1dyn/cm2 using syringe pump (Harvard Apparatus, St. Laurent, 
QC), PMNs (1x106/ml) isolated from healthy adults were added to the perfusion 
medium and the perfusion was continued for 15 minutes at the same shear 
stress. PMN-HUVECs adhesive interactions (i.e. rolling, adhesion) were captured 
in six random fields of view (10s/field) with a digital CCD camera (Sony Corp., 
Japan) connected to a computer, and analyzed offline. PMNs with velocity less 
than 100µm/s were considered “rolling”. Adhesion was defined as PMNs that 
remained stationary for at least 10s. PMN rolling/adhesion was expressed as a 
number of PMN/mm2. 
 
5.2.8 Transendothelial PMN Migration Assay 
HUVECs were grown to confluence on the apical aspect of fibronectin-
coated transwell inserts (3µm diameter pores) (BD Falcon), and stimulated with 
CS serum or serum of healthy volunteers placed in the basal compartment of the 
inserts (mimicking the interstitial aspect of the blood vessel) for 6 hours, in the 
presence of CORM-3 or iCORM-3. 
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For the PMN migration assay, 5x107 PMN/ml, isolated from healthy 
volunteers, were radiolabelled with 50µCi Na51CrO4 in PBS for 60 minutes at 
37°C (Cepinskas, Katada et al. 2008). Radiolabelled PMNs (5x105 cells/insert) 
were added to HUVEC monolayer; PMN transendothelial migration was 
assessed 60min later. PMN migration was quantified as follows: %migration = 
basal fluid (cpm)/[wash fluid (cpm)+membrane lysate (cpm)+basal fluid (cpm)]. 
The amount of radioactivity in the samples was assessed by a γ-counter (Wallac 
1480 Wizard, Turku, Finland). 
 
5.2.9 Statistical Analysis 
All parameters were expressed as means ± standard error of the mean 
(SEM), and analyzed using two-way analysis of variance (ANOVA) (GraphPad 
Prism, v. 5.0, San Diego, CA), with Bonferroni post-hoc test as needed. p<0.05 
was considered statistically significant. 
 
 
5.3 RESULTS 
5.3.1 ROS Production 
Incubation of HUVECs with 40% human CS serum induced a significant 
increase in the production of ROS within the endothelial cells, as shown in Figure 
5.1. DHR-123 fluorescence intensity increased from 644.8±114.5 FI/mg protein in 
cells treated with serum of healthy volunteers to 1059.6±56.3 FI/mg protein in CS 
serum-treated    endothelial    cells   (p<0.01).   CORM-3   treatment   completely   
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Figure 5.1. The effect of CORM-3 on the oxidative stress response in 
human vascular endothelial cells, elicited by stimulation with 
human CS serum. HUVECs were stimulated by patients’ CS 
serum for 3 hours in the presence of CORM-3 (or its inactive form, 
iCORM-3), and the levels of ROS production were assessed by 
DHR-123 assay.	CS serum-induced ROS production was reversed 
by CORM-3 application (two-way ANOVA p<0.05; *p<0.001 from 
control; †p<0.001 from CS serum+iCORM-3; N=6 per group). 
Serum of healthy patients served as a control.  
	 175 
prevented CS serum-induced ROS production (640.6±89.7 FI/mg protein versus 
1061.1±53.6 FI/mg protein in iCORM-3 group, p<0.01), while it had no effect on 
control or un-stimulated endothelial cells (Figure 5.1). 
Incubation of naïve PMNs with CS serum led to an increase in 
extracellular ROS production, as assessed by the oxidation of superoxide-
sensitive probe, L-012. Superoxide production by the CS serum-challenged 
PMNs persisted for up to 24 minutes, with the most profound increase observed 
at 2-8 minute time points after the addition of sera to PMNs (Figure 5.2). 
Superoxide production increased from 13.4±2.4 RLU/106 PMN in healthy serum-
stimulated PMNs to 36.1±5.9 RLU/106 PMN in CS-serum stimulated PMNs 
(p<0.001) (Figure 5.2). The presence of CORM-3 resulted in a significant 
decrease of superoxide production in CS-stimulated PMNs (10.1±4.6 RLU/106 
PMN, p<0.001), while having no appreciable significant effect on PMNs treated 
with the serum of healthy patients (9.0±2.7 RLU/106 PMN) (Figure 5.2). 
 
5.3.2 Transendothelial Electrical Resistance (TEER) 
 Incubation of HUVECs with CS serum produced a gradual decrease in 
TEER, from the baseline of 55.3±3.3Ωcm2 to 26.2±3.2Ωcm2 20.0±4.7Ωcm2 and 
12.2±3.2Ωcm2 at 1hr, 3hr and 6hr stimulation, respectively (Figure 5.3), resulting 
in ΔTEER of 28.0±7.0Ωcm2, 34.3±7.5Ωcm2 and 41.8±6.47.5Ωcm2, respectively, 
when compared to baseline. TEER remained virtually unchanged at 
53.7±3.2Ωcm2 in the endothelial cells treated with the serum of healthy 
volunteers  for  the duration  of  the  experiment.  CORM-3 treatment significantly   
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Figure 5.2. The effect of CORM-3 on leukocyte activation (quantified by 
the production of superoxide by PMNs), in response to 
stimulation with human CS serum. Naïve PMNs were stimulated 
with patients’ CS sera in the presence of CORM-3 (or its inactive 
form, iCORM-3), and the levels of superoxide production were 
assessed by L-012 assay.	 CS serum-associated PMN superoxide 
production was reversed by CORM-3 application (two-way 
repeated measures ANOVA p<0.05; *p<0.001 from healthy serum; 
†p<0.001 from CS serum+iCORM-3; N=10 per group). Serum of 
healthy patients served as a control.  
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Figure 5.3. The effect of CORM-3 on the integrity of human vascular 
endothelial cell monolayer following stimulation with CS 
serum. HUVECs were stimulated by patients’ CS sera for up to 6 
hours in the presence of CORM-3 (or its inactive form, iCORM-3), 
measuring transendothelial electrical resistance (TEER).	CS serum-
associated decrease in TEER was diminished by CORM-3 
application (two-way repeated measures ANOVA p<0.05; *p<0.01 
from control; †p<0.01 from CS serum+iCORM-3; N=6 per group). 
Serum of healthy patients served as a control.   
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diminished the magnitude of changes in TEER to 37.3±2.0Ωcm2, 39.9±3.7Ωcm2 
and 35.9±5.3Ωcm2 (ΔTEER of 6.2±2.3Ωcm2, 7.2±3.1Ωcm2 and 12.9±2.8Ωcm2 
from the baseline, respectively) at 1hr, 3hr and 6hr, respectively (p<0.01 from CS 
serum+iCORM-3), while having no effect on cells incubated with serum of 
healthy volunteers (Figure 5.3). 
 
5.3.3 Apoptosis 
 Incubation of HUVECs with human CS serum led to a significant increase 
in the activation of caspases, as shown in Figure 5.4 (10.3±1.0 RFU versus 
2.4±0.7 RFU in control, p<0.001). CORM-3 treatment resulted in a significant 
decrease in the caspases activation to 4.0±0.4 RFU (p<0.001), while having no 
effect on control or untreated endothelial cells (Figure 5.4) Treatment of HUVECs 
with serum of healthy volunteers produced no changes in the activity of caspases 
in both CORM-3 and iCORM-3 groups. 
 
5.3.4 PMN Rolling/Adhesion 
Incubation of HUVECs with CS serum resulted in a marked increase in 
PMN activation behaviour, from 0.5±0.1 rolling PMNs/0.1mm2 and 4.7±0.7 
adherent PMNs/0.1mm2 in control to 2.3±0.3 rolling PMNs/0.1mm2 and 17.0±1.8 
adherent PMNs/0.1mm2 in CS serum-treated HUVECs (p<0.001) (Figure 5.5). 
While iCORM-3 treatment had no effect, CORM-3 treatment of HUVECs resulted 
in a significant decrease in PMN rolling and adhesion in CS serum-treated cells   
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Figure 5.4. The effect of CORM-3 on the level of apoptosis in human 
vascular endothelial cells, elicited by stimulation with human 
CS serum. HUVECs were stimulated by patients’ CS sera for 6 
hours in the presence of CORM-3 (or its inactive form, iCORM-3), 
and the levels of active caspases were assessed by FAM-FLICA 
polycaspase assay.	 CS serum-induced activation of caspases 
(apoptosis) was inhibited by CORM-3 application (two-way ANOVA 
p<0.05; *p<0.001 from control; †p<0.001 from CS serum+iCORM-
3; N=6 per group). Serum of healthy patients served as a control.  
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Figure 5.5. The effect of CORM-3 on leukocyte (A) rolling and (B) adhesion 
in response to stimulation of the human vascular endothelial 
cells by CS serum. HUVECs were stimulated with CS patients’ 
sera for 6 hours, followed by application of healthy PMNs, while 
being superfused at a constant rate of 1dyn/cm2 with M199, in the 
presence of CORM-3 or iCORM-3. CS serum-induced PMN rolling 
and adhesion were significantly diminished by CORM-3 application 
(two-way ANOVA p<0.05; *p<0.001 from control and healthy 
serum; †p<0.001 from CS serum+iCORM-3, N=10 per group). PMN, 
polymorphonuclear cells.  
	 181 
(0.4±0.1 rolling PMN/0.1mm2 and 7.2±0.9 adherent PMN/0.1mm2, p<0.001) 
(Figure 5.5). Inactive CORM-3 treatment had no effect on PMN rolling/adhesion. 
 
5.3.5 PMN Migration 
In order to mimic changes occurring at the vascular-interstitial interface 
during the clinical conditions of compartment syndrome (i.e. impaired vascular 
function resulting in accumulation of serum in the interstitium and formation of 
severe edema (Blaisdell 2002)), HUVECs were grown on the apical aspect of the 
permeable supports (transwell inserts) and stimulated for 6 hours with the CS 
serum or serum obtained from healthy volunteers placed in to the basal 
compartment of the inserts, in the presence of CORM-3 or iCORM-3 (100µM). 
Subsequently, 51Cr-labeled PMNs were added to the apical aspect of HUVEC 
monolayer and allowed to migrate across the HUVECs for 60 minutes. 
Stimulation of HUVECs with CS serum in the basal compartment 
(representing interstitial aspect) led to an increased PMN migration across 
HUVECs, from 10.0±2.0% in control to 43±0.1% in CS serum-treated cells 
(p<0.05), as shown in Figure 5.6. The presence of CORM-3/iCORM-3 in the 
absence of serum had no effect on PMN migration; however, CORM-3 treatment 
completely prevented CS serum-induced PMN migration across the endothelial 
cells (18.5±0.5% versus 43.5±0.5% in iCORM-3 group, p<0.05). Stimulation of 
HUVECs with serum of healthy subjects had no significant effect on trans-
endothelial PMN migration in both CORM-3 and iCORM-3 groups (11.0±1.8%, 
n.s.).  
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Figure 5.6. The effect of CORM-3 on transendothelial leukocyte migration 
in response to stimulation of human vascular endothelial cells 
with CS serum. Na51CrO4-labelled human PMNs (5x105 cells) were 
added to the top of stimulated HUVECs (grown on apical surface) 
and allowed to migrate for 60min in response to CS serum (basal 
compartment), in the presence of CORM-3 (or iCORM-3). The 
amount of 51Cr radioactivity was assessed and percentage of PMN 
migration was calculated. CS stimulus-associated PMN migration 
was significantly diminished by CORM-3 application (two-way 
ANOVA p<0.05; *p<0.05 from control; †p<0.05 from CS+iCORM-3, 
N=3 per group). PMN, polymorphonuclear cells.  
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5.4  DISCUSSION 
CS poses a challenging clinical problem associated with significant patient 
disability (Giannoudis, Nicolopoulos et al. 2002). Few treatment modalities exist, 
apart from the gold standard of fasciotomy (Olson and Glasgow 2005). While 
some supportive therapies have shown limited potential in animal models 
(Manjoo, Sanders et al. 2010, Lawendy, Bihari et al. 2014), their use is hindered 
by the lack of understanding of the originating mechanism(s) of CS injury. 
CS is comprised of a complex chain of events, leading to upregulation of 
pro-inflammatory phenotype and subsequent inflammatory interactions between 
the vascular endothelial cells and leukocytes. As a result, impaired vascular cell 
integrity, increased vascular permeability and edema ensue (Sabido, Milazzo et 
al. 1994). One of the key features of CS appears to be an overwhelming 
production of pro-inflammatory mediators, and an accumulation of leukocytes in 
the affected limb. Leukocyte recruitment to the site of injury is an entirely normal 
host response (to remove pathogens or dead cells), but the extensive 
accumulation of PMNs and subsequent production of cytotoxic ROS, followed by 
the release of proteolytic enzymes contribute significantly to the extensive 
parenchymal damage seen in CS. Activated leukocytes impair surrounding cell 
viability (Toyokuni 1999), thus contributing to the tissue injury, dysfunction and 
subsequent development of systemic inflammation. 
Recent findings indicate that CO, either produced by the inducible form of 
HO (i.e. HO-1) or administered by inhalation (100-250ppm) offers potent anti-
inflammatory effects (Motterlini and Otterbein 2010). Nevertheless, the clinical 
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applicability of inhaled CO is limited due to a rapid formation of toxic levels 
(higher than 10%) of COHb (Ryter, Alam et al. 2006, De Backer, Elinck et al. 
2009). To overcome this limitation, transitional metal carbonyls, CO-releasing 
molecules (CO-RMs), have been developed that allow delivery of CO in a 
controlled manner without significant effects on COHb formation (<3-5%COHb) 
(Motterlini, Mann et al. 2005, Motterlini 2007, De Backer, Elinck et al. 2009)	The 
major advantage of using CO-RMs (e.g. the water soluble CORM-3) over the 
inhaled CO gas is the ability to control CO delivery and choice of various routes 
(IV, IP, SC or tissue superfusion) of CO administration to target specific 
organs/tissues. It has been demonstrated that CORM-derived CO offers 
cytoprotective/anti-inflammatory effects in animal models of inflammation and 
injury such as ischemia/reperfusion (Guo, Stein et al. 2004, Katada, Bihari et al. 
2010), pulmonary hypertension (Zuckerbraun, Chin et al. 2006), transplantation 
(Song, Kubo et al. 2003, Caumartin, Stephen et al. 2011) and sepsis (Cepinskas, 
Katada et al. 2008, Mizuguchi, Stephen et al. 2009). Research aimed at 
understanding the mechanisms of CO-mediated protection suggests the role of 
soluble guanylate cyclase (Ndisang, Tabien et al. 2004, Failli, Vannacci et al. 
2012), mitogen-activated protein kinases (MAPK) (Otterbein, Bach et al. 2000), 
phosphatidylinositol 3-kinase (PI3K), and NF-κB signaling pathways (Cepinskas, 
Katada et al. 2008). Hence, the actions mediated by CO appear to invoke unique 
stimulus-dependent signaling mechanism(s) in various cell types and organs. 
The studies addressing the role of CO-RMs in modulation of inflammatory 
response in compartment syndrome are extremely poorly investigated. Recently, 
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we have developed an experimental small animal model of CS (Lawendy, 
Sanders et al. 2011) and demonstrated potent protective effects of CORM-3 
through the suppression of CS-induced inflammation, tissue injury and 
microvascular perfusion deficits (Lawendy, Bihari et al. 2014). The 
cellular/molecular aspects of CS-induced tissue injury and dysfunction are also 
poorly understood. Moreover, no previous studies have used human material to 
assess vascular endothelial cell and/or leukocyte inflammatory activation in 
response to stimulation with CS-relevant stimulus. 
In the present study, we attempted to mimic the CS conditions in vitro, 
employing human vascular endothelial cells, human leukocytes and serum 
obtained from CS patients (as a CS-relevant stimulus) in order to assess the pro-
inflammatory potential of CS, as well as mechanisms of CORM-3 protection via 
its effect on modulation of cellular responses. To our knowledge, this is the first 
study to model CS in cell culture; not only does it permit the exploration of the 
mechanistic aspects of CS, but it allows for interventions currently not possible 
(or unethical) in humans. 
Incubation of endothelial cells (HUVECs) with serum obtained from CS 
patients resulted in a significant increase in intracellular production of ROS 
(Figure 5.1). It can be surmised that increased ROS production in response to 
CS is due, at least in part, to the upregulation of pro-inflammatory cytokines 
found in the CS serum (Donohoe 2015). Cytokines are known to induce oxidative 
stress, leading to cellular membrane compromise, changes in internal protein 
structure and downstream effects on enzymes (Sprague and Khalil 2009). 
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Similarly, incubation of naïve PMNs with CS serum resulted in the same type of 
response – significant PMN activation, as evidenced by an increase in the 
superoxide production (Figure 5.2). 
Application of CORM-3, but not of iCORM-3, was able to effectively 
diminish the CS serum-induced ROS production in both the endothelial cells and 
PMNs. The latter may be the result of CORM-3-dependent suppression of ROS-
generating pathways, such as inhibition of heme-containing redox enzymes (e.g. 
cytochrome c oxidase, NADPH oxidase (Babior, Lambeth et al. 2002), and/or 
myeloperoxidase (Patterson, Fraser et al. 2014). It is important to note that 
CORM-3 also interferes with PMN proteolytic potential by reducing the levels of 
cell surface-bound elastase in an inflammatory stimulus-activated PMN, thus 
reducing/preventing PMN tissue infiltration and proteolytic injury (Mizuguchi, 
Stephen et al. 2009). 
Under normal circumstances, intact endothelium provides a semi-selective 
barrier between the vessel lumen and surrounding tissue, controlling the passage 
of materials and the transit of leukocytes between the blood and interstitial space. 
In vivo, excessive increase in permeability of the endothelial monolayer may lead 
to tissue edema, creating non-perfused segments within the capillary system, 
thus further contributing to ischemia and the microvascular dysfunction (Sabido, 
Milazzo et al. 1994). In this regard, exposure of human endothelial cells to CS 
serum led to a significant, progressive breakdown of endothelial barrier, as 
evidenced by a decrease in trans-endothelial electrical resistance (Figure 5.3), 
suggesting the presence of potent injurious substances present in the circulation 
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of CS patients. Unlike plasma obtained from patients with pronounced systemic 
response (e.g. diabetic ketoacidosis), which had failed to impair the integrity of 
HUVECs (Omatsu, Cepinskas et al. 2014), CS serum appears to contain strong 
injurious and pro-inflammatory compounds that produce detrimental effect on 
cellular integrity. 
On the other hand, it is important to note that CS serum-induced 
impairment of endothelial cell integrity was coupled with endothelial cell 
apoptosis, as evidenced by activation of multiple caspases (marker of apoptosis) 
(Figure 5.4). Application of CORM-3 (but not iCORM-3) prevented both CS 
serum-induced decrease in HUVEC monolayer integrity and induction of cell 
apoptosis. 
Increased oxidative stress through ROS-based signalling (Toyokuni 1999) 
can modify endothelial cell cytoskeleton (e.g. F-actin assembly) and associated 
adherens junction protein function (e.g. VE-cadherin, β-catenin) (Corada, Liao et 
al. 2001, Giannotta, Trani et al. 2013), contributing to the breakdown of 
endothelial barrier. ROS also play a critical role in activation of the pro-
inflammatory pathways, as well as activation of caspases (e.g. caspase-3) 
responsible for the induction of cell apoptosis (Elmore 2007).  Given that CS 
produces a strong pro-oxidant and pro-inflammatory environment (characterized 
by the presence of ROS and inflammatory cytokines, particularly TNF-α 
(Lawendy, Bihari et al. 2014, Lawendy, Bihari et al. 2015)), it is plausible to 
assume that both intrinsic (mitochondria/cytochrome c-mediated) and extrinsic 
(TNF-α receptor-mediated) apoptotic pathways would be activated (Elmore 2007). 
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Therefore, the protective effects of CORM-3 associated with endothelial cell 
barrier function and/or cell apoptosis may be, at least in part, due to CORM-3-
dependent suppression of oxidant-generating redox system(s). It remains to be 
determined which specific redox system in the endothelial cells and/or PMN is 
affected by CORM-3. 
In our study, the application of CS serum to human endothelial cells led to 
a significant increase in leukocyte rolling and adhesion (Figure 5.5), a key feature 
of leukocyte and/or vascular endothelial cell inflammatory activation (Butcher 
1991, Ley, Laudanna et al. 2007). These results support our recent findings 
demonstrating significant accumulation of leukocytes in the microcirculation of 
the skeletal muscle of CS animals (Lawendy, Sanders et al. 2011, Bihari, 
Cepinskas et al. 2015). The potency of CS serum in the induction of PMN 
adhesion to endothelial cells in vitro was greater in comparison to that observed 
in sepsis-relevant stimulus (lipopolysaccharide (LPS)-challenged human 
cerebrovascular endothelial cells) (Serizawa, Patterson et al. 2015) or endothelial 
cells stimulated with plasma of diabetic ketoacidosis patients (Omatsu, 
Cepinskas et al. 2014). 
PMN recruitment to the inflamed tissues involves a series of complex, yet 
well coordinated PMN-endothelial cell adhesive interactions (PMN rolling, firm 
adhesion and migration across the endothelial barrier (Ley, Laudanna et al. 
2007)). It is well accepted that adhesion molecules expressed on the vascular 
endothelium (e.g. P-selectin, E-selectin, ICAM-1, VCAM-1) and their ligands on 
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PMNs (e.g. L-selectin, sialyl-LewisX, β2 integrins) play a critical role in leukocyte 
recruitment. 
 In the current study, treatment of human endothelial cells with CORM-3 
effectively reduced PMN rolling and adhesion to CS serum-stimulated HUVECs 
(Figure 5.5), replicating our in vivo animal data (Lawendy, Bihari et al. 2014, 
Bihari, Cepinskas et al. 2015). The exact mechanism(s) of CORM-3-induced 
suppression of the vascular endothelial cell pro-adhesive phenotype in an in vitro 
model of CS is not clear, yet it warrants further investigation. While previous 
studies in the field indicate that CO-RMs can modulate activation or expression 
of adhesion molecules on both the PMN and vascular endothelial cells, the 
experimental data appear to be rather controversial. It has been demonstrated 
that CORM-2 (DMSO-soluble CO-RM) suppressed tissue levels of intercellular 
adhesion molecule-1 (ICAM-1) in the liver of septic mice, as well as subsequent 
PMN adhesion to LPS-stimulated HUVECs (Cepinskas, Katada et al. 2008). In 
addition, CORM-2 effectively reduced tissue levels of E-selectin and ICAM-1 in 
the small intestine of mice undergoing ischemia-reperfusion (Katada, Bihari et al. 
2010). Studies in vitro indicate that CORM-2 reduces high glucose-induced 
expression of ICAM-1 in HUVECs (Nizamutdinova, Kim et al. 2009). CORM-3-
dependent inhibition of E-selectin and VCAM-1 expression in TNF-α-stimulated 
HUVECs has also been demonstrated (Song, Bergstrasser et al. 2009). On the 
other hand, and contrary to the above, CORM-3 failed to suppress ICAM-1 and 
E-selectin expression in TNF-α-stimulated HUVECs (Urquhart, Rosignoli et al. 
2007) or LPS-stimulated human cerebrovascular endothelial cells, while showing 
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high effectiveness in reducing expression of VCAM-1 (Serizawa, Patterson et al. 
2015). Finally, it has been found that CORM-3 suppressed PMN-HUVEC 
adhesive interaction by reducing CD11b (aMβ2-integrin) surface levels in platelet 
activating factor (PAF)-stimulated PMN (Urquhart, Rosignoli et al. 2007). 
Following firm leukocyte adhesion to the vascular endothelium, PMN 
migration into the interstitium is driven primarily by chemokines (e.g. CXCL1, 
CXCL8) and other chemotactic substances (e.g. PAF, leukotriene B4); these are 
produced by vascular endothelial cells and/or interstitial cells, such as 
macrophages, pericytes and fibroblasts. PMN migration across the vascular 
barrier is controlled by PECAM-1 (CD31), CD99 and JAM-A/B/C adhesion 
molecules, expressed on both leukocytes and the endothelial cells (Ley, 
Laudanna et al. 2007). It has been demonstrated that excessive migration of 
leukocytes (particularly neutrophils) across the vascular endothelium 
compromises microvessel integrity; this is associated with the disruption of the 
endothelial cell adherens/tight junctions and degradation of basement membrane 
(Cepinskas, Sandig et al. 1999, Cepinskas, Savickiene et al. 2003, Granger and 
Senchekova 2010). As a result, fluid (i.e. plasma) is allowed to pass into the 
parenchyma, contributing to edema formation (Giannotta, Trani et al. 2013). 
In our current study, basolateral stimulation of endothelial cells with the 
serum of CS patients (to mimic vascular-interstitial interface) resulted in 
significant increase in PMN transendothelial migration, the phenomenon that was 
effectively prevented by CORM-3 treatment (Figure 5.6). These findings suggest 
that CS serum may upregulate expression or activation of adhesion molecules 
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involved in PMN migration (e.g. CD31, JAM-C). Alternatively, CS serum may 
induce production of chemokines by the endothelial cells, or it itself contains 
sufficient amount of chemotactic molecules promoting PMN transendothelial 
migration. In fact, the pro-inflammatory potential of plasma obtained from patients 
with severe systemic inflammatory disorders was demonstrated, showing that the 
levels of pro-inflammatory cytokines IL-6 and CCL2 (MCP-1), as well as 
chemokines CXCL8 (IL-8), CCL4 (MIP-1β), and CXCL1 (GRO-α) are markedly 
upregulated in the circulation of human patients with severe sepsis. In addition, 
the circulating levels of IL-6, CXCL1 (GRO-α), CXCL8 (IL-8), and CXCL10 (IP-
10) chemokines have also been detected in the plasma of diabetic ketoacidosis 
patients (Omatsu, Cepinskas et al. 2014). While we have previously 
demonstrated, in a rat model, that CS resulted in upregulation of pro-
inflammatory cytokines and chemokines (Donohoe 2015), it remains to be 
determined whether pro-inflammatory cytokines/chemokines can be found in the 
serum of human CS patients. 
In summary, this is the first study demonstrating the beneficial effects of 
carbon monoxide, delivered by CORM-3, in an in vitro human model of 
compartment syndrome. It represents the first step in an attempt to translate the 
promising results obtained from animal studies into human patients. While the 
exact mechanisms of CORM-3 protective action remain to be determined, the 
obtained data strongly indicate a potential therapeutic application of CORM-3 to 
patients at risk of developing CS. 
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CHAPTER 6: GENERAL DISCUSSION AND CONCLUSIONS 
 
 
6.1 OVERVIEW OF RESULTS 
6.1.1 Pathophysiology of CS and Current Therapeutic Considerations 
Ever since the first description of limb ischemic contracture by Richard von 
Volkmann (von Volkmann 1881), CS has been recognized as one of the most 
devastating complications of musculoskeletal trauma, resulting in severe acute 
myonecrosis, with significant patient disability as an outcome. An attempt to 
highlight the major conceptual contributions to the current state of knowledge of 
CS and current therapeutic approaches was undertaken in Chapter 1. While the 
pathophysiology of the condition has not been completely elucidated, CS 
appears to occur as a consequence of ischemia-reperfusion injury secondary to 
an elevation of ICP. An increase in intra-compartmental pressure creates hypo-
perfused state, where oxygen and nutrient delivery to the tissue is limited, 
resulting in cellular anoxia and tissue necrosis (Sheridan and Matsen 1975, 
Whitesides, Haney et al. 1975, Sheridan, Matsen et al. 1977, Rorabeck and 
Clarke 1978). As a consequence, severe inflammatory response occurs, further 
contributing to the ischemia-induced microvascular dysfunction (Sadasivan, 
Carden et al. 1997, Lawendy, Sanders et al. 2011). Unlike complete ischemia, 
however, CS occurs in the face of patent vessels, since distal pulse is often 
present (Seddon 1966); the low-flow ischemic state appears to be even more 
injurious than complete ischemia, with severe acidosis and metabolic stress 
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rendering a more severe degree of the muscle deterioration (Heppenstall, Scott 
et al. 1986).  
CS constitutes surgical emergency, with fasciotomy as the only current 
gold-standard treatment. Fasciotomy, to decompress all tissues in the involved 
compartments must be carried out in a timely manner (within a surgical window 
of 6-8 hours), before the damage becomes permanent. Due to the uncertainty of 
the actual onset of CS (the condition does not develop instantaneously) and the 
lack of objective diagnostic test (CS diagnosis is based on a subjective clinical 
exam), targeting the window may not be easy – hence the need for prolongation 
of surgical window. 
 
6.1.2 Carbon Monoxide and CS 
It has been known for some time that ischemia results in an upregulation 
of protective stress-induced proteins, particularly HO (Otterbein, Lee et al. 1999, 
Petrache, Otterbein et al. 2000, Sato, Balla et al. 2001). While the global 
upregulation of HO may not be feasible clinically, exogenous application of its 
endproducts, particularly CO, can be accomplished with relative ease. 
 The effect of inhalational CO on the extent of CS-induced microvascular 
dysfunction in a rat model of CS is described in Chapter 2. Since CS poses great 
challenge to study in humans, various animal models have been developed to 
investigate the condition (Jepson 1926, Sheridan and Matsen 1975, Sadasivan, 
Carden et al. 1997, Vollmar, Westermann et al. 1999, Kalns, Cox et al. 2011, 
Lawendy, Sanders et al. 2011). The rat model (Lawendy, Sanders et al. 2011) 
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was chosen due to its relative ease of preparation, excellent reproducibility and 
low cost. Most importantly, rat model of CS allowed for the use of IVVM as a real-
time analysis of microcirculation. 
Direct imaging of the microcirculation by IVVM validated significant 
perfusion derangements, marked tissue injury and extensive leukocyte activation 
in response to 2 hours of elevated ICP; these effects were suppressed by 
administration of CO or CORM-3 at fasciotomy. Two hours were chosen based 
on previous studies, demonstrating that 1 hour of ischemia in a rodent 
approximates 4 hours of ischemia in human (Sheridan, Matsen et al. 1977, 
Hulbert, Pamplona et al. 2007). The CO dose of 250ppm was chosen on the 
basis of previous research demonstrating its effectiveness in suppressing various 
pathological inflammatory conditions (Otterbein, Mantell et al. 1999, Otterbein, 
Bach et al. 2000, Moore, Otterbein et al. 2003, Ott, Scott et al. 2005, Scott, 
Cukiernik et al. 2009). 
In our study, exogenous application of CO resulted in a significant 
improvement in microvascular perfusion, complete inhibition of leukocyte 
activation and tissue injury in CS-challenged animals; however, inhalation of CO 
significantly elevated COHb. 
 
6.1.2.1 CORM-3 as a Source of CO 
With the synthesis of a novel class of transition metal carbonyls, CO-
releasing molecules (CO-RMs) (Motterlini, Mann et al. 2005), as a 
pharmacological means of CO delivery, a new avenue of research opened up, 
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allowing application of CO directly to the tissues (i.e. bypassing the inhalational 
component). The effect of exogenous application of CO in the form of injectable 
CORM-3 on the severity of microvascular dysfunction due to CS is described in 
Chapter 3. CORM-3 was selected because of its excellent water solubility and 
rapid release of CO under physiological conditions, upon administration. Ex vivo 
studies indicate that CORM-3 is an equimolar CO donor (Motterlini, Clark et al. 
2002); the CORM-3 dose of 10mg/kg was chosen based on our inhalational CO 
studies (250ppm), to deliver the equivalent amount of CO. 
In our study, systemic application of CORM-3 at fasciotomy resulted in a 
significant improvement in muscle perfusion, 4-fold decrease in tissue injury, 8-
fold decrease in leukocyte activation, coupled with abolishment of CS-induced 
TNF-α release, all without any changes in blood levels of COHb. 
 
6.1.3 Preclinical Testing of CORM-3 in Porcine CS 
While the results of rat CS experiments show promise, it would be quite a 
leap to apply these to human subjects. Hence, the effect of CORM-3 was tested 
in a pre-clinical setting, using a large animal model – an animal more akin to 
human (i.e. pig), described in Chapter 4. Rodents respond differently to CO than 
humans (previous inhalational CO studies in humans using bacterial sepsis failed 
to demonstrate any significant effects of inhaled CO on the LPS-induced 
systemic response) (Mayr, Spiel et al. 2005). The purpose of the study described 
in this thesis was to evaluate the effect of CORM-3 on the severity of 
microvascular dysfunction in pigs undergoing CS. 
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We found that six hours of elevated compartment pressure in pigs resulted 
in severe microvascular perfusion deficit, progressive release of TNF-α coupled 
with significant systemic leukocyte activation, as well as a large increase in tissue 
necrosis, apoptosis and leukocyte infiltration (tissue inflammation). In addition, 
some end-organ damage was also observed (particularly in the kidney). 
Systemic administration of CORM-3 led to a marked decrease in tissue 
inflammation coupled with some improvement in microvascular dysfunction, 
lessening of tissue necrosis and a large decrease in tissue apoptosis. 
Systemically, CORM-3 blocked CS-induced increase in circulating TNF-α levels, 
coupled with complete abolishment of systemic leukocyte activation. Additionally, 
CORM-3 also attenuated the severity of end organ dysfunction (i.e. kidney). 
 
6.1.4 Human in vitro Model 
 In order to translate the results of animal experimentation, human CS was 
modelled in vitro, as described in Chapter 5. This study was designed to test the 
effect of CORM-3 on the cultured primary human vascular endothelial cells 
stimulated with CS-like conditions, attempting to provide a broad mechanistic 
insight into CS in terms of oxidative stress and leukocyte activation. The model 
did not involve elevation of hydrostatic pressure; rather, the CS-like conditions 
were mimicked by the use of serum obtained from CS patients, covering only the 
inflammatory component of CS pathophysiology. As such, the model may not 
accurately and completely mimic conditions that CS patients experience. 
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In our study, we found that CS challenge of the endothelial cells, in the 
form of serum isolated from CS patients, resulted in an increase in oxidative 
stress in the endothelial cells (as evidenced by increased ROS production), 
breakdown of endothelial layer integrity (changes in trans-endothelial electrical 
resistance), and significant upregulation of pro-adhesive phenotype, leading to 
changes in leukocyte-endothelial interactions (increased leukocyte adhesion and 
rolling, leukocyte transmigration). Application of CORM-3 was able to diminish 
the severity of both the oxidative stress and endothelial activation necessary for 
leukocyte recruitment within the endothelial cells. 
Our findings suggest that CORM-3 has potent anti-oxidant and anti-
inflammatory properties. While not a free-radical scavenger, it may have the 
ability to suppress the oxidative stress indirectly (e.g. by modulating the activity of 
redox enzymes), minimizing the extent of endothelial injury. 
 
 
6.2 LIMITATIONS AND FUTURE DIRECTIONS 
 The significance of the results described this thesis lies, in part, with the 
demonstration of the protective effects of CORM-3 on the severity of outcomes in 
multiple models of CS: that of a rat, pig and human. While the data looks 
promising, the studies were not without limitations. First, we used only a single 
concentration of CORM-3 and a single route of administration in each species 
(i.e. IP in rats, IV in pigs, direct exposure in human endothelial cells). Different 
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dosage, frequency, and alternative routes of CORM-3 administration may provide 
different dynamics of CORM-3-dependent protection. 
Second, despite the fact that the use of CORM-3 at micromolar 
concentrations shows no cytotoxic effects in cultured vascular endothelial cells 
and leukocytes, the potential toxicity of various concentrations of CORM-3 in vivo 
is yet to be determined. Very little data exists on the safety of the systemic 
CORM-3 administration in large animals, although they appear to be more 
sensitive to the effects of CORM-3. The data presented in our studies indicate 
that, at concentrations that offer potent anti-inflammatory effects, CORM-3 does 
not appear to be harmful with respect to hepatotoxicity and formation of toxic 
levels of COHb. However, CORM-3 is a ruthenium-based molecule; ruthenium is 
a transition metal that does not naturally occur in human body (Emsley 2003). 
Although ruthenium is relatively inert to other chemicals, heavy metal toxicity and 
effects on the DNA (Bergamo and Sava 2011) are still of major concern. 
Finally, the studies described here did not examine the effects of CORM-3 
on pathophysiology of CS in a very detailed mechanistic manner, primarily due to 
the lack of availability of genetically modified animals. The main purpose was to 
test the potential therapeutic applicability of CORM-3 in a rather crude approach: 
does it work or not? 
In the future, the evaluation of the effect of CORM-3 on the magnitude of 
functional deficits following CS would be of immense benefit. The studies that 
evaluate gait could be accomplished in rats with relative ease using automated 
gait analysis (e.g. the CatWalkTM system), currently available to us.  
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Another avenue of research could explore the role of CORM-3 in tissue 
repair and muscle regeneration. The concepts of developmental biology could be 
applied to tissue engineering and stem cell production. Successful muscle 
regeneration requires careful regulation of inflammation to clear up the debris, 
and the initiation of activation of muscle satellite cells (the normally quiescent 
muscle precursors) (Tidball 2011). Given that different classes of macrophages 
fulfill different function (M1 type furthers inflammation, while M2 type promotes 
tissue repair) the role of CORM-3 on the differential expression (induction or 
modulation) of M1 and M2 phenotypes could be explored. 
Finally, the first transition into an actual patient could be undertaken, by 
evaluating the efficacy of topical application of CORM-3 following fasciotomy. 
 
 
6.3  CONCLUSIONS 
The data in this thesis indicates that CORM-3 has strong anti-
inflammatory properties, and may be capable of diminishing the post-fasciotomy 
tissue injury.  While the exact mechanisms of its protective action remain to be 
determined, CORM-3 may have an enormous potential as a pharmacological 
adjunct to fasciotomy, and might, at least, be capable of prolongation of surgical 
window and improvement of muscle salvage after fasciotomy. 
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APPENDIX I: SURGICAL APPROACHES TO LIMB COMPARTMENT 
SYNDROME 
 
 
There is only one gold standard surgical option for the treatment of 
compartment syndrome: fasciotomy. The ultimate goal of the procedure is 
salvage of a functional extremity; this must be kept in mind by the surgeon when 
deciding on the fasciotomy technique to be employed.  
The surgical techniques for complete limb fascial release have been well 
studied in both the leg and the forearm. In the leg, three techniques are most 
commonly described: two-incision fasciotomy, single incision perifibular 
fasciotomy, and fibulectomy. In the forearm, two techniques are most commonly 
described: dorsal approach and volar approach. 
 
 
I.1 FASCIOTOMY IN THE LEG 
Most surgeons prefer the double incision technique, which allows for 
adequate visualization of all compartments, assessment of muscle viability, and 
sufficient surgical control to avoid neurovascular structures. The single incision 
four-compartment fasciotomy without fibulectomy is safe and can be useful in 
cases where soft tissue trauma or contamination is of concern, including 
situations in which only a single vessel perfuses the leg, or when flap coverage 
may be necessary. 
	 213 
Kelly and Whitesides (1967) described a four-compartment release with 
fibulectomy performed through one lateral incision (Kelly and Whitesides 1967). 
The technique takes advantage of the fascial anatomy, since all the fascial 
membranes insert onto the fibula. However, this method is technically 
challenging, may place the peroneal vessels at risk, and sacrifices the fibula 
(which is usually unnecessary). Both the double and single incision techniques 
are sufficiently effective at decreasing intracompartmental pressure (ICP) 
(Mubarak and Owen 1977, Vitale, Richardson et al. 1988). 
Subcutaneous fasciotomy is a technique in which the fascia is incised 
blindly with dissecting scissors through a small skin incision (Hutchinson and 
Ireland 1994). Advantages include technical ease and cosmesis; however, 
access is limited to the deep posterior compartment and the neurovascular 
bundle.  In addition, it is now recognized that intact skin may not allow for 
complete release of ICP. 
In acute compartment syndrome, the skin is an important boundary of all 
compartments that must be released to achieve the greatest decrease in ICP. 
While small incision fasciotomy and endoscopically-assisted fasciotomy may 
have a role in chronic exertional compartment syndrome, these techniques 
should not be used in acute compartment syndrome: the recurrence of limb-
threatening ischemia may occur despite fascial release when the skin is left intact 
(Illig, Ouriel et al. 1998, Leversedge, Casey et al. 2002, Hutchinson, Bederka et 
al. 2003, Apaydin, Basarir et al. 2008). 
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I.1.1 Surgical Technique:  Single-Incision Fasciotomy 
Single-incision fasciotomy was described in detail by Davey et al (Davey, 
Rorabeck et al. 1984). The operative technique starts with the patient positioned 
supine with a bump under the hip, tourniquet applied but not insufflated. The limb 
is prepped and draped free. The surgery begins with a single longitudinal, lateral 
incision in line with the fibula (Figure I.1). The incision extends from the fibular 
head to 3-4 cm proximal to the lateral malleolus, taking care to minimize the risk 
of injuring the superficial peroneal nerve toward the distal aspect of the incision. 
Skin flaps are developed anterior, and a longitudinal fasciotomy of the anterior 
and lateral compartments is performed with dissecting scissors.  
Next, a posterior flap is developed and a fasciotomy of the superficial 
posterior compartment is performed. The surgeon should identify the interval 
between and superficial and lateral compartments distally, and develop this 
interval proximally by detaching the soleus from the fibula. Flexor hallucis longus 
should be dissected subperiosteally from the fibula; the muscle and the peroneal 
vessels are retracted posteriorly. At this point, all four compartments would have 
been decompressed. However, on occasion tibialis posterior exists within a self-
contained fascial envelope and, therefore, it is beneficial to continue the deep 
dissection until tibialis posterior is decompressed.  The muscle and the peroneal 
vessels should be retracted posteriorly; the fascial attachment of the tibialis 
posterior muscle to the fibula should be identified and this fascia then incised 
longitudinally. At the conclusion of the surgery, wounds are packed open, or the 
skin may be loosely closed over suction drains. 
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Figure I.1. Single-incision fasciotomy. (A) Lateral aspect and (B) medial 
aspect of the leg. The incision extends from the fibular head to 3 
cm proximal to the lateral malleolus. Skin flaps are developed 
anterior, and a longitudinal fasciotomy of the anterior and lateral 
compartments is performed with dissecting scissors. Posterior flap 
is developed and a fasciotomy of the superficial posterior 
compartment is performed. Wounds are packed open or the skin 
may be loosely closed over suction drains. 
Reproduced with permission from Lawendy and Sanders (2010). 
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I.1.2. Surgical Technique:  Two-Incision Fasciotomy 
Two-incision fasciotomy was described in detail by Mubarak and Hargens 
(Mubarak and Hargens 1981). Patient is positioned supine, tourniquet applied 
and not insufflated.  The limb is prepped and draped free. The procedure begins 
with a 20-25cm incision in the anterior compartment, centered halfway between 
the fibular shaft and the crest of the tibia (Figure I.2), utilizing subcutaneous 
dissection for wide exposure of the fascial compartment. Transverse incision is 
made to expose the lateral intermuscular septum, and the superficial peroneal 
nerve lying posterior to the septum is identified. Using dissecting scissors, the 
anterior compartment is released proximally and distally in line with the tibialis 
anterior. The lateral compartment is accessed, and a fasciotomy of the lateral 
compartment is performed proximally and distally, in line with the fibular shaft. 
A second longitudinal incision 2 cm posterior to the posterior margin of the 
tibia is made, using wide subcutaneous dissection to allow identification of the 
fascial planes. Skin flaps are elevated and the saphenous vein and nerve are 
identified and protected. The septum between the deep and superficial posterior 
compartments is then identified, and the fascia over the gastrocnemius-soleus 
complex is released over its entire length. Another fascial incision is made over 
the flexor digitorum longus muscle and the entire deep posterior compartment is 
released.  As the dissection is carried proximally, if the soleus bridge extends 
more than halfway down the tibia, this extended origin must also be released. 
After release of the posterior compartment, the tibialis posterior muscle 
compartment  is  identified  and  released  over  the  extent  of  the muscle belly if  
	 217 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.2. Two-incision fasciotomy. An incision in the anterior compartment 
is centered halfway between the fibular shaft and the crest of the 
tibia. Lateral intermuscular septum is exposed. The anterior 
compartment is released proximally and distally in line with the 
tibialis anterior. Fasciotomy of the lateral compartment proximally 
and distally in line with the fibular shaft is performed. A second 
longitudinal incision 2cm posterior to the posterior margin of the 
tibia is made; fascia over the gastroc-soleus complex is released 
over its entire length. Then, the deep posterior compartment is 
released via fascial incision over the flexor digitorum longus.  
Reproduced with permission from Lawendy and Sanders (2010). 
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increased tension is evident in this compartment. The wound is packed open and 
a posterior plaster splint is applied, with the foot plantigrade  
 
 
I.2 FASCIOTOMY IN THE FOREARM 
Decompression fasciotomy of the forearm is performed through a volar 
approach, a dorsal approach, or both. Unlike the fascial compartments of the leg, 
the volar compartment, dorsal compartment, and mobile wad compartment 
(containing the brachioradialis and radial wrist extensors) are interconnected; 
thus, fasciotomies of all 3 compartments may be unnecessary. 
Superficial fasciotomy is usually adequate to decompress the entire 
forearm (Lawendy and Sanders 2010). The flexor digitorum profundus and flexor 
pollicis longus muscles (deep volar compartment) are among the most severely 
affected muscles, due to their deep location adjacent to the radius and ulna. Pre-
fasciotomy and post-fasciotomy pressures often are obtained from all 
compartments of the volar forearm, and if deep compartment pressures remain 
high after superficial fasciotomy, an additional release is indicated. 
Forearm fasciotomy requires decompression from the wrist to mid arm, 
including the lacertus fibrosus fascia, the fascial compartments over the flexor 
carpi ulnaris, and the edge of the flexor superficialis muscles. With median nerve 
involvement, in addition to carpal tunnel release, the surgeon must explore the 
nerve in the proximal forearm. 
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The median nerve is decompressed throughout its course, including high-
risk areas that are deep to the bicipital aponeurosis (lacertus fibrosus), between 
the humeral and ulnar heads of the pronator teres, the proximal arch, and deep 
fascial surface of the flexor digitorum superficialis, and the carpal tunnel. 
Preoperative prophylactic antibiotics against Staphylococcus aureus are 
generally recommended.  
 
I.2.1 Surgical Technique: Volar Approach 
Volar approach to the superficial and deep flexors of the forearm was first 
described in detail by Henry (Henry 1927). Standard surgical preparation and 
draping are performed, but no tourniquet should be used. A volar curvilinear 
incision medial to the biceps tendon, crossing the elbow flexion crease at an 
angle is first made (Figure I.3). The incision is carried distally into the palm to 
allow for a carpal tunnel release (similar to the McConnell’s combined exposure 
of the median and ulnar nerves), avoiding crossing the wrist flexion crease at a 
right angle. 
Lacertus fibrosus is divided proximally, evacuating any hematoma. The 
brachial artery is exposed to determine whether there is a normal blood flow. In 
case of the unsatisfactory flow, the adventitia is removed to expose any 
underlying clot, spasm or intimal tear, resecting the adventitia if necessary, and 
anastomosing or grafting the artery. The superficial volar compartment is then 
released throughout its length with open scissors under direct vision, freeing the 
fascia over the superficial compartment muscles. The flexor carpi ulnaris is 
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identified and retracted with its underlying ulnar neurovascular bundle medially. 
The flexor digitorum superificalis and median nerve are retracted laterally to 
expose the flexor digitorum profundus in the deep compartment. If its overlying 
fascia is tight, it is incised longitudinally. 
The dissection is continued distally, by incising the transverse carpal 
ligament along the ulnar border of the palmaris longus tendon and median nerve. 
The median nerve is then inspected and examined, to ensure that it is not injured 
or entrapped between the ulnar and humeral head of the pronator teres (if it is, a 
partial pronator tenotomy will be necessary). In the distal forearm, if the median 
nerve is exposed, the distal radial-based forearm skin flap is loosely sutured over 
the nerve, leaving the rest of the incision open. In case that an associated 
fracture is present, the fracture is reduced and stabilized to obtain hemostasis. 
At this point, the dorsal compartments are checked clinically, or repeated 
pressure measurements are made. Usually, the volar fasciotomy decompresses 
the dorsal musculature sufficiently; however, if the involvement of the dorsal 
compartments is still suspected, they are also released. A sterile moist dressing 
and a long arm splint are applied, taking care not to leave the elbow flexed 
beyond 90°. 
The volar ulnar approach (similar to the Henry approach) is used to 
release the flexor carpi ulnaris and flexor digitorum superficialis. The proximal 
edge of the flexor digitorum superficialis is carefully identified, and the ulnar 
nerve at the wrist is decompressed. 
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Figure I.3. Fasciotomy of the forearm. A volar curvilinear incision is made, 
releasing superficial volar compartment. The flexor digitorum 
superificalis and median nerve are retracted to expose the flexor 
digitorum profundus in the deep compartment, incising the fascia 
longitudinally. The dissection is continued by incising the transverse 
carpal ligament along the ulnar border of the palmaris longus 
tendon. The volar ulnar approach is used to release the flexor carpi 
ulnaris and flexor digitorum superficialis, decompressing the ulnar 
nerve at the wrist.  
Reproduced with permission from Lawendy and Sanders (2010).  
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I.2.2 Surgical Technique: Dorsal Approach 
 The technique for the dorsal approach has been described by Thompson 
(Thompson 1918). The arm is pronated, and the incision distal to the lateral 
epicondyle is made between the extensor digitorum communis and extensor 
carpi radialis brevis, extending approximately 10 cm distally toward the midline of 
the wrist. The subcutaneous tissue is gently undermined, and the fascia overlying 
the mobile wad of Henry and the extensor retinaculum is released. 
The skin is not closed at this time, anticipating secondary closure later. A 
sterile moist dressing and a long arm splint are applied, taking care not to leave 
the elbow flexed beyond 90°. 
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